

German-Israeli Cooperation in Cancer Research

Supplement
Publications 1976 – 2004



Deutsches
Krebsforschungszentrum
Heidelberg
State of Israel
Ministry of Science and Technology
Jerusalem

Table of Contents

Explanatory Notes.....		4
Ca 1	E. Winocour/G. Sauer	5
Ca 2	L. Sachs/W. Franke	5
Ca 3	M. Schlesinger/W. Dröge	6
Ca 4	R. Laskov/K. Eichmann	7
Ca 5	F.Doljanski/V.Kinzel	7
Ca 7	E. Shaaya/E. Sekeris	8
Ca 8	J. Haimovich/P. Krammer	8
Ca 9	S.Lavi, E. Winocour/G. Sauer	10
Ca 11	T. Mekori, E. Robinson/H. Kirchner, E. Storch	11
Ca 12	D. Sulitzeanu/M. Zoller, S. Matzku	11
Ca 13	A. J. Treves, S. Biran/W. Dröge, V. Schirrmacher	12
Ca 14	E. Pick/D. Gemsa, H. Kirchner	12
Ca 15	D. Givol, P. Lonai/K. Eichmann	14
Ca 16	R.Ben-Ishai/H.W.Thielmann	15
Ca 17	R. Simantov/F. Marks	15
Ca 18	S. Segal, E. Gorelik/G. Hämmerling, V. Schirrmacher	16
Ca 19	E. Canaani/T. Graf	17
Ca 20	M. Herzberg/D. Werner, K. Munk	17
Ca 21	J. Kapitulnik, R. Koren/F. Kolar, N. Fusenig	18
Ca 22	B. Geiger/W. Franke.....	18
Ca 23	U.Z. Littauer, I. Ginzburg/H. Ponstingl.....	19
Ca 24	I. Vlodaysky/V. Schirrmacher	20
Ca 25	S. Shaltiel/V, Kinzel, M. Gagelmann	22
Ca 26	A. Panet/H. Kirchner, H. Jacobsen.....	24
Ca 27	M. Bar-Eli/G. Hämmerling	24
Ca 28	R. Kaempfer/P. Krammer.....	25
Ca 29	A.Raz, A.Ben-Ze'ev/M. Zöller.....	27
Ca 30	V.Rotter/V. Schirrmacher.....	28
Ca 31	S. Mitrani-Rosenbaum/L. Gissmann.....	29
Ca 32	S.Lavi/J. Schlehofer	29
Ca 33	Y. Milner/M. Hergenhahn	30
Ca 34	J. Schlessinger/V. Kinzel, F. Marks	30
Ca 35	H. Manor/M. Pawlita	31
Ca 36	B.Czernobilsky/W. Franke	31
Ca 37	I. Friedberg/D. Kibbler, W. Pyerin	33
Ca 38	Y. Kaufman/W. Falk, P. Krammer.....	34
Ca 39	M. Revel, J.Chebath/R. Zawatzky, H. Kirchner	35
Ca 40	J.Kark/J.Wahrendorf	36
Ca 41	D. Wallach/H. Holtmann, D. Männel	36
Ca 42	G. Berke/W. Dröge	38
Ca 43	E. Kedar/V. Schirrmacher	39
Ca 44	R.N.Apte/M.Zöller	39
Ca 45	P. Rozen/H. Boeing	40
Ca 46	A. Ben-Ze'ev/J. Kartenbeck, W. Franke.....	41
Ca 47	Y. Shiloh/A. Weith, M. Schwab	43
Ca 48	J. Tal/J. Schlehofer.....	44
Ca 49	B.Geiger/W. Franke.....	44
Ca 50	M. Aboud/M. Lochelt, R. Flügel	46
Ca 51	M. Oren/R. Corvi, M. Schwab	47
Ca 52	H.Degani,Y.Salomon/W.Lehmann,W.E. Hull.....	48
Ca 53	S.A. Lamprecht/G. Fürstenberger, F. Marks.....	49



Ca 54	M. Liscovitch/V. Kinzel	49
Ca 55	J. Bar-Tana/D. Keppler	50
Ca 56	I. Ginzburg/H. Ponstingl.....	52
Ca 57	G. Neufeld/R. Schwartz-Albiez (V. Schirrmacher)	53
Ca 58	E.Keshet/E.Spiess	53
Ca 59	A. Kimchi/N. Fusenig	54
Ca 60	S. Lavi/R. Heilbronn, J. Kleinschmidt	55
Ca 61	V. Rotter/K.H. Richter (F. Marks)	55
Ca 62	B.-Z.Shilo/B.Mechler	55
Ca 64	S. Segal/F. Momburg (G. Hämmerling)	56
Ca 65	U.Zor, R. Goldmann/G. Fürstenberg, F. Marks	57
Ca 66	R. Apte/M. Zöller	58
Ca 67	G. Berke/P.Krammer	60
Ca 68	L. Eisenbach/M. Zöller	61
Ca 69	I. Witz/V. Schirrmacher	63
Ca 70	Y. Ben-Neriah/W. Dröge	63
Ca 71	Z. Fishelson/M. Kirschfink	64
Ca 72	Y. Shaul/Ch. Schröder	65
Ca 73	L. Sherman/M. Dürst	66
Ca 75	Y. Groner/M. Schwab.....	66
Ca 76	A. Hochberg/D. Komitowski.....	67
Ca 77	N. Arber/W. Pyerin	69
Ca 78	R. Bar-Shavit/P. Altevogt (V. Schirrmacher)	70
Ca 79	A. Ben-Ze'ev, B. Geiger/W. Franke.....	71
Ca 80	E. Canaani/R. Paro	72
Ca 81	A. Ciechanover/M. Scheffner	73
Ca 82	I. Friedberg/D. Kübler (V. Kinzel).....	73
Ca 83	A. Levitzki/F. Roesl	74
Ca 84	A. Panet/K-M. Debatin	74
Ca 85	A. Kimchi/M. Schwab.....	74
Ca 86	M. Oren/P. Krammer	75
Ca 87	E. Razin/P. Angel	76
Ca 88	G. Golomb/R. Berger	72
Ca 89	E. Keshet/N.E. Fusenig	77
Ca 90	I. Vlodavsky/V. Schirrmacher	78
Ca 91	Z. Fishelson/M. Kirschfink	78



Explanatory Notes

The following is an updated list of publications that have resulted from the joint projects carried out within the framework of the German-Israeli Cooperation Program in Cancer Research during the first 28 years of the Program, 1976 - 2004. The list of publications was originally intended to serve as a Bibliographic Supplement to the anniversary brochure entitled "German-Israeli Cooperation in Cancer Research: The First 20 Years", jointly issued by the Deutsches Krebsforschungszentrum (DKFZ) and the Israeli Ministry of Science (MOS). The list includes papers published in refereed journals, as well as articles and lectures published in books, but excluding conference abstracts and posters.

The 91 joint projects which have been successfully concluded during the period 1976 - 2002 are listed here according to their serial Ca-number, followed by the names and institutional affiliations of the Israeli and German partners. For each project, publications are listed in chronological order. Some publications have resulted from more than one project and therefore appear in the list more than once. However, in the overall statistics, such publications have been counted only once.

Of the 829 publications included in the list, 387 publications have resulted from the Israeli subprojects, 299 from the German subprojects, and 143 are joint publications co-authored by the Israeli and German partners. The joint publications are marked by an asterisk (*).

The Supplement of 1999 was updated to the present version in Spring 2005 covering now projects Ca 1 – Ca 91.



Ca 1 E. Winocour, Weizmann Institute of Science, Rehovot
G. Sauer, DKFZ, Heidelberg

- 1. Gluzman Y, Davidson J, Oren M and Winocour E**
Properties of permissive monkey cells transformed by UV-irradiated simian virus 40
J.Virol. 22, 256-266 (1977)
- 2. Gluzman Y, Kuff EL and Winocour E**
Recombination between endogenous and exogenous Simian virus 40 genes. I. Rescue of Simian virus 40 temperature-sensitive mutant by passage in permissive transformed monkey lines
J.Virol. 24, 534-540 (1977)
- 3. Vogel T, Gluzman Y and Winocour E**
Recombination between endogenous and exogenous Simian virus 40 genes. II. Biochemical evidence for genetic exchange
J.Virol. 23, 541-550 (1977)
- 4. Winocour E, Oron M, Lavi S, Vogel T and Gluzman Y**
Recombination events between Simian virus 40 and the host genome
In "Genetic Manipulation as it affects the Cancer Problem", J. Schultz, and Z. Brada, eds, Miami Winter Symposia, Academic Press, New York, Vol. 14, pp. 181-184 (1977)
- 5. Oren M, Lavi S and Winocour E**
The structure of a cloned substituted SV40 genome
Virology 85,404-421 (1978)
- 6. Hartman JR, Laub O, Aloni Y and Winocour E**
Transcription of the cellular DNA sequences in a cloned host-substituted SV40 DNA variant
Virology 94, 84-92 (1979)
- 7. Vogel T, Gluzman Y and Kohn N**
Altered restriction endonuclease cleavage pattern of SV40 DNA
J.Virol. 29, 153 (1979)
- 8. Vogel T**
Recombination between endogenous and exogenous Simian virus 40 genes. III. Rescue of SV40 tsA and tsBC mutants by passage in permissive transformed monkey lines
Virology 104, 73-83 (1980)
- 9. Winocour E, Singer M, and Kuff E**
The rapid detection, isolation and amplification of host-substituted SV40 variants
Cold Spring Harbor Symp. Quant. Biol. 44, 621-628 (1980)
- 10. Winocour E, Keshet I, Nedjar G and Vogel T**
Origins of SV40 genetic variation
Ann. N.Y. Acad. Sci. 354 (Genetic Variation in Viruses) 43-52 (1980)
- 11. Winocour E and Keshet I**
Indiscriminate recombination in SV40-infected monkey cells
Proc. Natl. Acad. Sci. USA 77, 4861-4865 (1980)
- 12.* Krieg P, Amtmann E, Sauer G, Lavi S, Kleinberger T and Winocour E**
The integrated SV40 genome in permissive transformed monkey cells
Virology 108, 453-461 (1981)

Ca 2 L. Sachs, Weizmann Institute of Science, Rehovot
W. Franke, DKFZ, Heidelberg

- 1. Lotem J and Sachs L**
Genetic dissection of the control of normal differentiation in myeloid leukemic cells



Proc. Natl. Acad. Sci. U.S.A. 74, 5554-5558 (1977)

2. Lotem J and Sachs L

In vivo induction of normal differentiation in myeloid leukemic cells

Proc. Natl. Acad. Sci. U.S.A. 75, 3781-3785 1978

3. Sachs L

Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukemia

Nature 274, 535-539 (1978)

4. Simantov R and Sachs L

Differential desensitization of functional adrenergic receptors in normal and malignant myeloid cells. Relationship to receptor mediated hormone cytotoxicity

Proc. Natl. Acad. Sci. U.S.A. 75, 1805-1809 (1978)

5. Simantov R and Sachs L

Cytoskeleton regulated B-adrenergic hormonal stimulation in normal and leukemic white blood cells

FEBS Letters 90, 69-70 (1978)

6. Sachs L

Diagnostic and therapeutic implications of cell cultures for human leukemia

In "Strategies in Clinical Hematology". Recent Results in Cancer Research, Springer, New York. Vol. 69, pp. 15-23 (1979)

7. Lotem J and Sachs L

Regulation of hormonal differentiation in mouse and human myeloid leukemic cells by phorbol esters and the mechanism of tumor promotion

Proc. Natl. Acad. Sci. U.S.A. 76, 5158-5162(1979)

8. Symonds G and Sachs L

Activation of chemotaxis in relation to other stages of normal differentiation in myeloid leukemia

Somat.Cell.Genet. 5, 931-944 (1979)

**Ca 3 M. Schlesinger, Hebrew University of Jerusalem
W. Dröge, DKFZ, Heidelberg**

1. Prebluda JL, Melmed RN, Rabinowitz R, and Schlesinger M

The relationship between cholera toxin receptor and the Thy-1 antigen determinants
Israel J.Med.Sci. 14, 876-881 (1978)

2. Schlesinger M and Kertes T

The formation of stable E-rosettes by human peripheral blood lymphocytes after short exposure to concanavalin A

Clin.immunol.Immunopathol. 12, 1-11 (1979)

3. Lobet S, Rabinowitz R and Schlesinger M

Mechanisms involved in the weak alloimmunogenicity of Thy-1 on mouse brain

Transplantation 28, 329-332 (1979)

4. Rabinowitz R, Laskov R and Schlesinger M

The effect of xenoantisera on T-lymphocyte functions in the absence of complement

In "Macrophages and Lymphocytes", M.R. Escobar and H. Friedman, eds., Plenum Publishing Corporation, pp. 247-260 (1980)

5. Rabinowitz R and Schlesinger M

Inhibition of the activity of cytotoxic murine T-lymphocytes by antibodies to idotypic determinants

Immunology 39, 93-99 (1980)



6. Rabinowitz R, Laskov R and Schlesinger M

Inhibition of cell-mediated lysis by xenoantibodies reactive with effector T-lymphocytes
Eur.J.Immunol. 10, 219-223 (1980)

7. Rabinowitz R and Schlesinger M

Reactivity of rat anti-Thy-1 serum with peripheral mouse T-lymphocytes
Transplantation 29, 173- 174 (1980)

8. Rabinowitz R and Schlesinger M

Relationship of Ly-3 and idiotypic determinants to the T-cell receptor
Transpl.Proc. 13. 1147-1149 (1981)

9. Schlesinger M, Rabinowitz R, Kertes T, Ravid L and Goldblum N

Antibodies to human T-lymphocytes in xenoantisera elicited with a new immature T-cell line
(Peer)

Thymus 2, 235-243 (1981)

Ca 4 R. Laskov, Hebrew University of Jerusalem
K. Eichmann, DKFZ, Heidelberg

1. Wallach M and Laskov R

A high production rate of translatable IgG mRNA accounts for the amplified synthesis of IgG
in myeloma cells

Eur.J.Biochem. 210, 545 (1980)

2. Wallach M, Yeshai-Michaeli R, Givol D and Laskov R

Analysis of immunoglobulin mRNA in murine myeloma cell variants defective in synthesis of
the light or heavy polypeptide chains

J.Immunol. 128, 684-690 (1982)

Ca 5 F. Doljanski, Hebrew University of Jerusalem
V. Kinzel, DKFZ, Heidelberg

1. Plesser YM, Doljanski F and Polliack A

Alteration in lymphocyte surface morphology and membrane fluidity induced by cholesterol
depletion

Cell.Molec.Biol. 25, 203-206 (1979)

2. Plesser YM, Weiss W, Markson Y and Doljanski F

Expression and shedding of major histocompatibility complex products and blood group
antigens by cells in monolayer cultures

Cell.Immunol. 51, 414-418 (1980)

3. Plesser YM, Weiss DW und Doljanski F

Cell-surface shedding by fibroblasts in culture

Israel J.Med.Sci. 16, 519-529 (1980)

4. Doljanski F

Cell surface shedding

In "The Glycoconjugates". M.I. Horowitz, ed. Vol. IV, Academic Press, pp. 157-187 (1981)

5. Kübler D, Pyerin W and Kinzel V

Protein kinase activity and substrates at the surface of intact Hela cells

J.Bio.Chem. 257, 322-329 (1982)

6. Kübler D, Pyerin W, and Kinzel V

Assays of cell surface protein kinase: Importance of selecting cytophilic substrates

Eur.J.Cell Biol. 26, 306-309 (1982)



7. Kübler D, Pyerin W, Burow E and Kinzel V

Substrate-effected release of surface-located protein kinase from intact cells
Proc. Natl. Sci, USA 80, 4021-4025 (1983)

**Ca 7 E. Shaaya, Hebrew University of Jerusalem
E. Sekeris, DKFZ, Heidelberg**

1. Shaaya E

Differential effect of ecdysone on RNA synthesis in the epidermal cells of Calliphora during development

Gen.Comp.Endoc. 34, 110 (1978)

2. Shaaya E

Synthesis of giant HnRNA in the epidermal cells of Calliphora and the role of the ring gland
Hoppe-Seyler's Z.Physiol.Chem. 360, 445-449 (1979)

**Ca 8 J. Haimovich, Tel Aviv University
P. Krammer, DKFZ, Heidelberg**

1. Blatt C and Haimovich J

The selective effect of tunicamycin on the secretion of IgM and IgG produced by the same cells

Eur.J.Immunol. 11, 65 (1981)

2. Marcucci F, Waller M, Kirchner H and Krammer PH

Production of immune interferon (IFN- γ) by murine T cell clones from long term cultures
Nature 291, 79-81 (1981)

3. Waller M, Marcucci F, Kirchner H, Michnay A and Krammer PH

A simple method for cryopreservation of murine T cell clones from long term cultures
Immunol.Letters 3, 263-266 (1981)

4. Krammer PH, Marcucci F, Waller M and Kirchner H

Heterogeneity of soluble T cell products. I. Precursor frequency and correlation analysis of cytotoxic and immune interferon (IFN- γ) producing spleen cells in the mouse
Eur.J.Immunol. 3, 200-204 (1982)

5. Krammer PH and Michnay A

Heterogeneity of soluble T cell products. III. Frequency of T cell growth factor producing murine spleen cells

In "Mechanisms of Lymphocyte Activation", Resch, K, Kirchner, H: (eds.), Elsevier/North Holland Biomed. Press, 357-360 (1981)

6. Staber F, Hültner L, Marcucci F and Krammer PH

Production of colony stimulating factors by murine T cells in limiting dilution and long term cultures

Nature 298, 79-82 (1982)

7. Krammer PH, Kees U, Marcucci F and Kirchner H

Immune interferon production by T cell clones

In "Interferon", Munk, K, Kirchner, H. (eds.) Contributions to Oncology 2, 144-149 (1982)

8. Kirchner H, Marcucci F, Zawatzky R and Krammer PH

The producer cells of interferon in murine lymphocyte cultures

In "The Biology of the Interferon System". De Maeyer, Galasso and Schellekens (eds.)
Elsevier/ North Holland, pp. 271-274 (1981)

9. Kirchner H, Marcucci F, Krammer PH, Landolfo S, Zawatzky R and Simon MM



The Producer cell of Interferon in murine lymphocyte cultures
In "The Interferon System. A review to 1982 - Part I. Texas Reports on Biology and Medicine", Vol. 41, 1981-1982 (Baron, S, Dianzani, F, Stanton, J, eds.) The University of Texas Medical Branch at Galveston, pp. 89-93

10. Marcucci F, Kirchner H and Krammer PH

Production of interferon- γ (IFN- γ) and IFN- α/β by a mouse lymphocyte clone from long term cultures in T cell growth factor

In "Mechanisms of Lymphocyte Activation". Resch, K, Kirchner, H, eds. Elsevier/North-Holland Biomed.Press, pp. 588-590 (1981)

11. Pawelec G, Borowitz A, Krammer PH and Wernet P

Constitutive interleukin-2 production by the Jurkat human leukaemic T cell line
Europ.J.Immunol. 12, 387-392 (1982)

12. Eichmann K, Goronzy J, Hamann U, Krammer PH, Kuppers RC, Melchers I, Simon MM and Zahn G

Clonal analysis of helper and cytolytic T cells. Multiple, independently regulated precursor sets at frequencies suggesting a limited repertoire

In "Isolation, Characterization and Utilization of T Lymphocyte Clones". Fathman, G. and Fitch, F. (eds.) Academic Press, N.Y, pp. 134-244 (1982)

13. Krammer PH, Dy M, Hültner I, Isakson P, Kees U, Lohmann-Mattes M-L, Marcucci F, Michnay A, Purç E, Schimpl A, Staber F, Vitetta E and Waller M

Production of lymphokines by murine T cells grown in limiting dilution and long term cultures
In "Isolation, Characterization and Utilization of T Lymphocyte Clones". Fathman, G. and Fitch, F. (eds.) Academic Press, N.Y, pp 253-262 (1982)

14. Isakson P, Purç E, Vitetta ES and Krammer PH

T cell derived B cell differentiation factors. Effect on the isotype switch of murine B cells
J.Exp.Med. 155, 734-748 (1982)

15. Krammer PH, Kees U, Hültner L, Staber FG, Kirchner H and Marcucci F

Analysis of lymphokine production by T cell clones. Relationship between specific and non-specific immunity

In "Hemalology Today" (Baum, S.J, Ledney, G.D, eds.) Karger, Basel, pp. 27-29 (1982)

16. Marcucci F, Nowak M, Krammer PH and Kirchner H

Production of high titers of interferon- γ by cells derived from short-term cultures of murine spleen leukocytes in T cell growth factor conditioned medium
J.Gen.Virol. 60, 195-198 (1982)

17. Northoff H, Stoeck M and Krammer PH

Effect of Phorbol-Myristate Acetate and Concanavalin A on the growth of Interleukin-2 dependent T cell lines
Immunobiology 161, 464-475 (1982)

18. Krammer PH, Dy M, Falk W, Gemsa D, Hultner L, Isakson P, Kees U, Kirchner H, Lohmann-Mattes M-L, Marcucci F, Purç E, Schimpl A, Staber F and Vitetta ES

Aspects of alloreactivity: Lymphokine release from alloreactive T cell clones in long term culture

In "B and T cell tumors". UCLA Symposium on Molecular and cellular Biology, Volume XXIV (Vitetta, E.S, ed.) Academic Press, New York, N.Y, pp. 107-113 (1982)

19. Isakson P, Purç E, Vitetta ES and Krammer PH

T cell derived B cell differentiation factors (BCDF): Definition of BCDFu and BCDF
In "B and T cell tumors", UCLA Symposium on Molecular and Cellular Biology, Volume XXIV (Vitetta, E.S, ed.) Academic Press, New York. N.Y, pp. 391-399 (1982)

20. Purç E, Isakson PL, Paetkau V, Caplan B, Vitetta ES and Krammer PH

Interleukin-2 does not induce murine B cells to secrete Ig
J.Immunol. 129, 2420-2425 (1982)

21. Kaltmann B, Gemsa D, Hültner L, Kees U, Marcucci F and Krammer PH



Production of Lymphokines by T cell hybridomas derived from a fusion of the AKR T cell tumor BW5147 and a selected high producer T cell clone in long term culture
In "Interleukins, Lymphokines, and Cytokines" (J.J. Oppenheim, S. Cohen, eds.) Academic Press, N.Y, pp 589-595 (1983)

22. Vitetta ES, Isakson PC, Purç E and Krammer PH

Identification and characterization of a lymphokine which induces murine B cells to secrete IgG

In "Interleukins, Lymphokines, and Cytokines" (J.J. Oppenheim, S. Cohen, eds.) Academic Press, N.Y, pp. 153-158 (1983)

23. Gemsa D, Debatin K-M, Kubelka C, Kramer W, Deimann W, Kees U and Krammer PH

Macrophage activating factors from different T cell clones induce distinct macrophage functions

J.Immunol. 131, 833-844 (1983)

24. Purç E, Isakson P, Kappler JW, Marrack P, Krammer PH, Vitetta ES

T cell derived B cell growth and differentiation factors: Dichotomy between the responsiveness of B cells from adults and neonatal mice

J.Exp.Med. 157, 600-612 (1983)

25. Brooks K, Yuan D, Uhr J, Krammer PH and Vitetta ES

Lymphokine-induced IgM secretion by clones of neoplastic B cells (BCL1)

Nature 302, 825-826 (1983)

26. Layton IE, Uhr JW, Purç.E, Krammer PH and Vitetta ES

T cell derived B cell growth (BCGF) and differentiation (BCDF) factors: Suppression of BCDF but not BCGF activity by bone marrow cells

J.Immunol. 130, 2502-2504 (1983)

27. Kaltmann B, Gemsa D, Hültner L, Kees U, Marcucci F and Krammer PH

Segregation of production of macrophage activating factor (MAF), colony stimulating factor (CSF) and immune intercyferon (IFN- γ) in T cell hybridomas derived from a fusion with a selected high producer T cell clone in long term culture secreting all three lymphokines

In "Intercellular communication in Leucocyte Function" (J.W. Parker and R.L. O'Brien eds.) John Wiley & Sons Ltd, Acad. Press, N.Y, pp. 51-54 (1983)

28. Krammer PH

Immuninterferon-Produktion in Lymphozytenkulturen

Jahresbericht des Deutschen Krebsforschungszentrums. pp. 94-96 (1981)

Ca 9 S. Lavi, E. Winocour, Weizmann Institute of Science,
Rehovot

G. Sauer, DKFZ, Heidelberg

1. Lavi S and Etkin S

Carcinogen-mediated induction of SV40 DNA synthesis in SV40 transformed Chinese hamster embryo cells

Carcinogenesis 2, 417-423 (1981)

2. Lavi S

Carcinogen-mediated amplification of viral DNA sequences in SV40-transformed Chinese hamster embryo cells

Proc. Natl. Acad. Sci. U.S.A. 78, 6144-6148 (1981)

3. Lavi S

Carcinogen-mediated amplification of specific DNA sequences

J.Supramolecular Structure & Cellular Biochem. 18, 149-156 (1982)



4. Lavi S

Carcinogen-mediated activation of SV40 replicons: a model system for initiation of carcinogenesis
In "Gene Amplification", R.T. Chimke, ed, Cold Spring Harbor Laboratory, pp. 225-250 (1982)

Ca 11 T. Mekori, E. Robinson, Technion, Haifa H. Kirchner, E Storch, DKFZ, Heidelberg

1. Robinson E, Bartal A, Cohen Y, Haim N, Mohilever J and Mekori T

Combined adjuvant therapy of radically operated colo-rectal cancer patients (chemotherapy, radiotherapy and MER-BCG)
Cancer Chemother.Pharmacol. 8, 35-40 (1982)

2. Storch E and Kirchner H

Induction of interferon in murine bone marrow-derived macrophage cultures by 10-carboxymethyl-9-acridanone
Eur.J.Immunol. 12, 793-796 (1982)

Ca 12 D. Sulitzeanu, Hebrew University of Jerusalem M. Zöller, S. Matzku, DKFZ, Heidelberg

1. Gilead Z, Troy FA and Sulitzeanu D

Isolation and electrophoretic analysis of immune complexes from patients with breast cancer
Eur.J.Cancer Clin.Oncol. 17, 1165-1176 (1981)

2. Gilead Z, Gazitt Y, Klein G and Sulitzeanu D

Purification and analysis of immune complexes with the aid of tubes coated with Rheumatoid Factor
Methods Enzymol. 74, 654-675 (1981)

3. Gilead Z, Gazitt Y and Sulitzeanu D

An improved technique for the isolation and analysis of immune complexes
J.Immunol.Methods 42, 67-77 (1981)

4. Gazitt Y, Gilead Z, Klein G and Sulitzeanu D

A technique for the identification of glycoprotein antigens in immune complexes. Application of this technique to the detection of a common glycoprotein in sera of patients with Burkitt's lymphoma and Nasopharyngeal carcinoma
J.Immunol.Methods 43, 49-57 (1981)

5. Sulitzeanu D

Markers in breast cancer
Israel J.Med.Sci. 17, 865-868 (1981)

6. Gilead Z, Hatzubai A and Sulitzeanu D

Antigens in immune complexes from patients with breast cancer. Identification of autoantigens in immune complexes isolated from breast cancer effusions
Cancer Immunol.Immunotherapy 11, 153-157 (1982)

7. Gazitt Y, Klein G and Sulitzeanu D

Reactivity with patient antibodies of partially purified gp40 antigen from immune complexes in Burkitt's lymphoma and nasopharyngeal carcinoma
Int.J.Cancer 29, 645-651 (1982)

8. Matzku S, Zöller M, Schulz U, Dietze W, Earth HO, Saeger HD and Price MR



Lack of correlation between carcinoembryonic antigen content of tumor extracts and leukocyte migration reactivity of tumor patients
J.Natl.Cancer Inst. 64, 1345-1348 (1980)

9. Matzku S, Zöller M, Ikinge U and Price MR

Organ-related and malignancy-associated reactivity of cancer patients' leucocytes: a leucocyte migration study with tumor and fetal extracts
Br.J.Cancer 42, 516-523 (1980)

10. Zöller M, Matzku S, Schulz U and Price MR

Sensitization of leukocytes of cancer patients against fetal antigens: leukocyte migration studies
J.Natl.Cancer Inst. 63, 285-293 (1979)

Ca 13 A.J. Treves, S. Biran, Hadassah University Hospital,
Jerusalem
W. Dröge, V. Schirmacher, DKFZ, Heidelberg

1. Treves AJ, Barak V and Fuks Z

Characterization of human lymphocytes which proliferate "spontaneously" in vitro
Eur.J.Immunol. 10, 883-887 (1980)

2. Treves AJ, Barak V and Fuks Z

Antigen presentation and regulatory functions of human monocytes
Eur.J.Immunol. 11, 487-492 (1981)

3. Treves AJ, Haimovitz A and Fuks Z

Changes in surface markers of human monocytes following their in vitro maturation to macrophage
In "Macrophages and Natural Killer Cells", Normann & Sorken, eds, Plenum Press N.Y, pp. 227-232 (1982)

4. Haimovitz A, Fuks Z, Galilli N and Treves AJ

Changes in peanut agglutinin binding to human monocytes during their maturation to macrophages
J.Reticuloendothelial Soc. 31 187-192 (1982)

5. Horowitz AT, Fuks Z, Okon E, Biran S and Treves AJ

The use of carcinoembryonic antigen for identification of human tumor cells in malignant effusions
Oncology 40, 18-25 (1983)

6. Carrol J, Fuks Z, Catane R, Fridkin M and Treves AJ

The effect of tuftsin on human monocyte cytotoxicity
J.Biol.Response Modif. 1, 245 (1983)

Ca 14 E. Pick, Tel Aviv University
D. Gemsa, H. Kirchner, DKFZ, Heidelberg

1. Pick E and Keisari Y

A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture
J.Immunol.Meth. 38, 161-171 (1980)

2. Pick E, Keisari Y and Bromberg Y



Mode of action of lymphokines: Are oxygen metabolites the intra- and extracellular mediators of lymphokine-induced macrophage activation?
In "Advances in Allergology and Immunology", A. Oehling et al, eds, Pergamon Press, 399-407 (1980)

3. Lapp WS, Mendes M, Kirchner H and Gemsa D

Prostaglandin synthesis by lymphoid tissue of mice experiencing a graft-versus-host reaction: Relationship to immunosuppression
Cell.Immunol. 50, 271-281 (1980)

4. Pick E and Keisari Y

Superoxide anion and hydrogen peroxide production by chemically elicited peritoneal macrophages - Induction by multiple non-phagocytic stimuli
Cell.Immunol. 59, 301-318 (1981)

5. Bromberg Y and Pick E

Activation of macrophage adenylate cyclase by stimulants of the oxidative burst and by arachidonic acid. Two distinct mechanisms
Cell.Immunol. 61, 90-103 (1981)

6. Keisari Y and Pick E

Macrophage mediated cytolysis of erythrocytes in the guinea pig. I. Activation by stimulators of the oxidative burst
Cell.Immunol. 62, 172-186 (1981)

7. Pick E, Keisari Y, Bromberg Y, Freund M and Jakubowski A

The oxidative burst in macrophages - Generation of superoxide and hydrogen peroxide; lipid peroxidation and effect on cyclic nucleotide levels
In "Heterogeneity of Mononuclear Phagocytes", O. Forster and M. Landy, eds, Academic Press, London, pp. 331-336 (1981)

8. Keisari Y and Pick E

Nonspecific induction of macrophage mediated cytotoxicity by stimulators of oxygen metabolite generation in macrophages
In "Heterogeneity of Mononuclear Phagocytes", O. Forster and M. Landy, eds, Academic Press, London, pp. 346-347 (1981)

9. Pick E and Mizel D

Role of transmethylation in the elicitation of an oxidative burst in macrophages
Cell.Immunol. 72, 277-285 (1982)

10. Pick E, Keisari Y, Bromberg Y and Freund M

Effect of tumor promoters in immunological systems - The macrophage as a target cell for the action of phorbol esters
In "Carcinogenesis", Vol. 7, Carcinogenesis and Biological Effects of TPromoters, E. Hecker, ed, Raven Press, New York, pp. 625-635 (1982)

11. Pick E, Bromberg Y and Freund M

Extrinsic regulation of macrophage function by lymphokines - Effect of lymphokines on stimulated oxidative metabolism of macrophages
In "Macrophages and Natural Killer Cells". Plenum Press, New York, 471-485 (1982)

12. Pick E and Bromberg Y

Quo vadis macrophage activation - Role of phospholipids in the elicitation of the oxidative burst in macrophages
Transpl. Proc. 14, 570-575 (1982)

13. Pick E and Bromberg Y

Regulation of macrophage function by Lymphokines - Role of membrane phospholipids
In "Proceedings of the 2nd International Congress of immunopharmacology", Pergamon Press, Oxford, 243-249 (1983)

14. Bromberg Y and Pick E



Oxidative metabolism of lymphokine activated macrophages - Free fatty acids as second messengers of superoxide generation
In "Proceedings of the 3rd International Lymphokine Conference", Academic Press, New York, 561-567 (1983)

15. Pick E and Freund M

Biochemical mechanisms of macrophage activation by lymphokines
In "Proceedings of the 11th International Congress of Allergology", Macmillan, London, 483-487 (1983)

**Ca 15 D. Givol, P. Lonai, Weizmann Institute of Science, Rehovot
K. Eichmann, DKFZ, Heidelberg**

1. Ben-Neriah Y, Givol D and Lonai P

Allotype-linked genetic control of a polymorphic VH framework determinant on mouse T-helper cell receptors
Nature 285, 257 (1980)

2.* Eichmann K, Ben-Neriah Y, Hetzelberger D, Polke C, Givol D and Lonai P

Correlated expression of VH framework and VH idiotypic determinants on T helper cells and on functionally undefined T cells binding group A streptococcal carbohydrate
Eur.J.Immunol. 10, 105 (1980)

3. Puri J, Ben-Neriah Y, Givol D and Lonai P

Antibodies to immunoglobulin heavy chain variable regions protect helper cells from specific suicide by radiolabeled antigen
Eur.J.Immunol. JO, 105 (1980)

4. Zakut R, Givol D and Mory YY

Structure of immunoglobulin Y2b heavy chain gene cloned from mouse embryo gene library
Nucleic Acids Res. 8, 453 (1980)

5. Zakut R, Cohen J and Givol D

Cloning and sequence of the cDNA corresponding to the variable region of immunoglobulin heavy chain MPC11
Nucleic Acids Res. 8, 3591 (1980)

6. Eshhar Z, Apte RN, Ben-Neriah Y, Givol D and Mozes E

T-cell hybridoma bearing heavy chain variable region determinants producing (T,G)-A-L specific helper factor
Nature 286, 270 (1980)

7.* Ben Neriah Y, Givol D, Lonai P, Simon MM and Eichmann K

Allotype linked genetic control of a polymorphic VH framework determinant on mouse T-helper cell receptors
Nature 285, 257 (1980)

8. Givol D, Zakut R, Effron K, Rechavi G, Ram D and Cohen JB

The diversity of germ-line VH genes
Nature 292, 426 (1981)

9. Ben-Neriah Y, Cohen JB, Rechavi G and Givol D

Polymorphism of germ-line immunoglobulin VH genes correlates with allotype and idiotype markers
Eur.J.Immunol. 11, 1017-1020 (1981)

10.* Lonai P, Puri J and Haemmerling GJ

H-2 restricted antigen binding by a hybridoma clone that produces antigen specific helper factor
Proc. Nat. Acad. Sci. 78, 549 (1981)



11.* Lonai P, Puri J, Bitton S, Ben-Neriah Y, Givol D and Haemmerling GJ

H-2 restricted helper factor secreted by cloned hybridoma cells
J.Exp.Med. 154, 942 (1981)

12.* Lonai P, Haemmerling GJ, Givol D, Ben-Neriah Y and Puri J

Specific T-helper factor production and H-2 restricted antigen binding by helper cells: studies with T-hybridoma clones

In "Monoclonal Antibodies and T Hybridomas", G.J. Haemmerling, H. Haemmerling and J.F. Kearney, eds, Elsevier, pp. 457-468 (1981)

13.* Lonai P, Arman E, Bitton-Grossfeld S, Grooten J and Haemmerling G

H-2 restricted helper hybridomas: One locus or two control dual specificity?

Curr.Top.Microbiol.Immunol. 100, 97-102 (1982)

14.* Lonai P, Arman E, Savelkoul HFC, Friedman V, Puri J and Haemmerling G

Factors, receptors, and their ligands: studies with H-2 restricted helper hybridoma clones

In "Isolation, Characterization and Utilization of T Lymphocyte Clones. C.G. Fathman and F.W. Fitch, eds, Academic Press, New York, pp. 109-117 (1982)

15.* Lonai P, Puri J and Haemmerling GJ

T hybridoma cells that produce genetically restricted helper factors and bind the carrier in association with Ia

Lymphokine 5, 197-221 (1982)

**Ca 16 R. Ben-Ishai, Technion, Haifa
H.W. Thielmann, DKFZ, Heidelberg**

1. Miskin R and Ben-Ishai R

Induction of plasminogen activator by ultraviolet light in normal and xeroderma pigmentosum fibroblasts

Proc. Natl. Acad. Sci. 78, 6236-6240 (1981)

2. Hagedorn R, Thielmann HW, Fischer H and Schroeder CH

SV40-induced transformation and T-antigen production is enhanced in normal and repair-deficient human fibroblasts after pretreatment of cells with UV light

J.Cancer Res.Clin.Oncol. 106, 93-96 (1983)

3. Hsie AW, Recio L, Schenley RL and Thielmann HW

Quantitative analysis of mammalian cell mutagenesis

Mutagenesis and Genetic Toxicology 119, 137-152 (1983)

4. Hagedorn R, Thielmann HW and Fischer H

SOS-type functions in mammalian cells

J.Cancer Res.Clin.Oncol. 109, 89-92 (1985)

5. Thielmann HW, Hagedorn R and Freber W

Evaluation of colony-forming ability experiments using normal and DNA repair-deficient human fibroblast strains and an automatic colony counter

Cytometry 6, 130-136 (1985)

**Ca 17 R. Simantov, Weizmann Institute of Science, Rehovot
F. Marks, DKFZ, Heidelberg**

1. Simantov R and Sachs L

Role of phospholipase A2 and prostaglandin E in growth and differentiation of myeloid leukemic cells

Biochim.Biophys.Acta 720, 111-119 (1982)



2. Simantov R and Sachs L

Enhancement of hormone action by a phorbol ester and anti-tubulin alkaloids involves different mechanisms

Biochim.Biophys.Acta 720, 120-125 (1982)

3.* Simantov R, Marks F, Fuerstenberger G and Sachs L

Control of endogenous cell regulators by the second stage tumor promoter phorbol-12-retinoate 13-acetate

Int.J.Cancer 31, 497-500 (1983)

Ca 18 S. Segal, E. Gorelik, Ben-Gurion University, Beer-Sheva G. Hämmerling, V. Schirmacher, DKFZ, Heidelberg

1.* Wallich R, Bulbuc N, Hämmerling GJ, Katzav S, Segal S and Feldman M

Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection

Nature 315, 301-305 (1985)

2.* Hämmerling GJ, Klar D, Katzav S, Segal S, Feldman M, Wallich R and Hämmerling A

Manipulation of metastasis and tumor growth by transfection with histocompatibility class I genes

J.Immunogen. 13, 153-157 (1986)

3.* Eisenbach L, Katzav S, Hämmerling G, Segal S and Feldman M

Gene products of the major histocompatibility complex control the metastatic phenotype of tumor cells

In "Biochemistry and Molecular Genetics of Cancer Metastasis". (Lapis, K, Liolta, L.A. and Rabson, A.S. (eds), Martinus Nijhoff. Boston, pp 167-184 (1986)

4.* Alon Y, Hämmerling GJ, Segal S and Bar-Eli M

Association in the expression of Kirsten-ras oncogene and the MHC complex class I antigens in fibrosarcoma tumor cell variants exhibiting different metastatic capabilities

Cancer Res. 47, 2553-2557 (1987)

5.* Rager-Zisman B, Gopas J, Bar-Eli M, Har-Vardi I, Hämmerling GJ and Segal S

NK sensitivity, H-2, Ki-ras proto-oncogene expression and metastasis: Analysis of the metastatic potential of H-2 gene transfected fibrosarcoma cells

Adv.Exp.Med.Biol. 233, 151-160 (1988)

6.* Gopas J, Segal S, Hämmerling GJ, Bar-Eli M and Rager-Zisman B

Influence of H-2K transfection on susceptibility of fibrosarcoma tumor cells to natural killer (NK) cells

Immunology Letters 17, 261-266 (1988)

7.* Gopas J, Rager-Zisman B, Bar-Eli M, Harva I, Hämmerling G and Segal S

The immunobiology of metastatic processes. Analysis of NK sensitivity and the metastatic potential of H-2 gene transfected fibrosarcoma cells

Natural Immunity and Cell Growth Regulation, 7, 155-162 (1988)

8.* Gopas J, Rager-Zisman B, Bar-Eli M, Hämmerling GJ and Segal S

The relationship between MHC antigen expression and metastasis

Advances in Cancer Research 53, 89-115 (1989)

9.* Hämmerling GJ, Sturmhofel K, Strauss G, Momburg F, Gopas J and Segal S

The influence of murine and human major histocompatibility complex class I expression on tumor growth and metastasis

In "Cancer Metastasis" (Schirmacher, V. and Schwartz-Albiez, R. eds.), Springer-Verlag. Berlin Heidelberg, pp. 121-128 (1989)



10.* Rager-Zisman B, Aboud M, Gopas J, Har-Vardi I, Hämmerling GJ and Segal S
Resistance to NK and metastatic potential of fibrosarcoma cells is associated with products encoded by the H-2D region
In "Seminars in Cancer Biology". (Eds) E. Klein, W.B. Saunders Company, 1991

Ca 19 E. Canaani, Weizmann Institute of Science, Rehovot
T. Graf, DKFZ, Heidelberg

1. Shtivelman E, Zakut R and Canaani E

Frequent generation of nonrescuable reorganized murine sarcoma viral genomes
Proc. Natl. Acad. Sci. U.S.A. 81, 294-298 (1984)

2. Canaani E, Steiner-Saltz D, Aghai E, Gale RP, Berrebi A and Januszewicz E

An altered expression of an oncogene in chronic myeloid leukemia
The Lancet I, 593-595 (1984)

3. Gale RP and Canaani E

An 8-kilobase abl RNA transcript in chronic myelogenous leukemia
Proc. Natl. Acad. Sci. U.S.A. 81, 5648-5652 (1984)

4. Shtivelman E, Lifshitz B, Gale RP and Canaani E

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
Nature 315, 550-554 (1985)

Ca 20 M. Herzberg, Tel Aviv University
D. Werner, K. Munk, DKFZ, Heidelberg

1. Herzberg M, Nethanel T, Bibor-Hardy V and Wreschner DH

Location of RNase activity in nuclear residual structure
Biol.Cell 49, 11-17 (1983)

2. Wreschner DH and Herzberg M

A new blotting medium for the simple isolation and identification of highly resolved messenger RNA

Nucleic Acids Res. 12, 1349-1359 (1984)

3. Neuer B, Plagens U and Werner D

Phosphodiester bonds between polypeptides and chromosomal DNA
J.Mol.Biol. 164, 213-235 (1983)

4. Müller M, Spiess E and Werner D

Fragmentation of nuclear matrix on a mica target
Europ.J.Cell Biol. 31, 158-166 (1983)

5* Werner D, Chemla Y and Herzberg M

Isolation of poly(A) RNA by paper affinity chromatography
Anal.Biochem, 141. 329-336 (1984)

6. Werner D, Shi Ch, Müller M, Spiess E and Plagens U

Antibodies to the most tightly bound proteins in eukaryotic DNA. Formation of immunocomplexes with 'nuclear matrix' components

Exp.Cell.Res. 151, 384-395 (1984)



Ca 21 J. Kapitulnik, R. Koren, Hebrew University of Jerusalem
F. Kolar, N. Fusenig, DKFZ, Heidelberg

1.* Tinenbaum T, Giloh H, Fusenig NE and Kapitulnik J

A rapid procedure for flow cytometric DNA analysis in cultures of normal and transformed epidermal cells

J.Invest.Dermatol. 90, 857-860 (1988)

2. Kolar GF and Habs M

3,7-Bis-(4-trifluoromethylphenyl)-1,5,3,7-dioxadiazocine: A novel cyclic product from a reaction of 4-trifluoromethyl-benzenediazonium chloride and methylamine-formaldehyde
Tetrahedron Letters 26 (8), 1043-1044 (1985)

Ca 22 B. Geiger, Weizmann Institute of Science, Rehovot
W. Franke, DKFZ, Heidelberg

1.* Franke WW, Schmid E, Grund C and Geiger B

Intermediate filament proteins in non-filamentous structures: Transient disintegration and inclusion of subunit proteins in granular aggregates

Cell 30, 103-113 (1982)

2.* Geiger B, Schmid E and Franke WW

Spatial distribution of proteins specific for desmosomes and adherens junctions in epithelial cells demonstrated by double immunofluorescence microscopy

Differentiation 23, 189-205 (1983)

3.* Kartenbeck J, Schmid E, Franke WW and Geiger B

Different modes of internalization of proteins associated with adherens junctions and desmosomes: Experimental separation of lateral contacts induces endocytosis of desmosomal plaque material

EMBO 1.1, 725-732 (1982)

4.* Schiller DL, Franke WW and Geiger B

A subfamily of relatively large and basic cytokeratin polypeptides as defined by peptide mapping is represented by one or several polypeptides in epithelial cells

EMBO J. 1, 761-769 (1982)

5.* Moll R, Franke WW, Schiller D, Geiger B and Krepler R

The catalogue of human cytokeratin polypeptides: Patterns of expression of specific cytokeratins in normal epithelia, tumors and cultured cells

Cell 31, 11-24 (1982)

6.* Gigi O, Geiger B, Eshhar Z, Moll R, Schmid E, Winter S, Schiller DL and Franke WW

Detection of a cytokeratin determinant common to diverse epithelial cells by a broadly 3. cross-reacting monoclonal antibody

EMBO J. 1, 1429-1437 (1982)

7.* Kreis TE, Geiger B, Schmid E, Jorcano JL and Franke WW

De novo synthesis and specific assembly of keratin filaments in non-epithelial cells after microinjection of mRNA for epidermal keratin

Cell 32, 1125-1137 (1983)

8.* Franke WW, Schmid E, Wellstead J, Grund C, Gigi O and Geiger B

Change of cytokeratin filament organization during the cell cycle: Selective masking of an immunologic determinant in interphase PtK2 cells

J.Cell Biol. 97, 1255-1260 (1983)

9.* Geiger B, Schmid E and Franke WW



Desmosomes and adherens junctions: Spatial distribution of junctional and cytoskeletal proteins in epithelial cells demonstrated by double immunofluorescence microscopy
Differentiation 23, 189-205 (1983)

10.* Geiger B, Kreis TE, Gigi O, Schmid E, Mittnacht S, Jorcano JL, von Bassewitz DB and Franke WW

Dynamic rearrangements of cytokeratins in living cells
Cold Spring Harbor Symp. on Cancer Cells I, 201-215 (1983)

11. Huszar M, Halkin H, Hertzeg E, Bubis J and Geiger G

Use of antibodies to intermediate filaments in the diagnosis of metastatic amelanotic malignant melanoma

Human Pathol. 14, 1006-1008 (1983)

12. Huszar M, Hertzeg E, Lieberman Y and Geiger B

Distinctive immunofluorescent labeling of epithelial and mesenchymal elements of carcinosarcoma with antibodies specific for different intermediate filaments

Human Pathol. 15, 532-538 (1984)

13.* Blobel G, Could VE, Lee I, Huszar M, Geiger B and Franke WW

Coexpression of neuroendocrine marker substances and epithelial cytoskeletal proteins in neuroendocrine neoplasms of the bronchopulmonary tract

Lab.Invest. 52, 39 (1985)

14. Geiger B, Avnur Z, Volberg T and Volk T

Molecular domains of adherens junctions

In "Cell in Contact: Adhesions and Junctions as Morphogenetic Determinants", G.M. Edelman and J.-P. Thiery, eds, pp. 461-489 (1985)

15. Shusler S, Huszar M and Geiger B

Immunofluorescent localization of intermediate filament subunits for the differential diagnosis of malignant melanoma

Am.J.Dermatopathol. 7, 79-86 (1985)

16. Geiger S, Czernobilsky B, Marshak G, Geiger B

Embryonal rhabdomyosarcoma: Immunohistochemical study

Oral Surgery, Oral Medicine, Oral Pathology 60, 517-523 (1985)

17.* Huszar M, Gigi-Leitner O, Moll R, Franke WW and Geiger B

Polypeptidc specific monoclonal antibodies in the differential diagnosis of squamous carcinomas and adenocarcinomas

Differentiation 31 141-153 (1986)

18. Gigi-Leitner O and Geiger B

Antigenic interrelationships between 40 Kd cytokeratin polypeptide and desmoplakin

Cell Motility and the Cytoskeleton 6, 628-639 (1986)

19. Gigi-Leitner O, Geiger B, Levy R and Czernobilsky B

Cytokeratin expression in squamous metaplasia of the human uterine cervix

Differentiation 31, 191-205 (1986)

20.* Volberg T, Geiger B, Kartenbeck J and Franke WW

Changes of membrane microfilament interaction in intercellular adherens junctions upon removal of extracellular Ca^{2+} ions

J.Cell Biol. 192, 1832-1842 (1986)

Ca 23 U.Z. Littauer, I. Ginzburg, Weizmann Institute of Science,
Rehovot
H. Ponstingl, DKFZ, Heidelberg

1. Ginzburg I and Littauer UZ



Expression and cellular regulation of microtubule proteins
In "Molecular Biology of the Cytoskeleton", Cold Spring Harbor Laboratory, pp. 357-366
(1984)

2. Ginzburg I and Littauer UZ

The expression of microtubule proteins during the development of the nervous system
In "Molecular Basis of Nerve Activity". J.P. Changcux et al, eds, Berlin, Gruyter p. 589
(1985)

3. Ginzburg I, Teichman A, Dodemont L, Behar L and Littauer UZ

Regulation of three beta-tubulin mRNAs during rat brain development
EMBO J. 4, 3667-3673 (1985)

4.* Littauer UZ, Giveon D, Thierauf M, Ginzburg I and Ponstingl H

Tubulin binding sites for microtubule associated proteins
In "Microtubules and Microtubule Inhibitors". M. De Brabander and J. De Mey, eds,
Amsterdam, Elsevier, pp. 171 -176 (1985)

5.* Littauer UZ, Giveon D, Thierauf M, Ginzburg I and Ponstingl H

Common and distinct tubulin binding sites for microtubule-associated proteins
Proc. Natl. Acad. Sci. U.S.A. 83, 7162-7166 (1986)

6. Ginzburg I, Teichman A and Littauer UZ

Isolation and characterization of two rat alpha-tubulin isotypes
Ann. N.Y. Acad. Sci. 466, 31-40 (1986)

7. Ginzburg I and Littauer UZ

The expression of microtubule proteins during the development of the nervous system
In "Role of RNA and DNA in brain function. A molecular biological approach" (A. Giuditta,
B.B. Kaplan and C. Zamzely-Neurath, eds.). Martinus Nijhoff Publishing, pp. 81-89 (1986)

8.* Littauer UZ, Giveon D, Thierauf M, Ginzburg I and Ponstingl H

Common and unique tubulin binding sites for MAP2 and Tau as a mechanism for microtubule
divergence

Annale de Desarrollo, Spanish Journal of Developmental Biology 31. Supplement, 27 (1987)

**Ca 24 I. Vlodavsky, Hadassah University Hospital, Jerusalem
V. Schirmmacher, DKFZ, Heidelberg**

1.* Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y and Schirmmacher V

Lymphoma cell mediated degradation of sulfated proteoglycans in the subendothelial
extracellular matrix: Relationship to tumor cell metastasis
Cancer Res. 43, 2704-2711 (1983)

2.* Vlodavsky I, Fuks Z and Schirmmacher V

In vitro studies on tumor cell interaction with the vascular endothelium and subsequent
degradation of the subendothelial extracellular matrix: Relationship to tumor cell metastasis
In "The Endothelial Cell - a Pluripotent Control Cell of the Vessel Wall", Thilo-Koerner and
Freshney, eds, Karger, Basel, pp. 126-157 (1983)

3.* Schirmmacher V and Vlodavsky I

In vitro interactions of aortic endothelial cell monolayers with tumor cell lines of different
invasive and metastatic capacity
In "Structure and Function of Endothelial Cells", K. Messmer, F. Hammersen, eds, Karger,
Basel, Vol. I, pp. 103-113 (1983)

4.* Schirmmacher V and Vlodavsky I

Interaction of metastatic and nonmetastatic tumor lines with aortic endothelial cell
monolayer and their underlying basal lamina
In Proc. 1st Eur. Conf. on Serum Free Cell Culture. Springer Verlag, pp. 159-163 (1983)



5.* Vlodavskys I, Schirmmacher V, Ariav Y and Fuks Z

Lymphoma cell interaction with cultured vascular endothelial cells and with the subendothelial basal lamina: Attachment, invasion and morphological appearance
Invasion and Metastasis 3, 81 -97 (1983)

6.* Schirmmacher V, Waller C and Vlodavsky I

In vitro invasion of lymphomas with different metastatic capacity
In "B and T cell tumors: Biological and clinical aspects", UCLA Symposia on Molecular and Cellular Biology, E. Vitetta and C.F. Fox, eds, Academic Press, New York, Vol. 24, pp 307-311 (1983)

7.* Schirmmacher V and Vlodavsky I

Interaction of metastatic and non-metastatic tumor lines with aortic endothelial cell monolayer and their underlying basal lamina
In "Hormonally Defined Media. A Tool in Cell Biology", Fischer, Wieser (eds.), Springer Verlag, Heidelberg, pp. 151-161 (1983)

8.* Kramer MD, Robinson P, Vlodavsky I, Barz D, Friberger P, Fuks Z and Schirmmacher V

Characterization of an extracellular matrix-degrading protease derived from a highly metastatic tumor cell line
Eur.J.Cancer & Clin.Oncol. 21(3), 307-316 (1985)

9.* Vlodavsky I, Fuks Z, Bar-Ner M, Yahalom J, Eldor A, Savion N, Naparstek Y, Cohen IR, Kramer M and Schirmmacher V

Degradation of heparan sulfate in the subendothelial basement membrane by normal and malignant blood-borne cells
In "Extracellular Matrix: Structure and Function", A.H. Reddi, ed, Alan R. Liss, Inc, New York, pp. 283-308 (1985)

10.* Bar-Ner, M, Kramer,M.D, Schirmmacher, V, Ishai-Michaeli, R, Fuks, Z. and Vlodavsky, I

Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells
Int. J. Cancer 35, 483-491 (1985)

11.* Kramer, M.D, Schirmmacher, V, Bar-Ner, M. and Vlodavsky, T

A T lymphoma derived proteinase, synergizing with an endoglycosidase in the degradation of sulphated proteoglycans in subendothelial extracellular matrix
In „Proteinases in Inflammation and Tumor Invasion" (Tschesche, H, ed.) Walter de Gruyter & Co, Berlin, New York, pp. 373-393 (1986)

12. Yahalom, J, Eldor, A, Biran, S, Fuks. Z. and Vlodavsky, I

Platelet tumor cell interaction with the subendothelial extracellular matrix: Relationship to cancer metastasis
Radiotherapy and Oncology, 3, 211-225 (1985)

13. Matzner, Y, Bar-Ner, M. Yahalom, J, Ishay-Michaeli, R, Fuks, Z. and Vlodavsky, I

Degradation of heparan sulfate in the subendothelial basement membrane by a readily released heparanase from human neutrophils
J. Clin. Invest. 76, 1306-1313 (1985)

14. Kramer M, Binninger L, Schirmmacher V, Moll H, Prester M, Nerz G and Simon MM

Characterization and isolation of a trypsin-like serine protease from a long term culture cytolytic T cell line and its expression by functionally distinct T cells
J. Immunol. 136. 4644-4651 (1986)

15.* Bar-Ner M, Mayer M, Schirmmacher V and Vlodavsky I

Involvement of both heparanase and plasminogen activator in lymphoma cell mediated degradation of heparan sulfate in the subendothelial extracellular matrix
J.Cell Physiol. 128, 299-307 (1986)



- 16. Schirmacher V, Brunner G, Waller CA and Vlodavsky I**
Mechanism of iransendothelial cell passage and matrix degradation by metastatic tumor cells
Progress in Applied Microcirculation 12, 185-194 (1987)
- 17. Bar-Ner M, Eldor A, Matzner Y, Wasserman L and Vlodavsky I**
Inhibition of heparanase mediated degradation of heparan sulfate by non anticoagulant heparin species
Blood 70, 551-557 (1987)
- 18. Vlodavsky I, Ishai-Michaeli R, Bar-Ner M, Fridman R, Horowitz AT, Fuks Z and Biran S**
Involvement of heparanase in tumor metastasis and angiogenesis
Is. J.Med. 24: 464-470 (1988)
- 19. Lider O, Baharav E, Mekori Y, Miller T, Naparstek Y, Vlodavsky I and Cohen IR**
Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with heparinoid inhibitors of T lymphocyte heparanase
J. Clin. Invest. 83: 752-756 (1989)
- 20. Ishai-Michaeli R, Eldor A and Vlodavsky I**
Heparanase activity expressed by platelets, neutrophils and lymphoma cells releases active fibroblast growth factor from extracellular matrix
Cell, Reg. 1:833-842 (1990)
- 21. Laskov R, Ishai-Michaeli R, Yefe-Nof E and Vlodavsky I**
Production of heparanase by normal and transformed murine B-lymphocytes
Int.J.Cancer, 47: 92-98 (1991)
- 22. Vlodavski I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, Levy E, Bash P, Lider O, Naparstek Y, Cohen IR and Fuks Z**
Expression of heparanase by platelets and circulating cells of the immune system: Possible involvement in diapedesis and extravasation
Invasion & Metastasis, 12, 112-127 (1992)
- 23. Vlodavsky I, Mohsen M, Lider O, Ishai-Michaeli R, Ekre H-P, Svahn CM, Vigoda M and Peretz T**
Inhibition of tumor metastasis by heparanase inhibiting species of heparin
Invasion & Metastasis, 14: 290-302 (1995)
- 24. Gilat D, Hershkoviz R, Cahalon L, Korner G, Vlodavsky I and Lider O**
Molecular behavior adapts to context: Heparanase functions as an extracellular matrix degrading enzyme or as a T cell adhesion molecule depending on the local pH
J.Exp.Med. 181, 1929-1934 (1995)
- 25. Bitan M, Mohsen M, Lider O, Ishai-Michaeli R, Ekrc H-P, Svahn CM, Vigoda M, Miao HQ, Levi E, Vlodavsky I and Peretz T**
Structural requirements for inhibition of melanoma cell metastasis by heparanase inhibiting species of heparin
Is.J.Med. 31, 106-118 (1995)

Ca 25 S. Shaltiel, Weizmann Institute of Science, Rehovot
V. Kinzel, M. Gagelmann DKFZ, Heidelberg

- 1. Zick Y, Cesla R and Shaltiel S**
Viable mouse thymocytes as a model system for studying the onset of hormone-induced cellular refractoriness
Biochim.Biophys.Acta, 762, 355-365 (1983)
- 2. Zick Y, Cesla R and Shaltiel S**



Exposure of thymocytes to a low temperature (4°C) inhibits the onset of their hormone-induced cellular refractoriness
J.Biol.Chem. 257, 4253-4259 (1983)

3. Shaltiel S

Hydrophobic chromatography
Methods Enzymol. 104, 69-96 (1984)

4. Shaltiel S

Hydrophobic chromatography and its relevance to biological recognition
In "Affinity Chromatography and Biological Recognition", Chaiken, Wilchek & Parikh, eds, Academic Press, pp.229-239 (1984)

5. Halperin G, Tauber-Finkelstein M and Shaltiel S

Hydrophobic chromatography of cells: Adsorption and resolution on homologous series of alkylagaroses
J.Chromatography 317. 103-118 (1984)

6. Alhanaty E, Tauber-Finkelstein M, Schmeeda H and Shaltiel S

The cAMP-triggered proteolysis of cAMP-dependent protein kinase in brushborder membranes
Current Topics in Cellular Regulation, 27, 267-278 (1985)

7.* Kinzel V, Hotz A, Konig N, Gagelmann M, Pyerin W, Reed J, Kubler D, Hofmann F, Obst C, Gensheimer HP, Goldblatt D and Shaltiel S

Chromatographic separation of two heterogeneous forms of the catalytic subunit of cyclic AMP-dependent protein kinase holoenzyme type I and type II from striated muscle of different mammalian species
Arch.Biochem.Biophys. 253, 341-349 (1987)

8. De Jonge H, Schmeeda H and Shaltiel S

Orientation of the brush-border membranal proteinase which specifically splits the catalytic subunit of cAMP-dependent protein kinase
Eur.J.Biochem. 169. 503-509 (1987)

9. Reed J, Gagelmann M and Kinzel V

Isolation and elucidation of some functional properties of the "mute" catalytic subunit of cAMP-dependent protein kinase
Arch.Biochem.Biophys. 222, 276-284 (1984)

10. Reed J and Kinzel V

Ligand binding site interaction in cAMP-dependent protein kinase catalytic subunit: Circular dichroic evidence for intramolecular transmission of conformational change
Biochemistry 23, 968-973 (1984)

11. Reed J and Kinzel V

The near- and far-ultraviolet circular dichroism of the catalytic subunit of cAMP-dependent protein kinase
Biochemistry 23, 1357-1362 (1984)

12. Reed J, Kinzel V, Kemp BE, Cheng HC and Walsh DA

Circular dichroic evidence for an order of sequence of ligand binding site interactions in the catalytic reaction of the cAMP-dependent protein kinase
Biochemistry 24, 2967-2973 (1985)

13. Van Patten SM, Hotz A, Kinzel V and Walsh DA

The inhibitor protein of the cyclic AMP-protein kinase-catalytic subunit interaction
Biochem.J. 256, 785-789 (1988)



Ca 26 A. Panel, Hebrew University of Jerusalem
H. Kirchner, H. Jacobsen, DKFZ, Heidelberg

1. Panel A, Gloger I and Falk H

Mechanisms of herpes simplex virus inhibition by interferon

In "The Biology of the Interferon System", H. Kirchner and H. Schellenkens, eds, Elsevier-North Holland, Biochemical Press, Amsterdam (1984)

2.* Domke I, Straub P, Jacobsen H, Kirchner H and Panet A

Inhibition of replication of herpes simplex virus in mouse macrophages by interferons
J.Gen.Virol. 66, 2231-2236 (1985)

3.* Straub P, Domke I, Kirchner H, Jacobsen H and Panet A

Synthesis of herpes simplex virus proteins and nucleic acids in interferon-treated macrophages

Virology 150. 411-418 (1986)

4. Heyns NP, Eldor A, Vlodaysky I, Kaiser N, Friedman R and Panel A

The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events

Experimental Cell Research 161, 297-306 (1986)

5. Mittnacht S, Straub P, Kirchner H and Jacobsen H

Interferon treatment inhibits onset of herpes simplex virus immediate early transcription

Virology, 164, 201-210 (1988)

6. Oberman F and Panet A

Inhibition of transcription of herpes simplex virus immediate early genes in interferon-treated cells

J.Gen.Virol. 69, 1167-1177 (1988)

7. Hochman J, Mador N, Gloger I, Falk H and Panel A

Isolation and characterization of interferon resistant variants of S49 mouse lymphoma

Experimental cell research, 177, 37-46 (1988)

8. Einhorn S, Eldor A, Vlodayski I, Fuks Z and Panet A

Production and characterization of interferon from endothelial cells

J.Cell.Physiol. 122, 200-204 (1985)

9. Gloger I, Arad G and Panet A

Regulation of Moloney murine leukemia virus replication in chronically infected cells arrested at the G₀/G₁ phase

J.Virology 54, 844-850 (1985)

Ca 27 M. Bar-Eli, Ben-Gurion University, Beer-Sheva
G. Hämmerling, DKFZ, Heidelberg

1.* Alon Y, Hämmerling GJ, Segal S and Bar-Eli M

Association in the expression of Kirsten-ras oncogene and the MHC complex class I antigens in fibrosarcoma tumor cell variants exhibiting different metastatic capabilities

Cancer Res. 47, 2553-2557 (1987)

2.* Rager-Zisman B, Gopas J, Bar-Eli M, Har-Vardi I, Hämmerling GJ and Segal S

NK sensitivity, H-2, Ki-ras proto-oncogene expression and metastasis: Analysis of the metastatic potential of H-2 gene transfected fibrosarcoma cells

In "Proc. of the Int. Congress on Cancer Metastasis: Biological and Biochemical Mechanisms and Clinical Aspects", Bologna, Italy (1987)

3.* Gopas J, Segal S, Hämmerling GJ, Bar-Eli M and Rager-Zisman B



Influence of H-2K transfection on susceptibility of fibrosarcoma tumor cells to natural killer (NK) cells

Immunology Letters 17, 261-266 (1988)

4. * Gopas J, Rager-Zisman B, Bar-Eli M, Harvardi I, Hämmerling G and Segal S

The immunobiology of metastatic processes. Analysis of NK sensitivity and the metastatic potential of H-2 gene transfected fibrosarcoma cells

Natural Immunity and Cell Growth Regulation, 7, 155-162 (1988)

5. * Gopas J, Rager-Zisman B, Bar-Eli M, Hämmerling GJ and Segal S

The relationship between MHC antigen expression and metastasis

Advances in Cancer Research 53, 89-115 (1989)

Ca 28 R. Kaempfer, Hebrew University of Jerusalem P. Krammer, DKFZ, Heidelberg

1. Kaempfer R and Efrat S

Regulation of human interleukin-2 gene expression

In "Cellular and Molecular Biology of Lymphokines" (C. Sorg and A. Schimpl, eds.), Academic Press, Orlando, Fla, pp. 605-618 (1985)

2. Kaempfer R and Efrat S

Regulation of human interleukin-2 gene expression

In "Leukocytes and Host Defense" (J.J. Oppenheim and D.M. Jacobs, eds.), Alan R. Liss, Inc, N.Y, pp. 57-68 (1986)

3. Kaempfer R, Efrat S and Marsh S

Regulation of human interleukin-2 gene expression

In "Molecular Cloning and Analysis of Lymphokines" (D.R. Wand D. Goeddel, eds.), Academic Press, Orlando, Fla, pp. 59-72 (1987)

4. Lebediker MA, Tal C, Sayar D, Pile S, Eilon A, Banai Y and Kaempfer R

Superinduction of the human gene encoding immune interferon

EMBO J. 6, 585-589 (1987)

5. Tal C, Arad G, Kelzinel M, Nussinovich R, Schlesinger M, Reshef A and Kaempfer R

Suppression of human interleukin-2 and interferon- γ gene expression by monocytes and macrophages

In "Molecular and Cellular Biology of Lymphokines" (J.J. Oppenheim, M.C. Powanda, M.J. Kluger and C.A. Dinarello, eds.) Wiley-Liss, Inc, New York, pp. 57-62 (1990)

6. Ketzinel M, Arad G, Tal C, Schlesinger M, Nussinovich R, Reshef A, Sayar D, Gerez L and Kaempfer R

The potential to express or suppress human interleukin-2 and interferon- γ genes is not restricted to distinct cell subsets

Molecular Immunology 27, 1325-1330 (1990)

7. Ketzinel M, Efrat S, Silberberg C, Reshef A, Yeheskel A, Deutsch E, Sayar D, Gerez L, Tal C, Arad G and Kaempfer R

Regulation of human interleukin-2 and interferon- γ gene expression by suppressor T lymphocytes

Scand.J.Immune, 33, 593-605 (1991)

8. Hamann U and Krammer PH

Activation of macrophage tumor cytotoxicity inducing factor 2 (MCIF2)

Eur.J.Immunol. 15, 18-24 (1985)

9. Kubelka CF, Krammer PM, Ruppel A and Gerns D



Macrophage cytotoxicity against schistosomula of *Schistosoma Mansoni* following stimulation with macrophage-activating factors produced by T cell clones
In "Tropenmedizin, Parasitologie" (J. Boch, ed.) Verlag P. Lang, Frankfurt, pp. 184-186 (1984)

10. Gemsa D, Staar U, Grimm W, Hausmann G, Korner CF, Krammer PH and Resch K
Stimulation of macrophage activity by 12-0-Tetradecanoyl-Phorbol-1 3-Acetate
Proceed. of a Symposium organized by the Hungarian Cancer Society and the IARC on Models, Mechanisms, and Etiology of tumor promotion. IARC. Lyon (Börzsöny, M, Lapis, K, Day, N.E, Yamasaki, H, eds.), pp. 319-336 (1984)

11. Krammer PH et al.

Regulation of hematopoietic differentiation and its disruption
In "Leukemia" Weissmann, J.L. (ed.), Life Sciences Research Report. Dahlem-Konferenzen, Berlin, Heidelberg, New York, Tokyo. Springer Verlag, pp. 251-260 (1984)

12. Gemsa D, Kubelka C, Debatin K-M and Krammer PH

Activation of macrophages by lymphokines from T cell clones: evidence for different macrophage activating factors

Molecular Immunology, 21, 1267-1276 (1984)

13. Krammer PH, Hamann U, Hültner L, Kaltmann B, Kees U, Kubelka C and Gemsa D

The activity of lymphokines secreted by normal and malignant T cells

Springer Semin. Immunopathol. 7, 291-298 (1984)

14. Krammer PH, Gemsa D, Hamann U, Kaltmann B and Kubelka C

Heterogeneity of macrophage activating factors and their effects in vivo

In "Mediators in cell growth and differentiation" (A. Maizel, R. Ford, eds.) Raven Press, N.Y., 37, 193-197 (1984)

15. Yuan D, Weiss EA, Layton J, Krammer PH and Vitetta ES

Activation of the $\gamma 1$ gene by lipopolysaccharide (LPS) and T cell derived lymphokines containing a B cell differentiation factor for IgG1 (BCDF γ)

J.Immunol. 135, 1465-1469 (1985)

16. Layton JE, Vitetta ES, Uhr JW and Krammer PH

Clonal analysis of B cells induced to secrete IgG by T cell derived lymphokine(s)

J.Exp.Med. 160, 1850-1863 (1984)

17. Krammer PH, Echtenacher B, Hamann U, Kaltmann B, Kees U, Kubelka C and Gemsa D

The role of T cell clone- and hybridoma-derived lymphokines in macrophage activation

In "Mononuclear Phagocytes, Characteristics. Physiology and Function" R.v. Furth (ed.), Martinus Nijhoff Publ, 533-540 (1985)

18. Noelle R, Krammer PH, Uhr J and Vitetta ES

Increased expression of Ia antigens on resting B cells: A new role for B cell growth factor
Proc. Natl. Acad. Sci. 8U 6149-6153 (1984)

19. Gemsa D, Kozan B, Kubelka C, Debatin K-M and Krammer PH

T cell clones secrete lymphokines that activate different macrophage functions

In "Lymphokines" Vol. 11 (Pick, E, Landy, M, eds.) Academic Press, N.Y, pp. 119-156 (1985)

20. Falk W, Männel DN, Katzer B, Kaltmann B, Krammer PH, Diamantstein T and Dröge W

Induction of IL-2 receptor expression and cytotoxicity of thymocytes by stimulation with T cell cytotoxicity inducing factor 1

J. Immunol. L35, 1160-1164, (1985)

21. Krammer PH, Gemsa D, Hamann U and Kubelka C

Activation of tumoricidal and schistosomicidal macrophages by sequential lymphokine signals



In "Cellular and molecular biology of lymphokines" (C. Sorg and A. Schimpl, eds.) Academic Press, N.Y, pp. 265-271 (1985)

22. Kubelka C, Ruppel A, Gemsa D and Krammer PH

In vivo activation of macrophages by T cell derived lymphokines: Killing of tumor cells and schistosomula of *S. mansoni*

Immunobiol. 171. 311-319 (1986)

23. Krammer PH, Kubelka CF, Falk W and Ruppel A

Priming and triggering of tumoricidal and schistosomucidal macrophages by two sequential lymphokine signals: Interferon-gamma and MCIF2

J.Immunol. 135, 3258-3264 (1985)

24. Kubelka CF, Ruppel A, Krammer PH and Gemsa D

Killing of schistosomula of *Schistosoma mansoni* by macrophages: Induction by T cell clone-derived lymphokines and interferon-gamma

Parasitology 92, 325-336 (1986)

25. Gemsa D, Nain M, Hansch GM, Lovett D, Krammer PH and Resch K

Release of prostaglandins and modulation of leukocyte functions

In "Advances in Immunopharmacology" (Chedid, L, Hadden, J.W, Spreafico. F, Dukor, P. and Willoughby. eds.). Pergamon Press Oxford, pp. 127-136 (1986)

Ca 29 A. Raz, A. Ben-Ze'ev, Weizmann Institute of Science,
Rehovot
M. Zöller, DKFZ, Heidelberg

1. Ben-Ze'ev A and Raz A

The relationship between the organization and synthesis of vimentin and the metastatic capability of B16 melanoma cells

Cancer Res. 45, 2632-2641 (1985)

2.* Raz A, Zöller M and Ben-Ze'ev A

Cell configuration and adhesive properties of metastasizing and non-metastasizing BSp73 rat adenocarcinoma cells

Exp.Cell Res. 162. 127-141 (1986)

3.* Ben-Ze'ev A, Zöller M and Raz A

Differential expression of intermediate filament proteins in metastatic and nonmetastatic variants of the BSp73 tumor

Cancer Res. 46, 785-790 (1986)

4. Raz A and Ben-Ze'ev A

Cell-contact and architecture of malignant cells and their relationship to metastasis

Cancer and Metastasis Reviews 6, 3-21 (1987)

5. Nabi IR and Raz A

Cell shape modulation alters glycosylation of metastatic melanoma cell-surface antigen

Int.J.Cancer 40, 396-402 (1987)

6. Nabi IR and Raz A

Loss of metastatic responsiveness to cell shape modulation in a newly characterized B16 melanoma adhesive cell variant

Cancer Res. 48, 1258-1264 (1988)

7. Zöller M

Acquired resistance towards immune defense during metastatic progression represents a secondary phenomenon

Int.J.Cancer 37, 115 (1986)

8.* Zöller M, Strubel A, Haemmerling GJ, Andrighetto G, Raz A and Ben-Ze'ev A



Interferon-gamma treatment of B16 melanoma cells: Opposing effects for non-adaptive and adaptive immune defense and its reflection by metastatic spread
Int.J.Cancer 41, 256-266 (1988)

9. Zöller M and Matzku S

Changes in adhesive properties of tumor cells do not necessarily influence metastasizing capacity

Clin.Exp.Metastasis. 7, 227-242 (1989)

10. Matzku S, Wenzel A and Zöller M

Anigenic differences between metastatic and nonmetastatic BSp73 rat tumor variants characterized by monoclonal antibodies

Cancer Res, 49, 1294-1299 (1989)

11. Zöller M

IFN-treatment of B16-F1 versus B16-F10; relative impact on non-adaptive and T-cell-mediated immune defense in metastatic spread

Clin.Exp.Metastasis 6, 411-29 (1988)

12. Zöller M

Acquired resistance towards immune defense during metastatic progression represents a secondary phenomenon

Int.J.Cancer, 37, 115-122 (1986)

13. Zöller M

Evaluation of in vivo and in vitro effectivity of immune defense against a spontaneously arising, nonlymphoid rat tumor. I. Analysis of natural immune defense

Cancer.Immunol.Immunother. 19, 183-188 (1985)

14. Zöller M

Cytotoxic T-cell precursors against non-immunogenic rat tumors: limiting dilution analysis
Int.J.Cancer, 37, 133-140 (1986)

15.* Rodriguez-Fernandez JL, Geiger B, Salomon D, Sabanay I, Zöller M and Ben Ze'ev A

Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA
J.Cell.Biol, 119, 427-438 (1992)

16. *Ben-Ze'ev A, Rodriguez F, Glück U, Salomon D, Zöller M and Geiger B

Regulation of adherens junction protein levels: its role in cell motility and tumorigenicity
In "Advances in Molecular and Cell Biology", Vol. 12 Cytoskeleton, E. Bittar and J. Hesketh. editors. Jai Press, Inc. Greenwich, Conn, pp. 143-163 (1995)

17.* Pankov R, Simcha L, Zöller M, Oshima RG and Ben-Ze'ev A

Contrasting effects of K8 and K18 on stabilizing K19 expression, cell motility and tumorigenicity in the BSP73 adenocarcinoma

J. Cell Science 110, 965-974 (1997)

Ca 30 V. Rotter, Weizmann Institute of Science, Rehovot
V. Schirmmacher, DKFZ, Heidelberg

1.* Pohl J, Goldfinger N, Radler-Pohl A, Rotter V and Schirmmacher V

p53 increases experimental metastatic capacity of murine carcinoma cells
Mol.Cell.Biol. 8, 2078-2081 (1988)



Ca 31 S. Mitrani-Rosenbaum, Hebrew University of Jerusalem
L. Gissmann, DKFZ, Heidelberg

- 1. Mitrani-Rosenbaum S, Gal D, Friedman M, Kitron N, Tsvieli R, and Anleby SO**
Papillomaviruses in lesions of the lower genital tract in Israeli patients
Eur.J.Cancer Clin.Oncol. 24, 725-731 (1988)
- 2. Gal D, Friedman M and Mitrani-Rosenbaum S**
Transmissibility and treatment failures of different types of human papillomavirus
Obstetrics and Gynecology 73, 308-314 (1989)
- 3. Mitrani-Rosenbaum S, Tsvieli R and Tur-Kaspa R**
Estrogen stimulates differential transcription of human papillomavirus type 16 in Siha cervical carcinoma cells
J.Gen.Virol. 70, 2227-2232 (1989)
- 4. Müller M, Kelly G, Fiedler M and Gissmann L**
Human papillomavirus type 48
J. Virol. 63: 4907-4908 (1989)
- 5. Gallahan D, Müller M, Schneider A, Delius H, Kahn T, de Villiers E-M and Gissmann L**
Human papillomavirus type 53
J.Virol. 63: 4911-4912 (1989)

Ca 32 S. Lavi, Tel Aviv University
J. Schlehofer, DKFZ, Heidelberg

- 1. Lavi S, Kleinberger T, Berko-Flint Y and Blank M**
Stable and transient amplification of DHFR and SV40 in carcinogen treated cells
In "Accomplishments in Oncology", Vol. 2, The Role of DNA Amplification in Carcinogenesis.
H. zur Hausen and J.R. Schlehofer, eds, J.A. Lippincott Company, Philadelphia, pp. 117-125
(1986)
- 2. Aladjem M, Koltin Y and Lavi S**
Carcinogen mediated amplification of the CUPT locus of Saccharomyces cerevisiae
Molec.Gen.Genetics 211. 88-94 (1987)
- 3. Kleinberger T, Berko-Flint Y, Blank Y, Etkin S and Lavi S**
Carcinogen induced trans-activation of gene expression
Molec.Cell.Biol. 8, 1366-1370 (1988)
- 4. Kleinberger T, Sahar E and Lavi S**
Carcinogen mediated co-activation of two independent genes in Chinese hamster cells
Carcinogenesis 9, 979-985 (1989)
- 5. Berko-Flint Y, Karby S and Lavi S**
Carcinogen induced factors responsible for SV40 DNA replication and amplification in Chinese hamster cells
In "Cancer Cells", Eukaryotic DNA replication, New York, Cold Spring Harbor Laboratory, Vol. 6, pp.183-189 (1988)
- 6. Berko-Flint Y, Karby S, Hassin D and Lavi S**
Carcinogen induced DNA amplification in-vitro: over-replication of the SV40 origin region in extracts from carcinogen treated CO60 cells
Molec.Cell.Biol. 10, 75-83 (1990)



Ca 33 Y. Milner, Hebrew University of Jerusalem
M. Hergenhahn, DKFZ, Heidelberg

1. Dvir A, Simon AJ, Michel B, Defiles M, Hergenhahn M and Milner Y

The involvement of two Protein Kinase C (PKC) subspecies in two distinct processes in keratinocytes: their role in cell adhesion and cell spreading

Journal of Investigative Dermatology 90, 555 (1988)

2. Simon A, Dvir A, Steingart R, Michel B and Milner Y

Protein Kinase C translocation in human and guinea-pig keratinocytes - the role of membrane physical organization

Journal of Investigative Dermatology 92, 319 (1989)

Ca 34 J. Schlessinger, Weizmann Institute of Science, Rehovot
V. Kinzel, F. Marks, DKFZ, Heidelberg

1. Livneh E, Dull TJ, Berent E, Prywes R, Ullrich A and Schlessinger J

Release of phorbol ester induced mitogenic block by mutation at Thr 654 and J4 EGF-receptor

Mol.Cell Biol. 8, 2302-2308 (1988)

2. Benveniste M, Livneh E, Schlessinger J and Kam Z

Overexpression of epidermal growth factor receptor in NIH-3T3-transfected cells slows its lateral diffusion and rate of endocytosis

J.Cell.Biol. 106, 1903-1909 (1988)

3. Espe U, Fuerstenberger G, Marks G, Kaszkin M and Kinzel V

Early changes in the arachidonic acid metabolism of HeLa cells in response to tumor promoter 12-0-tetradecanoylphorbol-13-acetate (TPA) and related compounds

J.Cancer Res.Clin.Oncol. 113, 137-144 (1987)

4. Kinzel V, Kaszkin M, Espe U, Richards J and Fuerstenberger G

Role of arachidonic acid release in the G2 delay induced by tumor promoter TPA in HeLa cells

Exp.Cell Res. 173, 305-310 (1987)

5. Kaszkin M, Espe U, Fuerstenberg G and Kinzel V

Dual effect of the phorbol ester TPA on arachidonic acid release from HeLa cells

FEBS Letters 233, 244-248 (1988)

6. Kinzel V, Bonheim G and Richards J

Phorbol ester-induced G2 delay in HeLa cells analyzed by time lapse photography

Cancer Res. 48, 1759-1762 (1988)

7. Marks F, Fuerstenberger G, Gschwendt M, Rogers M, Schurich B, Kaina B and Bauer G

The wound response as a key element for an understanding of multistage carcinogenesis in skin

In "Models and Mechanisms in Chemical Carcinogenesis". F. Feo et al, eds, Plenum Press, New York (1989)

8. Marks F and Fuerstenberger G

Conversion induced by transforming growth factors alpha and beta: The role of "wound hormones" in multi-stage skin carcinogenesis

In "Biochemistry of Chemical Carcinogenesis", J. Hradec, R.C. Garner, eds, Plenum Press, London (1989)

9. Fuerstenberger G, Roger M, Schapke R, Bauer G, Hoefler P and Marks F



A stimulatory role of transforming growth factors in multistage skin carcinogenesis: possible explanation for the tumor-inducing of wounding in initiated NMRI mouse skin
Int.J.Cancer, 43, 915-921 (1989)

10. Kinzel V, Kaszkin M, Blume A and Richards J

Epidermal growth factor inhibits transiently the progression from G2-phase to mitosis: A receptor-mediated phenomenon in various cells
Cancer Res. 50, 7932-7936 (1990)

**Ca 35 H. Manor, Technion, Haifa
M. Pawlita, DKFZ, Heidelberg**

1. Baran N, Lapidot A and Manor H

Unusual sequence element found at the end of an amplicon
Molecular and Cellular Biology 7, 2636-2640 (1987)

2. Manor H, Sridhara Rao B and Martin RG

Abundance and degree of dispersion of genomic d(GA)n.d(TC)n sequences
J.Mol.Evol. 27, 96-101 (1988)

3. Baru M and Manor H

Induction of polyomavirus DNA replication by cyclic AMP and a tumor promoter
Intervirology 29, 328-333 (1988)

4. Lapidot A, Baran N and Manor H

(dT-dC)n and (dG-dA)n tracts arrest single stranded DNA replication in vitro
Nucleic Acids Research II, 883-900 (1989)

5. Pawlita M, Bozenhardt I, Heilbronn R and zur Hausen H

Amplification of lymphotropic papovirus DNA sequences in hamster and human cell lines
In: "Accomplishments in Oncology (vol. 2,1). The role of DNA amplification in carcinogenesis", H. zur Hausen and J.R. Schlehofer (eds.), J.B. Lippincott Company, Philadelphia, pp. 133-139 (1987)

6. Forbes B, Gissman L and Pawlita M

Detection of individual virus infected cells by filter in situ hybridization
Molecular and Cellular Probes 2, 245-253 (1988)

7. Mühlbach P and Pawlita M

A stable flank of unstable lymphotropic papovavirus integration sites is associated with a cellular S1-nuclease sensitive sequence
Virology, 186, 65-73 (1992)

**Ca 36 B. Czernobilsky, Kaplan Hospital, Rehovot
W. Franke, DKFZ, Heidelberg**

1.* Czernobilsky B, Moll R, Leppien G, Schweikhart G and Franke WW

Desmosomal plaque-associated vimentin filaments in human ovarian granulosa cell tumors of various histologic patterns
Am.J.Pathol. 126, 476-486 (1987)

2.* Dockhorn-Dworniczak B, Franke WW, Schröder S, Czernobilsky B, Gould VE and Böcker W

Patterns of expression of cytoskeletal proteins in human thyroid gland and thyroid carcinomas
Differentiation 35, 53-71 (1987)



3.* Lifschitz-Mercer B, Czernobilsky B, Degani R, Dallenbach-Hellweg G, Moll R and Franke WW

Immunocytochemical study of an endometrial diffuse clear cell stromal sarcoma and other endometrial stromal sarcomas
Cancer 59, 1494-1499 (1987)

4. Czernobilsky B, Lifshitz-Mercer B, Luzon A, Jacob N, Ben-Hur H, Gorbacz S, and Fogel M

Cytokeratin patterns in the epidermis of human ovarian mature cystic teratomas
Human Pathology 20, 185-192 (1989)

5. Czernobilsky B, Shezen E, Lifschitz-Mercer B, Fogel M, Luzon A, Jacob N, Skalli O and Gabbiani G

Alpha smooth muscle actin in normal human ovaries, in ovarian stromal hyperplasia and in ovarian neoplasms

Virchows Arch. B (Cell Pathol.) 57, 55-61 (1989)

6.* Fogel M, Lifshitz-Mercer B, Moll R, Kushnir I, Jacob N, Waldherr R, Livoff A, Franke WW and Czernobilsky B

Heterogeneity of intermediate filament expression in human testicular seminomas
Differentiation 45, 242-249 (1990)

7. Longo FJ, Krohne G and Franke WW

Basic proteins of the perinuclear theca of mammalian spermatozoa and spermatids: A novel class of cytoskeletal elements

J.Cell Biol. 105, 1105-1120 (1987)

8. Moll R, Pitz S, Levy R, Weikel W, Franke WW and Czernobilsky B

Complexity of expression of intermediate filament proteins, including glial filament protein, in endometrial and ovarian adenocarcinomas

Hum.Pathol. 22, 989-1001 (1991)

9. Czernobilsky B

Differentiation patterns in human testicular germ cell tumors

Editorial & Virchows Archiv A 419, 77-78 (1991)

10.* Lifschitz-Mercer B, Fogel M, Moll R, Jacob N, Kushnir I, Livoff A, Waldherr R, Franke WW and Czernobilsky B

Intermediate filament protein profiles of human testicular non-seminomatous germ cell tumor: Correlation of cytokeratin synthesis to cell differentiation

Differentiation 48, 191-198 (1991)

11. Lifschitz-Mercer B, David R, Dharan M and Czernobilsky B

Small cell carcinoma of the ovary. An immunohistochemical study with review of the literature

Virchows Arch. A 421, 263-270 (1992)

12. Czernobilsky B

Intermediate filament profile of sex cord-stromal tumors and germ cell tumor of the ovary
In "Diagnostic Immunohistopathology of Gynecologic Tumors", ed. G. Kinderman, B. Lampe, Georg Thieme Verlag, Stuttgart, pp. 159-160 (1992)

13. Czernobilsky B

Intermediate filaments in ovarian tumors

Int.J.Gynecol.Pathol. 12, 166-169 (1993)

14. Azumi N and Czernobilsky B

Immunohistochemistry

In "Blaustein's Pathology of the Female Genital Tract", R.J. Kurman ed. Springer Verlag 4th ed. pp 1131-1159 (1994)

15. Lifschitz-Mercer B, Walt H, Kushnir I, Jacob N, Diner PA, Moll R and Czernobilsky B



Differentiation potential of ovarian dysgerminoma. An immunohistochemical study of 15 cases
Human Pathology 26, 62-66 (1995)

Ca 37 I. Friedberg, Tel Aviv University
D. Kübler, W. Pyerin, DKFZ, Heidelberg

- 1. Weisman GA, Lustig KD, Lane E, Huang N, Belzer Land Friedberg I**
Growth inhibition of transformed mouse fibroblasts by adenine nucleotides occurs via generation of extracellular adenosine
J.Biol.Chem. 263, 12367-12372 (1988)
- 2. Belzer I and Friedberg I**
ATP-resistant variants of transformed mouse fibroblasts
J.Cell.Physiol. 140, 524-529 (1989)
- 3. Gonzalez FA, Bonapace E, Belzer L, Friedberg I and Heppel LA**
Two distinct receptors for ATP can be distinguished in Swiss 3T6 mouse fibroblasts by their desensitization
Biochem.Biophys.Res.Commun. 164, 706-713 (1989)
- 4. Jakobi R, Voss H and Pyerin W**
Human phosphatase/casein kinase type II. Molecular cloning and sequencing of full length cDNA encoding subunit beta
Eur.J.Biochem. 183, 227-233 (1989)
- 5.* Friedberg I and Kuebler D**
The role of surface protein kinase in ATP-induced growth inhibition in transformed mouse fibroblasts
In "The Biological Actions of Extracellular ATP", G.R. Dubyak and J.S. Fedan, eds, Proc. N.Y. Acad. Sci. 603, 513-515 (1990)
- 6. Kübler D, Pyerin W, Bill O, Hotz A, Sonka J and Kinzel V**
Evidence for ecto-protein kinase activity that phosphorylates Kemptide in a cyclic AMP-dependent mode
J.Biol.Chem. 264, 14549-14555 (1989)
- 7. Kuebler D and Pyerin W**
Cell surface protein kinase mediated protein phosphorylation
In "The Biological Actions of Extracellular ATP", G.R. Dubyak and J.S. Fedan, eds, Proc. N.Y. Acad. Sci. 603, 516-518 (1990)
- 8. Voss H, Wirkner U, Jakobi R, Hewith NA, Schwager Ch, Zimmermann J, Ansorge W and Pyerin W**
Structure of the gene encoding human casein kinase II subunit β
J.Biol.Chem. 266, 13706-13711 (1991)
- 9. De BK and Friedberg L**
Effect of ionophore A23187 on the membrane permeability in mouse fibroblasts
Biochem. Biophys. Res. Commun, 178 (3), 830-841 (1991)
- 10.* Friedberg I, Belzer I, Oged-Plesz O and Kübler D**
Activation of cell growth inhibitor by ecto-protein kinase-mediated phosphorylation in transformed mouse fibroblasts
J.Biol.Chem. 270, 20560-20567 (1995)
- 11. Walter J, Schnölzer M, Pyerin W, Kinzel V and Kübler D**
Induced release of cell surface protein kinase yields CK1 and CK2-like enzymes in tandem
J.Biol.Chem. 271, 111-119 (1996)



Ca 38 Y. Kaufmann, Chaim Sheba Medical Center, Tel Hashomer
W. Falk, P.Krammer, DKFZ, Heidelberg

1. Esparza I, Männel DN, Ruppel A, Falk W and Krammer PH

Interferon- γ and lymphotoxin or tumor necrosis factor act synergistically to induce macrophage killing of tumor cells and schistosomula of *Schistosoma mansoni*
J.Exp.Med. 166, 589-594 (1987)

2. Falk W, Krammer PH and Männel DN

A new assay for Interleukin-1 in the presence of Interleukin-2
J.Immunol.Methods 99, 47-52 (1987)

3. Esparza I, Ruppel A, Mestan J and Krammer PH

Preactivation of macrophages in mice acutely infected with *Schistosoma mansoni*
Immunobiology 177, 105-119 (1988)

4. Echtenacher B, Hederer R and Krammer PH

Biological effects of a rat monoclonal anti-mouse IFN- γ antibody produced by in vitro immunization
Immunobiology 176, 96-107 (1987)

5. Ozery T, Berke G, Moskovich M, Ozato K and Kaufmann Y

T cell activation; independent induction of killing activity and IL-2 secretion in cytolytic hybridomas
Eur.J.Immunol. 19, 1965-1968 (1989)

6. Kaufmann Y, Davidsohn J, Levanon M, Icekson I, Revel M and Ramot B

Lymphokine-activated killer (LAK) cells; Interferon-gamma synergizes with IL-2 to induce LAK cytotoxicity in homogeneous leukemic preparations
Clin.Immun.Immunopathol. 58, 278-288 (1991)

7. Falk W, Männel DN, Darjes H and Krammer PH

Interleukin-1 induces high affinity interleukin-2 receptor expression of CD4-8-thymocytes
J.Immunol. 143, 513-517 (1989)

8. Von Hoegen I, Falk W, Kojouharoff G and Krammer PH

Internalization of interleukin-1 (IL-1) correlates with IL-1-induced IL-2 receptor expression and IL-2 secretion by EL4 thymoma cells
Eur.J.Immunol. 19, 329-334 (1989)

9. Falk W, Von Hoegen I and Krammer PH

Activation of T cells by interleukin-1 involves internalization of interleukin-1
Lymphokine Res. 8, 263-268 (1989)

10. Falk W, Albrecht MP, Stricker K, Serfling E and Krammer PH

Internalization of IL-1 is required for IL-2 gene activation in EL4 thymoma cells
Progress in Leukocyte Biology 10A, 191-196 (1990)

11. Lahm H, Fischer J, Reichert Y, Falk W, Debatin K-M and Krammer PH

Autocrine growth factors secreted by the malignant human B cell line BJAB are distinct from other known cytokines
Eur.Cytokine Net 1, 41-46 (1990)

12. Li-Weber M, Eder A, Albrecht M, von Hoegen I, Jaggle C, Klas C, Naher H, Pekar U, Hederer R, Peters A, Trauth B, Meinzer H-P, Scheppelmann D, Schmidt M, Wolf T, Falk W, Petzold D and Krammer PH

Die Grundlagen der Aktivierung von T-Helferzellen und ihre Beziehung zum Krankheitsbild Aids

In "Aids, Forschungsergebnisse im Rahmen des Statusseminars des BMFT", Hrsg.: Projektgruppe Aids des BGA, Berlin, pp: 156-169 (1987)



13. Debatin K-M, Woodroffe C, Lahm H, Fischer J, Falk W, Brandeis WE and Krammer PH

Lack of Interleukin-2 (IL-2) dependent growth of Tac positive T-ALL/NHL cells is due to the expression of only low affinity receptors for IL-2.
Leukemia, 8, 566-571 (1989)

14. Krammer PH, Kirchner H and Schimpl A

Lymphokines

In "Immunology in the Federal Republic of Germany"; Immunology Today, suppl. 10, S21-S22 (1989)

**Ca 39 M. Revel, J. Chebath, Weizmann Institute of Science, Rehovot
R. Zawatzky, H. Kirchner, DKFZ, Heidelberg**

1. Chen L, Novick D, Rubinstein M and Revel M

Recombinant interferon-beta-2 (interleukin-6) induces myeloid differentiation
FEBS Lett. 239, 299-304 (1988)

2. Shabo Y, Lotern J, Rubinstein M, Revel M, Clark SC, Wolf SF, Kamen R and Sachs L

The myeloid blood cell differentiation inducing protein MGI-2A is interleukin-6
Blood 72, 2070-2073 (1988)

3. Cohen B, Vaiman D and Chebath J

Enhancer functions and in vivo protein binding of native and mutated interferon responsive sequences
Nucl.Acids Res. 17, 1679-1695 (1989)

4. Revel M, Chen L, Mory Y, Zilberstein A and Michalevicz R

Interferon-type and other activities of IFN-beta-2/BSF/HSF
Advances in Immunopharmacology 4, Pergamon press, pp. 175-183 (1989)

5. Revel M, Zilberstein A, Chen L, Gothelf Y, Barash I, Novick D, Rubinstein M and Michalevicz R

Biological activities of recombinant human IFN-beta-2/IL-6 (E.coli)
Annals N.Y. Acad. Sci. 557, 144-156 (1989)

6. Revel M

Host defense against infections and inflammations: Role of the multifunctional IL-6/IFN-beta-2 cytokine
Experientia 45, 549-557 (1989)

7. Revel M, Chen L, Novick D, Shulman LM, Gothelf Y, Cohen B, Raber J and Chebath J

In "Cytokines, Basic Principle and Clinical Applications", S. Romagnani, ed, Raven Press, New York, Vol. 68, pp. 227-238 (1990)

8. Gothelf Y, Raber J, Chen L, Michalevicz R, Chebath J and Revel M

Differentiation of myeloleukemia cells by IL-6/IFN-beta-2
J.Interferon Res. 9, supt 2, S144 (1989)

9. Chen L, Gothelf Y, Raber J, Michalevicz R, Chebath J and Revel M

Effects of recombinant human IL-6/IFN-beta-2 on tumor cells
Cytokine 1, 153 (1989)

10. Cohen B, Vaiman D, Aloni N, Gesang C, Danovitch S and Chebath J

Activation of protein binding to interferon-responsive sequence (IRS) following type I interferon involves a phosphorylation
J.Interferon Res. 9, supt 2, S160 (1989)



11. Hoss A, Zwarthoff EC and Zawatzky R

Differential expression of interferon alpha and beta induced with Newcastle disease virus in mouse macrophage cultures

J.Gen.Virol. 70, 575-589 (1989)

12. Revel M, Chen L, Novick D, Shulman LM, Gothelf Y, Cohen B, Raber J, Chebath J and Michalevicz R

The growth-promotive, differentiative, and cytostatic properties of interleukin-6

Proc. Am. Assoc. Cancer Res. 31, 499-500 (1990)

13. Revel M, Chen L, Novick D, Shulman LM, Gothelf Y, Cohen B, Raber J and Chebath J

Control of cell growth and differentiation by IL-6

In "Cytokines: Basic Principles and Clinical Applications", S. Romagnani and A.K. Abbas, eds, Serono Symposia, Raven Press, New York, Vol. 68, pp. 227-238 (1990)

14. Chebath J, Cohen B, Gothelf Y, Cohen B, Raber J and Revel M

Protein binding to the interferon-responsive enhancer of the (2'-5')A synthetase gene induced by IFN and by IL-6 in M1 cells

Journal Interferon Res. 10, suppl. 1, S42 (1990)

15. Gileadi O, Schneider T, de Groot N, Chebath J, Revel M and Hochberg A

Interferon beta-2 in differentiating human cytotrophoblast

In "Trophoblast Research", R.K. Miller, ed, Plenum Press, N.Y, pp. 281-285 (1991)

16. Cohen B, Gothelf Y, Vaiman D, Chen L, Revel M and Chebath J

Interleukin-6 induces the (2'-5') oligo A synthetase gene in M1 cells through an effect on the interferon-responsive enhancer

Cytokine3, 83-91 (1991)

17. Gothelf Y, Raber J, Chen L, Schattner A, Chebath J and Revel M

Terminal differentiation of myeloleukemic M1 cells induced by IL-6: Role of endogenous interferon

Lymphokine and Cytokine Research, 10, 369-375 (1991)

18. Revel M, Gothelf Y, Chebath J and Michalevicz R

IL-6 potential for differentiation of acute myeloid leukemia

In "The Status of Differentiation Therapy of Cancer", S. Waxman, G.B. Rossi, F. Takaku, eds, Serono symposia, Raven Press, N.Y, Vol. 82, pp. 125-131 (1991)

Ca 40 J. Kark, Hebrew University of Jerusalem
J. Wahrendorf, DKFZ, Heidelberg

1. Kark JD, Yaari S and Goldbourt U

Are lean smokers at increased risk of lung cancer? The Israel Civil Servant Cancer Study
Arch.Intern.Med, 155, 2409-2416 (1995)

Ca 41 D. Wallach, Weizmann Institute of Science, Rehovot
H. Holtmann, Medizinische Hochschule, Hannover
D. Männel, DKFZ, Heidelberg

1.* Wallach D, Aderka D, Rubinstein M, Engelmann H, Shemer-Avi Y, Sarov I and Holtmann H



Mechanisms involved in regulation of the response to tumor necrosis factor. Possible roles for prostaglandin production in sensitization to TNF effects and for a specific TNF-binding protein in protection from them

In "Tumor Necrosis Factor II", B. Bonavida and G.A. Granger, eds, S. Karger verlag, Basel, pp 146-155 (1989)

2.* Wallach D, Holtmann H, Aderka D, Rubinstein M, Shemer-Avni Y, Sarov I and Engelmann H

Mechanisms which take part in regulation of the response to tumor necrosis factor
Lymphokine Res. 8, 359-363 (1989)

3. Engelmann H, Aderka D, Rubinstein M, Rotman D and Wallach D

A tumor necrosis factor (TNF)-binding protein purified to homogeneity from human urine protects cells from TNF toxicity

J.Biol.Chem. 264, 11974-11980 (1989)

4.* Yuhas Y, Holtmann H, Shemer-Avi Y, Sarov I and Wallach D

Inhibition of tumor necrosis factor-induced cell-killing by tryptophan and indole

Eur.Cytokine Net. 1, 35-40 (1990)

5. Engelmann H, Novick D and Wallach D

Two tumor necrosis factor binding proteins purified from human urine. Evidence for immunological cross reactivity with cell surface tumor-necrosis-factor receptors

J. Biol. Chem. 265, 1531-1536 (1990)

6.* Sarov L, Geron E, Shemer-Avni Y, Manor E, Zvillich M, Wallach D, Schmitz E and Holtmann H

Implications for persistent chlamydial infections of phagocyte-microorganism interplay

Eur.J.Clin.Microbiol.Infect.Dis. 10, 119-123 (1990)

7.* Engelmann H, Holtmann H, Brakebusch C, Shemer-Avni Y, Sarov I, Nophar Y, Hadas E, Leitner O and Wallach D

Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity

J.Biol.Chem. 265, 14497-14504 (1990)

8.* Nophar Y, Kemper O, Brakebusch C, Engelmann H, Zwang R, Aderka D, Holtmann H and Wallach D

Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor

EMBO J. 9, 3269-3278 (1990)

9. Holtmann R, Szamel M and Resch K

Cytokine receptors

In "Receptor Data for Biological Experiments", H.N. Doods, ed, Ellis Horwood Ltd, Chichester, England, pp. 241-244 (1991)

10.* Holtmann H, Brakebusch C, Koenig M, Klocke R, Winzen R, Resch K and Wallach D

Mechanisms controlling the level of receptors for tumor necrosis factor

Agents Actions 32, 106-108 (1991)

11. Derre J, Kemper O, Cherif D, Nophar Y, Berger R and Wallach D

The gene for the type 1 tumor necrosis factor receptor (TNF-RI) is localized on band 12p13

Human Genetics 87, 231-233 (1991)

12. Kemper O, Derre J, Cherif D, Engelmann N, Wallach D and Berger R

The gene for the type II (p75) tumor necrosis factor receptor (TNF-RII) is localized on band 1p36.2-p.36.3

Human Genetics 87, 623-624 (1991)

13.* Koenig M, Wallach D, Resch K and Holtmann H

Induction of hyporesponsiveness to an early post-binding effect of tumor-necrosis-factor (TNF) by TNF and interleukin 1



Eur.J.Immunol. 21, 1741-1745 (1991)

14. Aderka D, Engelmann H, Hornik V, Skornick Y, Levo Y, Wallach D and Kushtai G
Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients
Cancer Res. 51, 5602-5607 (1991)

15. Aderka D, Engelmann H, Maor Y, Brakebusch C and Wallach D
Stabilization of the bioactivity of tumor necrosis factor (TNF) by its soluble receptors
J.Exp.Med. 175, 323-329 (1992)

16. Brakebusch C, Nophar Y, Kemper O, Engelmann H and Wallach D
Cytoplasmic truncation of the p55 tumor necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor
EMBO J. 11, 943-950 (1992)

17.* Winzen R, Wallach D, Engelmann H, Nophar Y, Brakebusch C, Kemper O, Resch K and Holtmann H

Selective decrease in cell surface expression and mRNA level of the 55 kDa tumor necrosis factor receptor during differentiation of HL-60 cells into macrophage-like but not granulocyte-like cells

J.Immunol. 148, 3454-3460 (1992)

18. Schreck R, Meier B, Maennel DN, Droege W and Bauerle PA
Dithiocarbamate as potent inhibitors of nuclear factor-kB activation in intact cells
J.Exp.Med, 175, 1181-1194 (1992)

19. Stiemer RH, Westenfelder U, Gausepohl H, Mirshahi M, Gundt A, Frank RW and Maennel DN

A common epitope on human tumor necrosis factor alpha and an autoantigen "S antigen/arrestin" induces tumor necrosis factor alpha production

J.Autoimmun, 5, 15-26 (1992)

20. Winzen R, Wallach D, Kemper O, Resch K and Holtmann H

Selective up-regulation of the 75-kDa tumor necrosis factor (TNF) receptor and its mRNA by TNF and IL-1

J.Immunol. 150, 4346-4353 (1993)

21. Bigda J, Beletsky I, Brakebusch C, Varfolomeev Y, Engelmann H, Bigda J, Holtmann H and Wallach D

Dual role of the p75 tumor necrosis factor (TNF) receptor in the induction of TNF cytotoxicity
J.Exp.Med. 180, 445-460 (1994)

Ca 42 G. Berke, Weizmann Institute of Science, Rehovot W. Dröge, DKFZ, Heidelberg

1. Schick B and Berke G

The lysis of cytotoxic T lymphocytes and their blasts by cytotoxic T lymphocytes
Immunology 71, 428-433 (1990)

2. Berke G

T-cell mediated cytotoxicity
Curr.Opin.Immunol. 3, 320-325 (1991)

3. Berke G

The mechanism of lymphocyte-mediated killing: Lymphocyte-triggered internal target disintegration

Immunol.Today 12, 396-399 (1991)

4. Berke G, Rosen D and Ronen D

Mechanism of Lymphocyte-Mediated Cytolysis: Functional cytolytic T cells lacking perforin and granzymes



Immunology 78, 105-112 (1993)

5.* Hack V, Gross A, Kinscherf R, Bockstette M, Fiers W, Berke G and Dröge W
Abnormal glutathione and sulfate levels after interleukin-6 treatment and in tumor-induced cachexia

FASEB J. 10, 1219-1226 (1996)

**Ca 43 E. Kedar, Hebrew University of Jerusalem
V. Schirmacher, DKFZ, Heidelberg**

1.* Gazit Z, Weiss DW, Shouval D, Yechezkei M, Schirmacher V, Notter M, Walter J and Kedar E

Chemo-adoptive immunotherapy of nude mice implanted with human coleractal carcinoma and melanoma cell lines

Cancer Immunol.Immunother. 35, 135-144 (1992)

2. Kedar E and Klein E

Cancer Immunotherapy: Are the results discouraging? Can they be improved? A review
Adv.Cancer Res. 59, 245-321 (1992)

**Ca 44 R.N. Apte, Ben-Gurion University, Beer-Sheva
M. Zöller, DKFZ, Heidelberg**

1. Douvdevani A, Huleihel M, Segal S and Apte RN

Constitutive interleukin-1-alpha expression in fibroblastoid lines: Regulation by oncogenes
In "Molecular and Cellular Biology of Cytokines", J.J. Oppenheim, M.C. Powanda, M.J. Kluger, M.J. and C.A. Dinarello, eds, Wiley-Liss, N.Y, pp. 99-104 (1990)

2. Douvdevani A, Huleihel A, Segal M and Apte RN

Aberrations in interleukin-1 expression in oncogene-transformed fibrosarcoma lines: Constitutive interleukin-1-alpha transcription and manifestation of biological activity
Eur.Cytokine Net. 2, 257-264 (1991)

3. Huleihel M, Douvdevani A, Segal S and Apte RN

Regulation of interleukin-1 generation in immune-activated fibroblasts
Eur.J.Immunol. 20, 731 (1990)

4. Apte RN and Huleihel M

Immunoregulatory functions of fibroblasts: Implications for rheumatoid arthritis
Isr.J.Med.Sci. 28, 133-136 (1992)

5.* Zoeller M, Douvdevani A, Segal S and Apte RN

Interleukin-1 produced by tumorigenic fibroblasts influences tumor rejection
Int.J.Cancer 50, 443-449 (1992)

6.* Zoeller M, Douvdevani A, Segal S and Apte RN

Interleukin-1 production by transformed fibroblasts. II. Influence on antigen presentation and T-cell-mediated anti-tumor response
Int.J.Cancer 50, 450-457 (1992)

7.* Douvdevani A, Huleihel M, Zoeller M, Segal S and Apte RN

Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1-alpha either spontaneously or following IL-1-alpha gene transfer
Int.J.Cancer 52, 822-830 (1992)

8. Apte RN, Douvdevani A, Huleihel M, Fima E, Hacham M, Shimoni N and Segal S

IL-1 and pro-inflammatory cytokines produced by primary and transformed fibroblasts abrogate the tumorigenic potential of fibrosarcomas



Folia Biological (Praha) 38, 240-257 (1992)

9. Apte RN, Douvdevani A, Huleihel M, Fima E, Hacham M, Shimoni N and Segal S
IL-1 and pro-inflammatory cytokines produced by primary and transformed fibroblasts abrogate the tumorigenic potential of fibrosarcoma

In "Immunologia 1991", M. Derencik (ed.), Czechoslovakia Acad. Sci, pp. 141-158 (1992)

10.* Apte RN, Douvdevani A, Zöller M, White RM, Dvorkin T, Shimoni N, Fima E, Hacham M, Huleihel M, Benharroch D, Vornov E and Segal S

Involvement of immune responses in the eradication of IL-1 alpha gene-transduced tumor cells. Mechanisms of tumor rejection and immunotherapeutical implications

Folia Biologica (Praha) 40, 1-18 (1994)

11.* Apte RN, Douvdevani A, Zöller M, White RM, Dvorkin T, Shimon N, Fima E, Hacham M, Huleihel M, Benharroch D, Voronov E and Segal S

Cytokine-induced tumor immunogenicity: Interleukin-1 alpha expressed by fibrosarcoma cells confers reduced tumorigenicity

Immunol.Lett. 39, 45-52 (1994)

12.* Apte RN, Douvedeni A, Zöller M, White RM, Dvorkin T, Shimoni N, Fima E, Hacham M, Voronov E and Segal S

Immune recognition and rejection of IL-1 alpha gene transduced tumor cells

In "Cytokine-Induced Tumor Immunogenicity. From Exogenous Molecules to Gene Therapy", (Forni, G, Foa, R, Santoni, A. and Frati, L. eds.). Academic Prpp. 97-111 (1994)

13. Apte RN

Mechanisms of cytokine production by fibroblasts. Implications to normal connective tissue homeostasis and pathological conditions

Folia Microbiologica 40, 392-404 (1995)

Ca 45 P. Rozen, Ichilov Hospital, Tel Aviv
H. Boeing, DKFZ, Heidelberg

1.* Lubin F, Boeing H and Rozen P

Design and background of the Tel-Aviv-Heidelberg dietary study of colonic adenoma patients and calcium intervention trial

In "Large Bowel Cancer Policy, Prevention, Research and Treatment", P. Rozen, C.B. Reich, S.J. Winawer, eds, Karger, Basel, pp. 74-97 (1991)

2. Rozen P

Short-term calcium-intervention studies, in animals and humans, using epithelial proliferation as a biomarker of response. The initiation of a calcium intervention trial in adenoma patients

In "Calcium, Vitamin D and Colon Cancer", M. Lipkin, C.W. Boone, G. Kelloff, W. Malone and V. Steele, eds, CRC Press, New York, pp. 251-266 (1991)

3. Rozen P and Lubin F

Tel-Aviv-Heidelberg studies of adenoma dietary etiology and calcium intervention for prevention of adenoma recurrence

In "Recent Progress in Colorectal Cancer", F.P. Rossini, ed., Elsevier, Amsterdam, pp. 175-178 (1992)

4. Rozen P, Liberman V, Angel S, Owen R, Trostler N, Shkolnika T and Kritchevsky D

A new dietary model to study colorectal carcinogenesis: Experimental design, food preparation, and experimental findings

Nutr.Cancer 25, 79-100 (1996)

5. Liberman V, Nyska A, Kashtan H, Zajicek G, Lubin F and Rozen P



Differing proliferative responses in the proximal and distal colons of growing rats fed the human food eaten by adenoma patients
Digestive Diseases and Sciences 41, 1057-1064 (1996)

6. Weisgerber UM, Boeing H, Waldherr R, Owen RW, Raedsch R, Sinsbach C, Hilswicht H-G, Ohl V, Rexroth W, Scheppach W, Singer R, Weber JCF and Wahrendorf J

Effect of a long-term, placebo controlled calcium intervention on sigmoidal cell proliferation in patients with sporadic colorectal adenomatous polyps
Gut 38, 396-402 (1996)

7. Lubin F, Rozen P, Arieli B, Farbstein M, Knaani Y, Bat L and Farbstein H
Nutritional and lifestyle habits and water-fiber interaction in colorectal adenoma etiology
Cancer Epidemiology, Biomarkers & Prevention 6, 79-85 (1997)

8. Rozen P, Lubin F, Papo N and Zajicek G
Rectal epithelial proliferation in persons with or without a history of adenoma and its association with diet and lifestyle habits
Cancer 83, 1319-1327 (1998)

Ca 46 **A. Ben-Ze'ev, Weizmann Institute of Science, Rehovot**
J. Kartenbeck, W. Franke, DKFZ, Heidelberg

1. Rodriguez Fernandez JL, Geiger B, Salomon D and Ben-Ze'ev A
Overexpression of vinculin suppresses cell motility in Balb/C 3T3 cells
Cell Motil.Cytoskel. 22, 127-134 (1992)

2. Glück U, Rodriguez Fernandez JL, Pankov R and Ben-Ze'ev A
Induction of adherens junction protein expression in growth-activated 3T3 cells and in regenerating liver
Exp.Cell Res. 202, 477-486 (1992)

3.* Rodriguez Fernandez JL, Geiger B, Salomon D, Sabanay I, Zoeller M and Ben-Ze'ev A
Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA
J.Cell Biol. 119, 427-438 (1992)

4. Ben-Ze'ev A
Cytoarchitecture and signal transduction
Critical Reviews in Eukaryotic Gene Expression 2, 265-281 (1992)

5. Geiger B, Ginsberg D, Ayalon O, Volberg T, Rodriguez Fernandez JL, Yarden Y and Ben-Ze'ev A
Cytoplasmic control of cell adhesion
Cold Spring Harbor Symp. Quant. Biol. 57, 631-642 (1992)

6. Koch PJ, Goldschmidt MD, Zimbelmann R, Troyanovsky R and Franke WW
Complexity and expression patterns of the desmosomal cadherins
Proc. Natl. Acad. Sc. USA 89, 353-357 (1992)

7. Glück U, Kwiatkowski DJ and Ben-Ze'ev A
Suppression of tumorigenicity in simian virus 40-transformed 3T3 cells transfected with alpha-actinin cDNA
Proc. Natl. Acad. Sci. USA. 90, 383-387 (1993)

8. Buxton RS, Cowin P, Franke WW, Garrod DR, Green KJ, King IA, Koch PJ, Magee AI, Rees DA, Stanley JR, Steinberg MS
Nomenclature of the desmosomal cadherins
J.Cell Biol. 121, 481-483 (1993)

9. Rodriguez Fernandez JL, Geiger B, Salomon D and Ben-Ze'ev A



Suppression of vinculin expression by antisense transfection confers changes in cell morphology, motility, and anchorage dependent growth
J.Cell.Biol. 122, 1285-1294 (1993)

10. Kartenbeck J, Koch PJ, Franke WW
Desmoglein

In "Guide Book to the Extracellular Matrix and Adhesion Proteins". T.E. Kreis, R.D. Vale, eds, Oxford University Press, Oxford, pp. 133-135 (1993)

11. Theis DG, Koch PJ and Franke WW

Differential synthesis of type 1 and type 2 desmocollin mRNAs in human stratified epithelia
Int.J.Dev.Biol. 37, 101-110 (1993)

12. Schaefer S, Troyanovsky S, Heid H, Eshkind LG, Koch P and Franke WW

Cytoskeletal architecture and epithelial differentiation: Molecular determinants of cell interaction and cytoskeletal filament anchorage
C.R.Acad.Sci.Paris 316, 1316-1323 (1993)

13. Ben-Ze'ev A

The role of the cytoskeleton in the relationship between cell shape, gene expression and morphogenesis

In "Developmental Biology and Cancer", G.M. Hodges, C. Rowlatt, eds, CRC Press, pp. 211-234 (1994)

14. Ben-Ze'ev A, Rodriguez Fernandez JL, Glück U, Salomon D and Geiger B

Changes in adhesion plaque protein levels regulate cell motility and tumorigenicity
Adv.Exp.Med.Biol. 358, 147-157 (1994)

15. Schäfer S, Koch P and Franke WW

Identification of the ubiquitous human desmoglein, DSG2, and the expression catalogue of the desmoglein subfamily of desmosomal cadherins
Exp.Cell Res. 211, 391-399 (1994)

16. Franke WW, Koch PJ, Schaefer S, Heid H, Troyanovsky SM, Moll I and Moll R

The desmosome and the syndesmos: Cell junctions in normal development and in malignancy

In "Molecular and cellular Basis for Cell to Cell Interaction: Its Significance in Cancer". S. Hirohashi, ed, Princeton Scientific Publ, Princeton, pp. 14-27 (1994)

17. Troyanovsky SM, Troyanovsky RB, Eshkind LG, Krutovskikh VA, Leube RE and Franke WW

Identification of the plakoglobin-binding domain in desmoglein and its role in plaque assembly and intermediate filament anchorage
J.Cell Biol. 127, 151-160 (1994)

18. Coll J-L, Ben-Ze'ev A, Ezzell RM, Rodriguez Fernandez JL, Baribault H, Oshima RG and Adamson ED

Targeted disruption of the vinculin genes in F9 and embryonic stem cells changes cell morphology, adhesion and locomotion
Proc. Natl. Acade. Sci. USA, 92, 9161-9165 (1995)

19. Troyanovsky SM, Troyanovsky RB, Eshkind L, Leube RE and Franke WW

Identification of amino acid sequence motifs in desmocollin, a desmosomal glycoprotein, that are required for plakoglobin binding and plaque formation
Proc. Natl. Acad. Sci. USA 91, 10790-10794 (1994)

20.* Ben Ze'ev A, Rodriguez Fernandez JL, Glück U, Salomon D, Zöller M and Geiger B

Regulation of adherens junction protein levels: role in motility and tumorigenicity
In "Advances in Molecular and Cell Biology", J. Hesketh, ed, Vol. 12, 143-168 (1995)

21. Simcha I, Geiger B, Levenberg-Yehuda S, Salomon D and Ben-Ze'ev A

Suppression of tumorigenicity by plakoglobin: An augmenting effect of N-cadherin
J.Cell.Biol. 133, 199-209 (1996)



22. Chitaev NA, Leube RE, Troyanovsky RB, Eshkind LG, Franke WW and Troyanovsky SM

The binding of plakoglobin to desmosomal cadherins: patterns of binding sites and topogenic potential
J.Cell Biol. 133, 359-369 (1996)

**Ca 47 Y. Shiloh, Tel-Aviv University
A. Weith, M. Schwab, DKFZ, Heidelberg**

1. Mor O, Messinger Y, Rotman G, Bar-Am I, Ravia Y, Eddy RL, Shows TB, Park J-G, Gazdar AF and Shiloh Y

Novel DNA sequences at 10q26 are amplified in human gastric carcinoma cell lines: Molecular cloning by competitive DNA reassociation
Nucleic Acids Res, 19, 117-123 (1991)

2. Haman U, Wenzel A, Frank R and Schwab M

The MYCN protein of human neuroblastoma cells is phosphorylated by casein kinase II in the central region and at scrinc 367
Oncogene, 6, 1745-1751 (1991)

3. Wenzel A, Czielpuch C, Haman U, Schurmann J and Schwab M

The N-myc oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in human neuroblastoma cells
EMBO J. 10, 3703-3712 (1991)

4. Shiloh Y, Mor O, Manor A, Bar-Am I, Rotman G, Eubanks J, Gutman M, Ranzani GN, Houldsworth J, Evans G and Avivi L

DNA sequences amplified in cancer cells: an interface between tumor biology and human genome analysis
Mutat.Res, 276, 329-337 (1992)

5. Bar-Am L, Mor O, Yeger H, Shiloh Y and Avivi L

Detection of amplified DNA sequences in human tumor cell lines by fluorescent in situ hybridization
Genes, Chromosomes and Cancer, 4, 314-320 (1992)

6. Amler LC, Shibasaki Y, Savelyeva L, and Schwab M

Amplification of the N-myc gene in human neuroblastomas: tandemly repeated amplicons within homogeneously staining regions on different chromosomes with the retention of single copy gene at the resident site
Mutation Res, 276, 291-297 (1992)

7. Schwab M

Molecular cytogenetics of human neuroblastoma
Biochim.Biophys.Acta, 114, 43-50 (1992)

8.* Mor O, Ranzani GN, Ravia Y, Rotman G, Gutman M, Manor A, Amadori D, Houldsworth J, Hollstein M, van der Bosch K, Schwab M and Shiloh Y

DNA amplification in human gastric carcinomas
Cancer Genet.Cytogenet. 65, 111 -114 (1993)

9. Schwab M

Amplification of N-myc as a prognostic marker for patients with neuroblastoma
Cancer Biol., 4, 13-18, (1993)

10. Czielpuch C, Wenzel A, Schurmann J and Schwab M

Activation of gene transcription by the amino terminus of the N-myc protein does not require association with the protein encoded by the retinoblastoma suppressor gene RB1
Oncogene 8, 2833-2838 (1993)



11. Corvi R, Amler LC, Savelyeva L, Gehring M and Schwab M

MYCN is retained in a single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells

Proc. Natl. Acad. Sci. U.S.A, 91, 5523-5527 (1994)

**Ca 48 J. Tal, Ben-Gurion University, Beer-Sheva
J. Schlehofer, DKFZ, Heidelberg**

1. Walz C and Schlehofer JR

Modification of some biological properties of HeLa cells containing adeno-associated virus DNA integrated into chromosome-17

J.Virol, 66, 2990-3002 (1992)

2. Schlehofer JR

Tumor suppressive properties of adeno-associated viruses

Mutation Research 305, 303-313 (1994)

**Ca 49 B. Geiger, Weizmann Institute of Science, Rehovot
W. Franke, DKFZ, Heidelberg**

1. Geiger B, Ginsberg D, Salomon D and Volberg T

The molecular basis for the assembly and modulation of adherens-type junctions

Cell.Differ.Develop. 32, 343-354 (1990)

2. Ginsberg D, DeSimone D and Geiger B

Expression of a novel cadherin (EP-cadherin) in unfertilized eggs and early Xenopus embryos

Development 111, 315-325 (1991)

3.* Kartenbeck J, Schmelz M, Franke WW and Geiger B

Endocytosis of junctional cadherins in bovine kidney epithelial (MDBK) cells cultured in low Ca^{2+} ion medium

J.Cell Biol. 113, 881-892 (1991)

4. Geiger B and Ginsberg D

The cytoplasmic domain of adherens-type junctions

Cell Motility and the Cytoskeleton 20, 1-6 (1991)

5. Goncharova EJ, Kam Z and Geiger B

The involvement of adherens junction components in myofibrillogenesis in cultured cardiac myocytes

Development 114, 173-183 (1992)

6. Volberg T, Zick Y, Dror R, Sabanay I, Gilon C, Levitzki A and Geiger B

The effect of tyrosine-specific protein phosphorylation on the assembly of adherens-type junctions

EMBO J. 11, 1733-1742 (1992)

7. Salomon O, Ayalon O, Patel-King R, Hynes RO and Geiger B

Extrajunctional distribution of N-cadherin in cultured human endothelial cells

J.Cell.Sci. 102, 7-17 (1992)

8. Geiger B and Ayalon O

Cadherins

Ann.Rev.Cell Biol. 8, 307-332 (1992)

9. Rodriguez Fernandez JL, Geiger B, Salomon D and Ben-Ze'ev A

Overexpression of vinculin suppresses cell motility in 3T3 cells



Cell Motility and the Cytoskeleton 22, 127-134 (1992)

10.* Rodriguez Fernandez JL, Geiger B, Salomon D, Sabanay I, Zöller M and Ben-Ze'ev A

Suppression of tumorigenicity in transformed cells following transfection with vinculin cDNA
J.Cell.Biol, 119, 427-438 (1992)

11. Fouquet B, Zimbelmann R and Franke WW

Identification of plakoglobin in oocytes and early embryos of *Xenopus laevis*: Maternal expression of a gene encoding a junctional plaque proteins
Differentiation 51, 187-194 (1992)

12. Franke WW, Troyanovsky SM, Koch PJ, Troyanovsky R, Fouquet B and Leube RE
Desmosomal proteins - mediators of intercellular coupling and intermediate filament anchorage

Cold Spring Harbor Symp. Quant. Biol, 57, 647-652 (1992)

13. Koch PJ, Goldschmidt MD, Zimbelmann R, Troyanovsky R, Franke WW

Complexity and expression patterns of the desmosomal cadherins
Proc. Natl. Acad. Sci. USA, 89, 353-357 (1992)

14. Rodriguez Fernandez JL, Salomon D, Ben-Ze'ev A and Geiger B

Suppression of vinculin expression by antisense transfection confers changes in cell morphology, motility and anchorage-dependent growth of 3T3 cells
J.Cell Biol. 122, 1285-1294 (1993)

15. Buxton RS, Cowin P, Franke WW, Garrod DR, Green KJ, King IA, Koch PJ, Magee AI, Rees DA, Stanley JR, Steinberg MS

Nomenclature of the desmosomal cadherins

J.Cell Biol, 121, 481-483 (1993)

16. Schmelz M, Franke WW

Complexus adhaerentes, a new group of desmoplakin-containing junctions in endothelial cells. I. The syndesmos connecting retothelial cells of lymph nodes

Eur.J.Cell Biol. 61, 274-289 (1993)

17. Theis DG, Koch PJ, Franke WW

Differential synthesis of type 1 and type 2 desmocollin mRNAs in human stratified epithelia
Int.J.Dev.Biol. 37, 101-110 (1993)

18. Troyanovsky SM, Eshkind LG, Troyanovsky RB, Leube RE, Franke WW

Contributions of cytoplasmic domains of desmosomal cadherins to desmosome assembly and intermediate filament anchorage

Cell 72, 561-574 (1993)

19. Koch PJ, Franke WW

Desmosomen: Von der Ultrastruktur zum molekularen Bauplan

In "Zeillbiologie und Klinische Pharmakologie", H.J. Dengler, ed, Gustav Fisher Verlag, Stuttgart, pp. 110-123 (1993)

20. Ayalon O, Lampugnani M-G, Dejana E, Geiger B

Spatial and temporal relationships between cadherins and PECAM-I in cell-cell junctions of human endothelial cells

J.Cell Biol. 126, 247-258 (1994)

21. Heasman J, Ginsberg D, Geiger B, Goldstone K, Pratt T, Yoshida-Noro C, Wylie C

A functional test for maternally inherited cadherin in *Xenopus* shows its importance in cell adhesion at the blastula stage

Development 120, 49-57 (1994)

22. Schäfer S, Koch PJ, Franke WW

Identification of the ubiquitous human desmoglein, Dsg2, and the expression catalogue of the desmoglein subfamily of desmosomal cadherins

Exp.Cell Res. 211, 391-399 (1994)

23. Schmelz M, Moll R, Kuhn C, Franke WW



Complexus adhaerentes, a new group of desmoplakin-containing junctions in endothelial cells: II. Different types of lymphatic vessels
Differentiation 57, 97-117 (1994)

Ca 50 M. Aboud, Ben-Gurion University, Beer-Sheva
R. Flügel, M. Löchelt, DKFZ, Heidelberg

1.* Aboud M, Rosner M, Dombrovsky A, Revasova T, Feldman G, Tolpolar L, Strilitz-Hassan Y and Flügel RM

Interactions between retroviruses and environmental carcinogens and their role in animal and human leukemogenesis

Leukemia Res. 16, 1061-1069 (1992)

2.* Aboud M, Dombrovsky A, Rosner M, Feldraan G, Revazov T, Strilitz-Hassan Y, Priel E, Wolfson M, Segal S and Flügel RM

Regulatory elements and leukemogenicity of HTLV-I and HTLV-II

J.Viral Dis. I, 31-49 (1993)

3.* Löchelt M, Aboud M and Flügel RM

Increase in basal transcriptional activity of the human foamy virus internal promoter by the homologous long terminal repeat promoter in cis

Nucleic Acids Res. 21, 4226-4230 (1993)

4.* Löchelt M, Flügel MR and Aboud M

The human foamy virus internal promoter directs the expression of the functional Bel-1 trans-activator and bet protein early after infection

J.Virol. 68, 638-645 (1993)

5. Feldman G and Aboud M

Stimulation of HTLV-I expression by subtoxic dose of 3-methylcholanthrene

Leukemia Res. 17, 429-435 (1993)

6.* Wolfson M, Lev M, Avinoia I, Malik Z, Löchelt M, Flügel RM and Aboud M

Stimulation of virus production and induction of self-syncytium formation in human T-cell leukemia virus type-I and type-II infected T-cells by 12-O-tetradecanoyl phorbol-13-acetate

J.Virol. 68, 4695-4699 (1994)

7. Mor-Vaknin N and Aboud M

Effect of 3-methylcholanthrene on the expression and structure of HTLV-I in infected cells

In "Proceedings of XVI International Cancer Congress 1994, New Delhi, India", Monduzzi Editor, International Proceedings, Div. Bologna, Italy, pp. 213-217 (1994)

8.* Kogel D, Aboud M and Flügel RM

Molecular biological characterization of foamy virus reverse transcriptase and ribonuclease H domains

Virology 213, 97-108 (1995)

9.* Revasova T, Dombrovsky A, Löchelt M, Flügel RM and Aboud M

Tax independent stimulation of human T-cell leukemia virus type-I-expression and

differential effects on its infectivity by subtoxic and toxic doses of 3-methylcholanthrene

Cell.Molec.Biol.Res. 41, 377-385 (1995)

10.* Dias HW, Aboud M and Flügel RM

Analysis of the phylogenetic placement of different spumaretroviral genes reveals complex pattern of foamy virus evolution

Virus Genes 11, 183-190 (1996)

11.* Kogel D, Aboud M and Flügel RM

Mutational analysis of the reverse transcriptase and ribonuclease H domains of human foamy virus



Ca 51 M. Oren, Weizmann Institute of Science, Rehovot
M. Schwab, R. Corvi, DKFZ, Heidelberg

- 1. Barak Y, Juven T, Haffner R, Oren M**
mdm2 expression is induced by wild type p53 activity
EMBO J. 12, 461-468 (1993)
- 2. Barak Y, Ginsberg D, Michael D, Ragimov N, Shaulian E, Yonish-Rouach E, Zauberman A, Aloni Y and Oren M**
Mechanisms of action of p53
In "The pharmacology of cell differentiation", R.A. Rifkind, Ed, Elsevier, Amsterdam, pp. 129-145 (1993)
- 3. Juven T, Barak Y, Zauberman A, George D and Oren M**
Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene
Oncogene 8, 3411-3416 (1993)
- 4. Ohgaki H, Eibl RE, Schwab M, Reichel MB, Mariani L, Gehring M, Petersen L, Höll T, Wiestler OD and Kleihues P**
Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system
Mol.Carcinogenesis 8, 74-80 (1993)
- 5. Barker PE, Savelyeva L and Schwab M**
Translocation junctions cluster at the distal short arm of chromosome 1 (Ip36.1-2) in human neuroblastoma cells
Oncogene 8, 3353-3358 (1993)
- 6. Ohgaki H, Eibl RH, Schwab M, Reichel MB, Mariani L, Gehring M, Petersen I, Höll T, Wiestler OD, Kleihues P**
Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system
Mol.Carcinogenesis 8, 74-80 (1993)
- 7. Barker PE, Schwab M**
Junction mapping of translocation chromosomes by fluorescence in situ hybridization and computer image analysis in human solid tumors
Methods in Molecular Genetics 2, 129-153 (1993)
- 8. Savelyeva L, Corvi R and Schwab M**
Translocation involving Ip and 17q is a recurrent genetic alteration of human neuroblastoma cells
Am.J.Hum.Genet. 55, 334-340 (1994)
- 9. Corvi R, Amler LC, Savelyeva L, Gehring M and Schwab M**
MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells
Proc. Natl. Acad. Sci. USA, 91, 5523-5527 (1994)
- 10. Barak Y, Gottlieb E, Juven-Gershon T and Oren M**
Regulation of mdm2 expression by p53: alternatively promoters produce transcripts with non-identical translation potential
Genes Dev.8, 1739-1749 (1994)
- 11.* Corvi R, Savelyeva L, Breit S, Wenzel A, Handgretinger R, Barak Y, Oren M, Amler L and Schwab M**
Non-syntenic amplification of *MDM2* and *MYCN* in human neuroblastomas
Oncogene 10, 1081-1086 (1995)



12. Barak Y, Lupo A, Zauberman A, Juven T, Aloni-Grinstein R, Gottlieb E, Rotter V and Oren M

Targets for transcriptional activation by wild-type p53: endogeneous retroviral LTR, immunoglobulin-like promoter, and an internal promoter of the mdm2 gene
Cold Spring Harb. Symp. Quant. Bio1 , LIX, 225-235 (1995)

13. Amler LC, Corvi R, Praml C, Savelyeva L, Le Paslier D and Schwab M

A reciprocal translocation (1;15)(36.2;q24) in a neuroblastoma cell line is accompanied by DNA duplication and may signal the site of a putative tumor suppressor-gene
Oncogene 10, 1095-1101 (1995)

14. Amler LC, Corvi R, Praml C, Savelyeva L, Le Paslier D and Schwab M

Reciprocal translocation at Ip36. 2/DIS160 in a neuroblastoma cell line: Isolation of a YAC clone at the break

Europ.J.Cancer, 31A, 527-530 (1995)

15. Corvi R, Savelyeva L, Amler LC, Handgretinger R and Schwab M

Cytogenetic evolution of N-MYC and MDM2 amplification of the neuroblastoma tumour, LS and its cell line

Europ.J.Cancer, 31A, 520-523 (1995)

Ca 52 H. Degani, Y. Salomon, Weizmann Institute of Science,
Rehovot
W. Lehmann, W.E. Hull, DKFZ, Heidelberg

1. Degani H, DeJordy JO and Salomon Y

Determination of the response melanoma cells to melanocyte stimulating hormone by ³¹P nuclear magnetic resonance spectroscopy
J.Receptor Res. 13 (1-4), 55-68 (1993)

2. Salomon Y, Zohar M, Dejordy JO, Eshel Y, Shafir I, Leiba H, Garty NB, Schmidt-Stole J, Azrad A, Shai E and Degani H

Signaling mechanisms controlled by melanocortins in melanoma, lacrimal, and brain astroglial cells

Ann. N.Y. Acad. Sci. 680, 364-380 (1993)

3. Shedd SF, Lutz NW and Hull WE

The influence of medium formulation on phosphomonoester and UDP-hexose levels in cultured human colon tumor cells as observed by ³¹P NMR spectroscopy

NMR Biomed. 6, 254-263 (1993)

4. Metzger K, Angres G, Maier H and Lehmann WD

Oral cancer: risk factors and quantification of arachidonic acid metabolites in human saliva by gas chromatography/mass spectrometry

In "Mass Spectrometry in Cancer Research", E. Constantine, ed, Amudes, Strasbourg, pp. 137-151 (1994)

5. Lehmann WD, Metzger K, Stephan M, Beilecke U, Zalan I, Habenicht AJR and Fürstenberger G

Quantitative lipoxygenase product profiling by gas chromatography negative-ion chemical ionization mass spectrometry

Anal.Biochem. 224, 227-234 (1995)

6. Metzger K, Angres G, Maier H, Lehmann WD

Lipoxygenase products in human saliva - patients with oral cancer compared to controls
Free Radic. Biol. Med. 18, 185-194 (1995)

7. Tyagi RK, Azrad A, Degani H and Salomon Y



Simultaneous extraction of cellular lipids and water soluble metabolites: Evaluation by NMR spectroscopy

Magn.Reson.Med. 35, 194-200 (1995)

8. Metzger K, Rehberger PA, Erben G, Lehmann WD

Identification and quantification of lipid sulfate esters by electrospray MS/MS techniques: cholesterol sulfate

Anal.Chem. 67, 4178-4183 (1995)

**Ca 53 S. A. Lamprecht, Ben-Gurion University, Beer-Sheva
G. Fürstenberger, F. Marks, DKFZ, Heidelberg**

1. Krieg P, Schnapke R, Fürstenberger G, Vogt I and Marks F

TGF β 1 and skin carcinogenesis: Antiproliferative effect in vitro and TGF- β 1 mRNA expression during epidermal hyperproliferation and multistage tumorigenesis

Molecular Carcinogenesis 4, 129-137 (1991)

2. Fürstenberger G, Krieg P, Schnapke R, Feil S and Marks F

The role of endogenous factors in skin carcinogenesis

In; "Recent results in cancer research", Vol. 128, pp.323-337: Proceedings of the international symposium on skin in man and experimental models", E. Hecker, F. Marks, E.G. Fung and W. Tilgen, eds, Springer-Verlag, Heidelberg (1993)

3. Schwartz B, Ben Harroch D, Prinsloo I, Cagnano E and Lamprecht SA

Phosphotyrosine, p62 c-myc and p21 c-Ha-ras proteins in colonic epithelium of normal and dimethylhydrazine-treated rats: an immunohistochemical approach

Anticancer Research 15, 211-218 (1995)

4. Friling R, Yassar Y, Levy R, Kost J, Schwartz B, Michailowski R and Lamprecht SA

The role of transforming growth factor- β in the control of corneal neovascularization

In Vivo 10, 59-64 (1996)

**Ca 54 M. Liscovitch, Weizmann Institute of Science, Rehovot
V. Kinzel, DKFZ, Heidelberg**

1. Kaszkin M, Seidler L, Kast R and Kinzel V

Epidermal growth factor-induced production of phosphatidylalcohol by HeLa cells and A431 cells through activation of phospholipase D

Biochem.J. 287, 51-57 (1992)

2. Plein P, Kaszkin M and Kinzel V

Accumulation of ester- and ether-linked phosphatidates by HeLa cells in response to ionophore A23187 through activation of phospholipase D

Biological Chemistry Hoppe-Seyler 373, 151-157 (1992)

3. Schiess K, Kaszkin M, Jordan P, Seidler L and Kinzel V

Mobilization of diacylglycerol in intact HeLa cells by exogenous phospholipase C from *C. perfringens* is accompanied by release of fatty acids including arachidonic acid

Biochim.Biophys.Acta 1137, 82-94 (1992)

4. Kaszkin M, Richards J and Kinzel V

Proposed role of phosphatidic acid in the extracellular control of the transition from G2-phase to mitosis exerted by epidermal growth factor in A431 cells

Cancer Res. 52, 5627-5634 (1992)

5. Ben-Av P, Eli Y, Schmidt US, Tobias KE and Liscovitch M



Distinct mechanisms of phospholipase D activation and attenuation utilized by different mitogens in NIH-3T3 fibroblasts
Eur.J.Biochem. 215, 455-463 (1993)

6. Eldar H, Ben-Av P, Schmidt U.S, Livneh E

Up-regulation of phospholipase D induced by over-expression of protein kinase C-alpha. Studies in intact cells and in detergent-solubilized membranes in vitro
J.Biol.Chem. 268, 12560-12564 (1993)

7. Liscovitch M, Ben-Av P, Danin M, Faiman G, Eldar H and Livneh E

Phospholipase D-mediated hydrolysis of phosphatidylcholine: role in cell signaling
J.Lipid Medial. 8, 177-182 (1993)

8. Liscovitch M and Chalifa V

Signal-activated phospholipase D

In "Signal-activated Phospholipases", M. Liscovitch, ed, R.G. Landes Co, Austin, pp. 31-63 (1994)

9. Barth H and Kinzel V

Phorbol ester TPA rapidly prevents activation of p34^{cdc2} histone H1 kinase and concomitantly the transition from G₁ phase to mitosis in synchronized HeLa cells

Exp.Cell Res. 212, 383-388 (1994)

10. Williger B, Reich R, Neeman M, Bercovici T and Liscovitch M

Release of gelatinase A (matrix metalloproteinase 2) induced by photolysis of caged phosphatidic acid in HT 1080 metastatic fibrosarcoma cells

J.Biol.Chem. 270, 29656-29659 (1995)

11. Barth H and Kinzel V

Epidermal growth factor rapidly impairs activation of p34^{cdc2} protein kinase in HeLa cells at the G₂-M-boundary

J.Cell.Physiol. 162, 44-51 (1995)

12. Barth H, Hoffmann I, Klein S, Kaszkin M, Richards J and Kinzel V

Inhibition of cdc25-C phosphatase in the immediate G₁-phase delay induced by the exogenous factors EGF and phorbol ester TPA

J.Cell.Physiol. 168, 589-599 (1996)

13. Kaszkin M, Richards J and Kinzel V

Phosphatidic acid mobilized by phospholipase D is involved in the TPA-induced G₂ delay of A431 cells

Biochem.J. 314 Part I, 129-138 (1996)

Ca 55 J. Bar-Tana, Hebrew University of Jerusalem
D. Keppler, DKFZ, Heidelberg

1. Keppler D, Müller M, Klünemann C, Guhlmann A, Krauss K, Müller J, Berger U, Leier I and Mayatepek E

Transport and *in vivo* elimination of cysteinyl leukotrienes
Advan.Enzyme Regul. 32, 107-116 (1992)

2. Keppler D

Leukotrienes: biosynthesis, transport, inactivation, and analysis
Revs.Physiol.Biochem.Pharmacol, 121, 1-30 (1992)

3. Hertz R, Kalderon B and Bar-Tana J

Thyromimetic effect of peroxisome proliferators
Biochimie 75, 257-261 (1993)

4. Kadmon M, Klünemann C, Böhme M, Ishikawa T, Gorgas K, Otto G, Herfath C and Keppler D



Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile

Gastroenterology 104 1507-1514 (1993)

5. Böhme M, Büchler M, Müller M and Keppler D

Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane

FEBS Lett. 333, 193-196 (1993)

6. Jedlitschky G, Mayatepek E and Keppler D

Peroxisomal leukotriene degradation : Biochemical and clinical implications

Advan.Enzyme Regul. 33, 181-194 (1993)

7. Böhme M, Jedlitschky G, Leier I, Büchler M and Keppler D

ATP-Dependent export pumps and their inhibition by cyclosporins

Advan.Enzyme Regul. 34, 371-380 (1994)

8.* Jedlitschky I, Leier M, Böhme C, Buchholz C, Bar-Tana J and Keppler D

Hepatobiliary elimination of the peroxisome proliferator nafenopin by conjugation and subsequent ATP-dependent transport across the canalicular membrane

Biochem.Pharmacol. 48, 1113-1120 (1994)

9. Frenkel B, Bishara-Shieban J and Bar-Tana J

The effect of beta, beta'-tetramethyl hexadecanedioic acid (MEDICA 16) on plasma very low density lipoprotein metabolism in rats: Role of apolipoprotein C-III

Biochem. J. 298, 409-414 (1994)

10. Hertz R, Berman I and Bar-Tana J

Transcriptional activation by amphipathic carboxylic peroxisome proliferators is induced by the free acid rather than the acyl-CoA derivative

Eur.J.Biochem. 221, 611-615 (1994)

11. Leier I, Jedlitschky G, Buchholz U and Keppler D

Characterization of the ATP-dependent leukotriene C₄ export carrier in mastocytoma cells

Eur.J.Biochem. 220, 599-606 (1994)

12. Büchler M, Böhme M, Ortlepp H and Keppler D

Functional reconstitution of ATP-dependent transporters from the solubilized hepatocyte canalicular membrane

Eur.J.Biochem. 224, 345-352 (1994)

13. Jedlitschky G, Leier I, Buchholz U, Center M and Keppler D

ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein

Cancer Research 54, 4833-4836 (1994)

14. Leier I, Jedlitschky G, Buchholz U, Cole SPC, Deeley RG and Keppler D

The *MRP* gene encodes an ATP-dependent export pump for leukotriene C₄ and structurally related conjugates

J.Biol.Chem. 269, 27807-27810 (1994)

15. Hertz R, Bishara-Shieban J and Bar-Tana J

Mode of action of peroxisome proliferators as hypolipidemic drugs: Suppression of apolipoprotein C-III

J.Biol.Chem. 270, 13470-13475 (1995)

16. Mayer R, Kartenbeck J, Büchler M, Jedlitschky G, Leier I and Keppler D

Expression of the *MRP* gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes

J.Cell.Biol. 131, 137-150 (1995)

17.* Hertz R, Berman I, Keppler D and Bar-Tana J

Activation of gene transcription by prostacyclin analogues is mediated by the peroxisome proliferators activated receptor (PPAR)

Eur.J.Biochem. 235, 242-247 (1996)



18. Hertz R, Nikodem V, Ben-Ishai A, Berman I and Bar-Tana J

Thyromimetic mode of action of peroxisome proliferators: Activation of malic enzyme gene transcription

Biochem.J. 319, 241-248 (1996)

19. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G and Keppler D

Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump

Cancer Res. 56, 988-994 (1996)

20. Hertz R, Seckbach M, Zakin M and Bar-Tana J

Transcriptional suppression of the transferrin gene by hypolipidemic peroxisome proliferators

J.Biol.Chem. 271, 218-224 (1996)

**Ca 56 I. Ginzburg, Weizmann Institute of Science, Rehovot
H. Ponstingl, DKFZ, Heidelberg**

1. Sadot E, Marx R, Barg J, Behar L and Ginzburg I

Complete sequence of 3'-untranslated region of Tau from rat central nervous system

J.Mol.Biol. 241, 325-331 (1994)

2. Sadot E, Barg J, Rasouly D, Lazarovici P and Ginzburg I

Short- and long-term mechanisms of Tau regulation in PC 12 cells

J.Cell.Sci. 108, 2857-2864 (1995)

3. Bischoff FR, Krebber H, Smirnova E, Dong W and Ponstingl H

Co-activation of RanGTPase and inhibition of GTP dissociation by Ran-GTP binding protein RanBPI

EMBO J. 14, 705-725 (1995)

4. Bischoff FR, Krebber H, Kempf T and Ponstingl H

Human RanGTPase activating protein RanGAPI is a homologue of yeast Rnalp involved in mRNA processing and transport

Proc. Natl. Acad. Sci. USA 92, 1749-1753 (1995)

5. Sadot E, Heicklen-Klein A, Barg J, Lazarovici P and Ginzburg I

Identification of a Tau promoter region mediating tissue-specific-regulated expression in PC12 cells

J.Mol.Biol. 256, 805-812 (1996)

6. Krebber H and Ponstingl H

Ubiquitous expression and testis-specific alternative polyadenylation of mRNA for the human Ran GTPase activator RanGAP 1

Gene 180, 7-11 (1996)

7. Krebber H, Bastians H, Hoheisel J, Lichter P, Ponstingl H and Joos S

Localization of genes encoding the proteins Ran and RanBP2 to human chromosomes 6p21 and 2q11-q13, respectively, by fluorescence in situ hybridization

Genomics 43, 247-248 (1997)

8. Sadot E, Jaaro H, Seger R and Ginzburg I

Ras-signaling pathways: Positive and negative regulation of tau expression in PC 12 cells

J.Neurochem. 70, 428-431 (1998)

9. Bastians H, Krebber H, Hoheisel J, Ohi S, Lichter P, Ponstingl H and Joos S

Assignment of the human serine/threonine protein phosphatase 4 gene (PPP4C) to chromosome 16p11-p12 by fluorescence in situ hybridization

Genomics 42, 181-182 (1997)

10. Bastians H, Krebber H, Vetrie D, Hoheisel J, Lichter P, Ponstingl H and Joos S



Localization of the novel serine/threonine protein phosphatase 6 gene (PPP6C) to human chromosome Xq22.3
Genomics 41, 296-297 (1997)

Ca 57 G. Neufeld, Technion, Haifa
R. Schwartz-Albiez (V. Schirmacher), DKFZ, Heidelberg

1. Soker S, Goldstaub D, Svahn C, Cohen T, Levy B-Z, Vlodavsky I and Neufeld G
Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF 165 to its receptors

Biochem.Biophys.Res.Commun. 203, 1339-1347 (1994)

2. Tessler S, Rockwell P, Hicklin D, Cohen T, Levi B-Z, Lemischka IR, Witte L, and Neufeld G

Heparin modulates the interaction of VEGF₁₆₅ with soluble and cell associated *flk-1* receptors
J.Biol.Chem. 269, 12456-12461 (1994)

3. Neufeld G, Tessler S, Gitay-Goren H, Cohen T and Levi B-Z

Vascular endothelial growth factor and its receptors

Prog.Growth Factor Res. 5, 89-97 (1994)

4. Cohen T, Gitay-Goren H, Sharon R, Shibuya M, Halaban R, Levi B-Z and Neufeld G
VEGF₁₂₁, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan-sulfates for efficient binding to the VEGF receptors of human melanoma cells

J.Biol.Chem. 270, 11322-11326 (1995)

5. Gengrinovitch S, Greenberg SM, Cohen T, Gitay-Goren H, Rockwell P, Maione TE, Levy B-Z and Neufeld G

Platelet factor-4 inhibits the mitogenic activity of VEGF₁₂₁ and VEGF₁₆₅ using several concurrent mechanisms

J.Biol.Chem. 270, 15059-15065 (1995)

6. Neufeld G, Cohen T, Gitay-Goren H, Poltorak Z, Tessler S, Gengrinovitch S and Levy B-Z

Similarities and differences between vascular endothelial growth factor splice variants

Cancer Metastasis Rev. 15, 153-158 (1996)

7. Engelmann S, Ebeling O and Schwartz-Albiez R

Modulated glycosylation of proteoglycans during differentiation of human B lymphocytes
Biochim.Biophys.Acta 1267, 6-14 (1995)

Ca 58 E. Keshet, Hebrew University of Jerusalem
E. Spiess, DKFZ, Heidelberg

1. Spiess E, Brüning A, Gack S, Ulbricht B, Spring H, Trefz G and Ebert W

Cathepsin B activity in human lung tumor cell lines. Ultrastructural localization, pH sensitivity and inhibitor status at the cellular level

J.Histochem.Cytochem. 42, 917-929 (1994)

2. Ebert W, Knoch H, Werle B, Trefz G, Muley Th and Spiess E

Prognostic value of increased lung tumor Cathepsin B

Anticancer Res. 14, 895-900 (1994)

3. Werle B, Ebert W, Klein W and Spiess E

Cathepsin B in tumors, normal tissue and isolated cells from the human lung



Anticancer Res. 14, 1169-1176 (1994)

4. Knoch H, Werle B, Ebert W and Spiess E

Imbalance between cathepsin B and cystein proteinase inhibitors is of prognostic significance in human lung cancer

Int.J.Oncology 5, 77-85 (1994)

5. Werle B, Ebert W, Klein W and Spiess E

Assessment of cathepsin L activity by use of the inhibitor CA-074 compared to cathepsin B activity in human lung tumor tissue

Biological Chemistry Hoppe Seyler 376, 157-174 (1995)

6. Ulbricht B, Spiess E, Schwartz-Albiez R and Ebert W

Quantification of intracellular cathepsin activities in human lung tumor cell lines by flow cytometry

Biological Chemistry Hoppe-Seyler 376, 407-414 (1995)

7. Becharach E, Itin A and Keshet E

Apposition-dependent induction of PAT-1 expression: A mechanism for balancing pericellular proteolysis

Blood 92, 939-945 (1998)

8. Strohmaier A-R, Porwol T, Acker H and Spiess E

Tomography of cells by confocal laser scanning microscopy and computer-assisted image reconstruction. Localization of cathepsin B in invading tumor cells in vitro

J.Histochem.Cytochem. 45, 975-983 (1997)

9. Ulbricht, B, Hagmann, W, Ebert, W. and Spiess, E

Differential secretion of cathepsins B and L from normal and tumor human lung cells stimulated by 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE)

Exp.Cell Res. 226, 255-263 (1996)

10. Strohmaier A-R, Spring H and Spiess E

Three dimensional analysis of the substrate dependent invasive behaviour of a human lung tumor cell line with a confocal laser scanning microscope

Histochem.Cell Biol. 105, 179-85 (1996)

Ca 59 A. Kimchi, Weizmann Institute of Science, Rehovot

N. Fusenig, DKFZ, Heidelberg

1.* Landesman Y, Bringold F, Kimchi A

P53 undergoes epitopic changes in vitro by sodium-vanadate

Oncogene 9, 1241-1245 (1994)

2. Deiss LP, Feinstein E, Berissi H and Kimchi A

Identification of a novel serine/threonine kinase and a novel 15 Kd protein as potential mediators of the interferon-gamma-induced cell death

Genes Dev. 9, 15-30 (1995)

3. Tiefenbrun N, Melamed D, Levy N, Resnitzky D, Hoffman I, Reed SI and Kimchi A

Interferon- α suppresses cyclin D3 and cdc25A genes leading to a reversible G0-like arrest

Molec.Cell.Biol. 16, 3934-3944 (1996)

4. Landesman Y, Bringold F, Milne DD and Meek DA

Modifications of p53 protein and accumulation of p21 and gadd45 mRNA in TGF- β growth inhibited cells

Cellular Signalling 9, 291-298 (1997)



Ca 60 S. Lavi, Tel Aviv University
R. Heilbronn, Max-Planck-Institut für Biochemie, München
J. Kleinschmidt, DKFZ, Heidelberg

1. Hölscher C, Hörer M, Kleinschmidt JA, Zentgraf H, Bürkle A and Heilbronn R

Cell lines inducibly expressing the adeno-associated virus (AAV) rep gene: requirements for productive replication of rep-negative AAV-mutants
J.Virol. 68, 7169-7177 (1994)

2. Kleinschmidt JA, Möhler M, Weindler FW and Heilbronn R

Sequence elements of the adeno-associated virus rep gene required for suppression of herpes simplex virus-induced DNA amplification
Virology 206, 254-262 (1995)

3. Hörer M, Weger S, Butz K, Hoppe-Seyler F, Geisen K and Kleinschmidt JA

Mutational analysis of Adeno-associated virus (AAV) Rep protein mediated inhibition of heterologous and homologous promoters
J.Virol. 69, 5485-5496 (1995)

Ca 61 V. Rotter, Weizmann Institute of Science, Rehovot
K.H. Richter (F. Marks), DKFZ, Heidelberg

1. Aloni-Grinstein R, Zan-Bar I, Alboum I, Goldfinger N and Rotter V

Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage
Oncogene 8, 3297-3305 (1993)

2. Richter KH, Rehberger PA and Marks F

Differentiation of murine keratinocytes in culture is independent of tumor suppressors p53 and the Retinoblastoma protein
Conference at the Cold Spring Harbor Laboratory, The Cell Cycle (1994)

3. Aloni-Grinstein R, Schwartz D and Rotter V

Accumulation of wild type p53 protein, upon 7-irradiation, induces a G2 dependent immunoglobulin kappa light chain gene expression
EMBO J. 14, 1392-1401 (1995)

4. Wolkowicz R, Peled A, Elkind NB and Rotter V

The augmented DNA binding activity of an alternative spliced C'-terminal p53 is blocked by regular spliced p53 protein
Proc. Nat. Acad. of Science USA 92, 6842-6846 (1995)

5. Elkind NB, Goldfinger N and Rotter V

Spot-1, a novel NLS-binding protein that interacts with p53 through a domain encoded by p(CA)_n repeats
Oncogene 11, 841-851 (1995)

Ca 62 B.-Z. Shilo, Weizmann Institute of Science, Rehovot
B. Mechler, DKFZ, Heidelberg

1. Raz E and Shilo B-Z

Establishment of ventral cell fates in the *Drosophila* embryonic ectoderm requires DER, the EGF receptor homolog



Genes and Development 7, 1937-1948 (1993)

2. Strand D, Jakobs R, Merdes G, Neumann B, Kalmes A, Heid HW, Husmann I and Mechler BM

The *Drosophila lethal(2) giant larvae* tumor suppressor protein forms homo-oligomers and is associated with nonmuscle myosin 11 heavy chain

J.Cell Biol. 127, 1361-1373 (1994)

3. Schweitzer R, Shaharabany M, Seger R and Shilo B-Z

Secreted Spitz triggers the DER signaling pathway and is a limiting component in embryonic ventral ectoderm determination

Genes and Development 9, 1518-1529 (1995)

4. Schweitzer R, Howes R, Smith R, Shilo B-Z and Freeman M

Inhibition of *Drosophila* EGF receptor activation by the secreted protein Argos

Nature 376, 699-702 (1995)

5. Rogge R, Green PJ, Urano J, Horn-Saban S, Mlodzik M, Shilo B-Z, Hartenstein V and Banerjee U

The role of *yan* in mediating the choice between cell division and differentiation

Development 121, 3947-3958 (1995)

6. Strand D, Unger S, Corvi R, Harteinstein K, Schenkel H, Kalmes A, Merdes G, Neumann B, Krieg-Schneider F, Coy J F, Poustka A, Schwab M and Mechler BM

A Human homologue of the *Drosophila* tumor suppressor gene *l(2)gl* maps to 17p11.2-12 and codes for a cytoskeletal protein that associates with nonmuscle myosin II heavy chain

Oncogene 11, 291-301 (1995)

7. Kalmes A, Merdes G, Neumann B, Strand D and Mechler BM

A serine-kinase associated to the p12701(2)gl tumor suppressor of *Drosophila* may regulate the binding of p127 to nonmuscle myosin II heavy chain and the attachment of p127 to the plasma membrane

Journal of Cell Science 109, 1359-1368 (1996)

8. Golembo M, Schweitzer R, Freeman M and Shilo B-Z

Argos transcription is induced by the *Drosophila* EGF receptor pathway, to form an inhibitory feedback loop

Development 122, 223-230 (1996)

9. Gabay L, Scholz H, Golembo M, Klaes A, Shilo B-Z and Klambt C

EGF receptor signaling induces pointed PI transcription and inactivates Yan protein in the *Drosophila* embryonic ventral ectoderm

Development 122, 3355-3362 (1996)

10. Golembo M, Raz E and Shilo B-Z

The *Drosophila* embryonic midline is the site of Spitz processing, and induces activation of the EGF receptor in the ventral ectoderm

Development 122, 3363-3370 (1996)

Ca 64 S. Segal, Ben-Gurion University, Beer Sheva
F. Momburg (G. Hämmerling), DKFZ, Heidelberg

1. Momburg F, Roelse J, Howard JC, Butcher GW, Hämmerling G and Neefjes JJ

Selectivity of MHC-encoded peptide transporters from human, mouse and rat

Nature 367, 648-651 (1994)

2. Momburg F, Roelse J, Neefjes J and Hämmerling G

Peptide transporters and antigen processing

Behring Inst. Mitt. 94, 26-36 (1994)



3. Momburg F, Roelse J, Hämmerling G and Neefjes JJ

Peptide size selection by the major histocompatibility complex-encoded peptide transporter
J. Exp. Med. 179, 1613-1623 (1994)

4. Neefjes J, Gottfried E, Roelse J, Grommé M, Obst R, Hämmerling G and Momburg F

Analysis of the fine specificity of rat, mouse and human TAP peptide transporters
Eur. J. Immunol. 25, 1133-1136 (1995)

5. Obst R, Armandola EA, Nijenhuis M, Momburg F and Hämmerling G

TAP polymorphism does not influence transport of peptide variants in mice and human
Eur. J. Immunol. 25, 2170-2176 (1995)

6. Momburg F, Hämmerling G and Neefjes JJ

TAP peptide transporters and antigen presentation, In: RG Urban and RM Chicz (Eds), MHC Molecules: Expression, Assembly and Function Landes, Georgetown (USA) pp. 35-63 (1996)

7. Momburg F, Armandola EA, Post M and Hämmerling G

Residues in transporters associated with antigen processing TAP2 subunits controlling substrate specificity
J. Immunol. 156, 1756-1763 (1996)

8. Seliger B, Höhne A, Knuth A, Bernhard H, Meyer R, Tampé R, Momburg F and Huber C

Analysis of the MHC class I antigen presentation machinery in normal and malignant renal cells: Evidence for deficiencies associated with transformation and progression
Cancer. Res. 56, 1756-1760 (1996)

9. Seliger V, Höhne A, Jung D, Kallfelz M, Knuth A, Jaeger E, Bernhard H, Momburg F, Tampé R and Huber C

Expression and function of the peptide transporters in escape variants of human renal cell carcinoma
Exp. Hematol. 25, 608-614 (1997)

Ca 65 U. Zor, R. Goldmann, Weizmann Institute of Science, Rehovot

G. Fürstenberger, F. Marks, DKFZ, Heidelberg

1.* Goldman R, Moshonov S, Chen X, Berchansky A, Fürstenberger G and Zor U

Crosstalk between elevation of $[Ca^{2+}]_i$, reactive oxygen species generation and phospholipase A2 stimulation in a human keratinocyte cell line
Adv. Exp. Med. Biol. 433, 41-45 (1977)

2.* Goldman R, Zor U, Mueller R, Moshonov S, Fürstenberger G and Seger R

Activation of MAP kinases, cPLA₂ and reactive oxygen species formation by EGF and calcium mobilizing agonists in a human keratinocyte cell line
Adv. Exp. Med. Biol. 407, 289-293 (1979)

3. Müller-Decker K, Scholz K, Marks F and Fürstenberger G

Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis
Molecular Carcinogenesis 12, 31-41 (1995)

4. Scholz K, Fürstenberger G, Müller-Decker K and Marks F

Differential expression of prostaglandin-H synthase isoenzymes in normal and activated keratinocytes in vivo and in vitro
Biochem. J. 309, 263-269 (1995)



Ca 66 R. Apte, Ben Gurion Univ, Beer Sheva
M. Zöller, DKFZ, Heidelberg

1.* Apte RN, Douvdevai A, Zöller M, White RM, Dvokin T, Shimoni N, Fima E, Hacham M, Voronov E and Segal S

Immune recognition and rejection of IL-1 α gene transduced tumor cells In: Cytokine-induced tumor immunogenicity, eds Forni G, Foa R, Santoni A and Frati L Academic Press, 97-111 (1995)

2. Apte, RN

Mechanisms of cytokine production by fibroblasts-implications for normal connective tissue homeostasis and pathological conditions
Folia Microbiol. (Praha) 40, 392-404 (1995)

3. Bernharroch D, Prinsloo I, Apte RN, Yermiahu T, Geffen DB Yanai-Inbar I and Gopas J

Interleukin-1 and tumor necrosis factor- α in the Reed-Sternberg cells of Hodgkin's disease Correlation with clinical and morphological "inflammatory" features
Eur. Cytokine Netw. 7, 51-57 (1996)

4. Apte RN

Intracellular IL-1 α in fibroblasts as a possible endogenous mediator of joint damage in rheumatoid arthritis
Isr. J. Med. Sci. 33, 285-288 (1997)

5.* Apte RN, Dvorkin T, Fima E, Song X, White RM, Ofir R, Benharroch D, Argov S, Werman A, Bjorkdahl O, Gyorloff Wingren A, Dohlsten M, Zöller M, Segal S and Voronov E

Differential anti-tumor effects of Interleukin-1 (IL-1) α and IL-1 β in cytokine gene-transfer approaches in tumor
In: Proc. 10th Intl. Cong. Immunol., Talwar GP, Nath I, Ganguly NK and Rao KVS (Eds), Monduzzi Editore, SpA Bologna (Italy), pp. 1383-1389 (1998)

6. Zawadzki V, Perschl A, Rösel M, Hekele A and Zöller M

Blockade of metastasis formation by CD44 receptor globulin
Int. J. Cancer 75, 919-924 (1998)

7. Cochlovius B, Zawadzki V, Perschl A and Zöller M

Stable expression of a retrovirally transferred adhesion molecule in a human melanoma-specific cytotoxic T lymphocyte clone
Cancer Immunol. Immunother. 446, 61-66 (1998)

8. Riedle S, Rösel M, Seither S and Zöller M

Effector cell targeting by bispecific antibodies in the therapy of human malignant melanoma: Evaluation in the SCID mouse model
Int. J. Cancer 75, 908-918 (1998)

9.* Voronov E, Weinstein Y, Bernharroch D, Cagnano E, Ofir R, Dobkin M, White RM, Zöller M, Barak V, Segal S and Apte RN

Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1 α expression
Cancer Res. 59, 1029-35 (1999)

10. Pitzer C, Schindowski K, Pomer S, Wirth T and Zöller M

In vivo manipulation of IL-2 expression by retroviral tetracycline (tet)-regulated system
Human Gene Therapy 6, 139-146 (1999)

11.* Apte RN, Dvorkin T, Song X, Fima Y, Krelin Y, Ulevitch A, Gurfinkekl R, Werman A, White RM, Bjorkdahl O, Dohlsten M, Zöller M, Segal S and Voronov E



Opposing effects of IL-1 α and IL-1 β on malignancy patterns; Tumor cell-associated IL-1 α potentiates anti-tumor immune responses and tumor regression whereas IL-1 β potentiates invasiveness

Adv. Exp. Med. Biol. 479, 277-288 (2000)

12. Mullerad J, Voronov E, Cohen S and Apte RN

Intracellular activation of macrophages by delivering Interleukin-1 via microspheres
Cytokine 12, N11, 1683-1690 (2000)

13. Hacham M, Argov S, White RM, Segal S and Apte RN

Distinct patterns of IL-1 α and IL-1 β organ distribution-a possible basis for organ mechanisms of innate immunity

Adv. Exp. Med. Biol. 479, 185-202 (2000)

14. Zöller M and Matzku S

Vaccination: a future modality of cancer therapy

Drugs Today 36, 557-581 (2000)

15. Bar D, Voronov E, Ben-Harroch D, Dinarello CA, Apte RN and Cohen S

Inhibition of tumor growth by the continuous delivery of IL-1 receptor antagonist (IL-1Ra) from microencapsulated genetically engineered cells

J. Control Rel. 72, 228-229 (2001)

16. Banat A, Christ O, Cochlovius B, Pralle HB and Zöller M

Tumor-induced suppression of immune response and its correction

Cancer Immunol. Immunother. 49, 573-586 (2001)

17. Matzku S and Zöller M

Specific immunotherapy of cancer in elderly patients

Drugs & Aging 18, 639-664 (2001)

18. Zöller M and Christ O

Prophylactic Tumor Vaccination: Comparison of effector mechanisms initiated by protein versus DNA vaccination

J. Immunol. 166, 3440-3450 (2001)

19. Christ O, Seiter S, Matzku S, Burger C and Zöller M

Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy

Clin. Cancer Res. 7, 985-998 (2001)

20. Christ O, Matzku S, Burger C and Zöller M

Interleukin-2-antibody and tumor necrosis factor-antibody fusion proteins induce different antitumor immune responses *in vivo*

Clin. Cancer Res. 7, 1385-1397 (2001)

21. Weth R, Christ O, Stevanovic S and Zöller M

Gene delivery by attenuated *Salmonella typhimurium*: Comparing the efficacy of the helper versus cytotoxic T cell priming in tumor vaccination

Cancer Gene Therapy 8, 559-611 (2001)

22. Apte RN and Voronov E

IL-1 – a major cytokine in tumor-host interactions

Sem. Cancer Biol. 427, 1-14 (2002)

23. Hacham M, Argov S, White RM, Segal S and Apte RN

Differential patterns of IL-1 α and IL-1 β organ expression under steady-state conditions in young and old mice

Eur. Cyt. Netw. 13, 55-65 (2002)

24. Zöller M

Tolerance induction by tumor vaccination

J. Immunother. 25, 162-175 (2002)

25. Voronov E, Shouval D, Krelin Y, Cagnano E, Benharoch D, Iwakura Y, Dinarello CA and Apte RN



IL-1 is required for tumor invasiveness and angiogenesis

Proc. Natl. Acad. Sci. (USA) 100, 2645-2650 (2003)

26. Bar D, Apte RN, Voronov E, Dinarello CA and Cohen S

A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development

FASEB J. 18, 161-163 (2003)

27. Song X, Voronov E, Dvorkin T, Fima E, Cagnano E, Benhharoch D, Shindler Y, Bjorkdahl O, Segal S, Dinarello CA and Apte RN

Differential effects of IL-1 α and IL-1 β on tumorigenicity patterns and invasiveness

J. Immunol. 171, 6448-6456 (2003)

28. Mullerad J, Cohen S, Benhharoch D and Apte RN

Local delivery of IL-1 α polymeric microspheres for immunotherapy of an experimental fibrosarcoma

Cancer Invest. 21, 720-728 (2003)

29. Werman A, Werman-Venkert R, White RM, Lee JK, Werman B, Krelin Y, Voronov E, Dinarello CA and Apte RN

The precursor form of IL-1 α is an intracrine proinflammatory activator of transcription

Proc. Natl. Acad. Sci. (USA), 101, 2434-2439 (2004)

30. Hacham M, Argov S, White RM, Segal S and Apte RN

IL-6 and IL-10 are similarly expressed in organs of normal young and old mice

Eur. Cyt. Netw. 15, 37-46 (2004)

**Ca 67 G. Berke, Weizmann Institute of Science, Rehovot
P. Krammer, DKFZ, Heidelberg**

1. Felzen B, Lavy R, Garcia M, Berke G, Gardner P and Binah O

Interaction of cytotoxic T lymphocytes and guinea pig ventricular myocytes: Pharmacological modulation by blocking K⁺ currents in the CTL

Circulation Res. 78, 253-261 (1996)

2. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer P and Galle PR

Lymphocyte apoptosis induced by CD95(APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion?

Nature Med. 12, 1361-1366 (1996)

3. Felzen B, Berke G, Gardner P and Binah O

Involvement of the IP3 cascade in the damage to guinea pig ventricular myocytes induced by cytotoxic T lymphocytes

Eur. J. Physiol. Pflugers Arch. 433, 721-726 (1997)

4. Binah O, Liu CC, Young JD and Berke G

Channel formation and [Ca²⁺] accumulation induced by perforin N-terminus peptides: comparison with purified perforin and whole lytic granules

Biochem. Biophys. Res. Com. 240(3), 647-650 (1997)

5. Scaffidi C, Medema JP, Krammer P and Peter ME

FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase 8/b

J. Biol. Chemistry 272, 26953-26958 (1997)

6. Medema JP, Toes REM, Scaffidi C, Zheng TS, Flavell RA, Melief CJM, Ofringa R and Krammer P

Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T-lymphocyte apoptosis

Eur. J. Immunol. 27, 3492-3498 (1997)



7. Krammer P

The tumor strikes back: New data on expression of the CD95(APO-1/Fas) receptor/ligand system may cause paradigm changes in our view on drug treatment and tumor immunology

Cell Death & Differentiation 4, 362-364 (1997)

8. Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer P and Peter ME

FLICE is activated by association with the CD95 death-inducing signaling complex (DISC)
EMBO J. 10, 2794-2804 (1997)

9.* Li JH, Rosen D, Ronen D, Behrens CK, Krammer P, Clark WR and Berke G

The regulation of CD95 ligand expression and function in CTL

J. Immunol. 161, 3943-3949 (1998)

10. Felzen B, Shilkrot M, Less H, Sarapov I, Maor G, Coleman R, Robinson RB, Berke G and Binah O

Fas (CD95/Apo1)-mediated damage to ventricular monocytes induced by Cytotoxic T lymphocytes from perforin deficient mice: a major role for inositol 1,4,5tri-phosphate
Circulation Res. 82, 438-450 (1998)

11. Li JH, Rosen D, Ronen D, Behrens CK, Peter H, Krammer P, Clark WR and Berke G

The regulation of CD95 ligand expression and function in CTL

J. Immunol. 161, 3943-3949 (1998)

12. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Feng L, Tomaselli KJ, Debatin KM, Krammer P, Peter ME

Two CD95(APO-1/Fas) signaling pathways

EMBO J. 17, 1675-1687 (1998)

13. Rosen D, Li JH, Keidar S, Markon I, Orda R and Berke G

Tumor immunity in perforin-deficient mice: a role for CD95 (Fas/APO-1)

J. Immunol. 164, 3229-3235 (2000)

Ca 68 L. Eisenbach, Weizmann Institute of Science, Rehovot
M. Zöller, DKFZ, Heidelberg

1. Popovic D, El-Shami KM, Vadai E, Feldman M, Tzehoval E and Eisenbach L

Antimetastatic vaccination against Lewis lung carcinoma with autologous tumor cells modified to express murine interleukin 12

Clin. Exp. Metastasis 16, 623-632 (1998)

2. Tucek-Kerkmann A, Banat A, Cochlovius B and Zöller M

Antigen loss variants of a murine renal cell carcinoma: Implications for tumor vaccination
Int. J. Cancer 77, 114-122 (1998)

3. El-Shami KM, Tirosh B, Bar-Haim E, Carmon L, Vadai E, Fridkin M, Feldman M and Eisenbach L

MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope

Eur. J. Immunol. 29, 3295-3301 (1999)

4. Tirosh B, El-Shami KM, Vaisman N, Carmon L, Bar-Haim E, Vadai E, Feldman M, Fridkin M and Eisenbach L

Immunogenicity of H-2Kb-low affinity, high affinity, and covalently-bound peptides in anti-tumor vaccination

Immunol. Lett. 70, 21-28 (1999)



- 5. El-Shami KM, Tzevoval E, Vadai E, Feldman M and Eisenbach L**
Induction of antitumor immunity with modified autologous cells expressing membrane-bound murine cytokines
J. Interferon Cytokine Res. 19, 1391-1401 (1999)
- 6. Zöller M and Matzku S**
Cancer therapy: New concepts on active immunization
Immunobiol. 201, 1-21 (1999)
- 7. Cochlovius B, Perschl A, Figdor C and Zöller M**
Human melanoma therapy in the SCID mouse: Targeting and activation of melanoma-specific cytotoxic T cells by bispecific antibody fragments is curative
Int. J. Cancer 81, 486-493 (1999)
- 8. Zöller M and Matzku S**
Immuntherapie bei gastrointestinalen Tumoren
Chir. Gastroenterol. 15, 188-194 (1999)
- 9. Cochlovius B, Linnebacher M, Zewe-Welchhof M and Zöller M**
Recombinant Gp100 protein presented by dendritic cells elicits a T helper cell response in vitro and in vivo
Int. J. Cancer 83, 547-554 (1999)
- 10. Tirosh B, Fridkin M, Tzevoval E, Lemonnier FA and Eisenbach L**
Antigenicity and immunogenicity of an intracellular delivery system of major histocompatibility complex class I epitopes that bypasses proteasome processing
J. Immunother. 23, 622-630 (2000)
- 11. El-Shami KM, Tirosh B, Popovic D, Carmon L, Tzevoval E, Vadai E, Feldman M and Eisenbach L**
Induction of antitumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a modified TAA peptide
Int. J. Cancer 85, 236-242 (2000)
- 12. Carmon L, El-Shami KM, Paz A, Pascolo S, Tzevoval E, Tirosh B, Koren R, Feldman M, Fridkin M, Lemonnier FA and Eisenbach L**
Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x β 2 microglobulin (β 2m) null mice transgenic for a chimeric HLA-A21/Db- β 2 microglobulin single chain
Int. J. Cancer 85, 391-397 (2000)
- 13. Zier K, Johnson K, Maddux JM, Sung M, Mandeli J, Eisenbach L, Schwartz M**
IFN γ secretion following stimulation with total tumor peptides from autologous human tumors
J. Immunol. Methods 241, 61-68 (2000)
- 14. Carmon L, Tzevoval E, Tirosh B, El-Shami KM, Bar-Haim E, Vadai E, Feldman M and Eisenbach L**
Anti-tumor vaccination in heterozygous congenic F1 mice: presentation of tumor-associated antigen by the two parental class I alleles
J. Immunother. 23, 344-352 (2000)
- 15. Eisenbach L, Bar-Haim E and El-Shami K**
Antitumor vaccination using peptide based vaccines
Immunol. Lett. 74, 27-34 (2000)
- 16. Haack K, Linnebacher M, Eisold S, Zöller M, Knebel-Doerberitz M and Gebert J**
Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene
Canc. Gene Ther. 7, 1357-1364 (2000)



17. Cochlovius B, Stassar M, Christ O, Radrizzani L, Hammer J, Mytilineos I and Zöller M

In vitro and in vivo induction of a T cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program
J. Immunol. 165, 4731-4741 (2000)

18. Zier K, Madduc JM, Hohnson K, Sung M, Mandeli J, Eisenbach L and Schwartz M
Surrogate markers of antitumor responses: in vitro activation of T cells by autologous tumor peptides

Clin. Cancer Res. 7, 818s-821s (2001)

19. Stassar M, Radrizzani L, Hammer J and Zöller M

T-helper cell-response to MHC class II-binding peptides of the renal cell carcinoma-associated antigen RAGE-1

Immunobiol. 203, 743-755 (2001)

**Ca 69 I. Witz, Tel Aviv University, Tel Aviv
V. Schirmacher, DKFZ, Heidelberg**

1. Witz I, Sagi-Assif O and Ran M

The shaping of the malignancy phenotype – An interplay between cellular characteristics and microenvironmental factors In: Premalignancy and Tumor Dormancy E Yefenof and RH Scheuermann, Eds Medical Intelligence Unit, RG Landes Co. pp. 147-1566 (1996)

2. Witz I

The shaping of a malignancy phenotype by microenvironmental host factors In: Recent Advances in Gastroenterological Carcinogenesis
IF Tahara, K Sugimachi and T Oohara, Eds, Monduzzi Editore Bologny, pp. 287-294 (1996)

3. Sagi-Assif O, Traister A, Katz BZ, Anavi R, Eskenasy M and Witz I

TNF α and anti Fas antibodies regulate Ly-6E1

Immunol. Lett. 54, 207-213 (1996)

4. Treister A, Sagi-Assif O, Meer M, Smorodinsky NI, Anavi R, Golan I, Kahana O, Eshel R, Katz BZ, Shevach E and Witz I

The expression of Ly-6, a marker for highly malignant murine tumor cells, is regulated by growth conditions and stress

Int. J. Cancer 77, 306-313 (1998)

**Ca 70 Y. Ben-Neriah, Hebrew Univ. - Hadassah Med. School,
Jerusalem
W. Dröge, DKFZ, Heidelberg**

1. Avraham A, Jung S, Samuels Y, Seger R, and Ben-Neriah Y

Costimulation-dependent activation of a JNK-kinase in T lymphocytes
Eur. J. Immunol. 28, 2320-2330 (1998)

2. Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V, Schulze-Osthoff K, Dröge W and Schmitz ML

Sesquiterpene lactones specifically inhibit activation of NF- κ B by preventing the degradation of NF- κ B - α and I- κ B- β

J. Biol. Chem. 273, 1288-1298 (1998)

3. Umansky V, Hehner SP, Dumont A, Hofmann TG, Schirmacher V, Dröge W and Schmitz ML



Co-stimulatory effect of nitric oxide on endothelial NF- κ B implies a physiological self-amplifying mechanism

Eur. J. Immunol. 28, 2276-2282 (1998)

4. Hehner SP, Hofmann TG, Ratter F, Dumont A, Dröge W and Schmitz ML

Tumor necrosis factor- α -induced cell killing and activation of transcription factor NF- κ B are uncoupled in L929 cells

J. Biol. Chem. 273, 18117-18121 (1998)

5. Dumont A, Hehner SP, Gustafsson JA, Lidén J, Okret S, van der Saag PT, Wissink S, van der Burg B, Herrlich P, Haegemann G, De Bosscher K, Fiers W and Schmitz ML

Cross-talk between steroids and NF- κ B: what language ?

Trends Biochem. Sci. 23, 233-235 (1998)

6. Schmitz ML, Hehner SP, Bacher S, Dröge W and Heinrich M

Transkriptionsfaktor NF- κ B: Seine Aktivierungswege als Target für antiinflammatorische Substanzen

Deutsche Apothekerzeitung 138, 59-69 (1998)

7. Hofmann TG, Hehner SP, Bacher S, Dröge W and Schmitz ML

Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF- κ B-dependent transcription

FEBS Lett. 441, 441-446 (1998)

8. Dumont A, Hehner SP, Hofmann TG, Ueffing M, Dröge W and Schmitz ML

Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF- κ B

Oncogene 18, 747-759 (1999)

9. Kaltschmidt B, Kaltschmidt C, Hehner SP, Dröge W, and Schmitz ML

Repression of NF- κ B impairs HeLa cell growth by functional interference with cell cycle checkpoint regulators

Oncogene 18, 3113-3225 (1999)

10. Hehner SP, Hofmann TG, Dröge W, and Schmitz ML

The anti-inflammatory sesquiterpene lactone pathenolide inhibits NF- κ B by targeting the I κ B kinase complex

J. Immunol. 163, 5617-5623 (1999)

11. Kaltschmidt B, Kaltschmidt C, Hofmann TG, Hehner SP, Dröge W and Schmitz ML

The pro- or anti-apoptotic function of NF- κ B is determined by the nature of the apoptotic stimulus

Eur. J. Biochem. 267, 3828-3835 (2000)

Ca 71 Z. Fishelson, Tel Aviv University, Tel Aviv
M. Kirschfink, University of Heidelberg

1.* Jurianz K, Maslak S, Garcia-Schüler H, Fishelson Z and Kirschfink M

Neutralization of complement regulatory proteins augments lysis of mammary carcinoma cells targeted with rhuAb anti-HER2

Immunopharmacol. 42, 209-218 (1999)

2.* Jurianz K, Ziegler S, Garcia-Schüler H, Kraus S, Bohana-Kastan O, Fishelson Z and Kirschfink M

Complement resistance of tumor cells: Basal and induced mechanisms

Mol. Immunol. 36, 929-939 (1999)

3. Paas Y, Bohana-Kashtan O and Fishelson Z



Phosphorylation of the complement component C9 by an ecto-protein kinase of human leukemic cells

Immunopharmacology 42, 175-185 (1999)

4. Kraus S and Fishelson Z

Cell desensitization by sublytic C5b-9 complexes and calcium ionophores depends on activation of protein kinase C

J. Immunol. 30, 1272-1280 (2000)

5.* Jurianz K, Ziegler S, Donin N, Reiter Y, Fishelson Z and Kirschfink M

K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement

Int. J. Cancer 93, 848-854 (2001)

6. Kraus S, Seger R and Fishelson Z

Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis

Clin. Exp. Immunol. 123, 366-374 (2001)

7. Fishelson Z, Hochman I, Greene LE and Eisenberg E

Contribution of heat shock proteins to cell protection from complement-mediated lysis

Int. Immunol. 8, 983-991 (2001)

8.* Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M and Fishelson Z

Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid

Clin. Exp. Immunol. 131, 254-263 (2003)

9.* Fishelson Z, Donin N, Sell S, Schultz S and Kirschfink M

Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors

Mol. Immunol. 40, 109-123 (2003)

10.* Kirschfink M and Fishelson Z

Complement resistance in cancer, In: The complement system: Novel roles in health and disease

Szebeni, J ed Kluwer Academic Publishers, MA, USA 2004

**Ca 72 Y. Shaul, The Weizmann Institute of Science, Rehovot
CH. Schröder, DKFZ, Heidelberg**

1. Ori A, Zauberman A, Doitch G, Paran N, Oren M and Shaul Y

P53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53

EMBO J. 17, 544-553 (1998)

2. Haviv I, Matza Y and Shaul Y

PX, the HBV encoded coactivator, suppresses the phenotypes of TBP and TAFII250 mutants

Genes and Dev. 12, 1217-1226 (1998)

3. Doitch G and Shaul Y

Repression of the hepatitis B virus transcription, in response to genotoxic stress, is p53 dependent and abrogated by pX

Oncogene 18, 7506-7513 (1999)

4. Su Q, Schröder CH, Otto G and Bannasch P

Overexpression of p53 is not directly related to hepatitis B x protein expression and is associated with neoplastic progression in hepatocellular carcinoma rather than hepatic preneoplasia

Mutation Res. 462, 365-380 (2000)



Ca 73 L. Sherman, Sackler Med. School, Tel Aviv University,
Tel Aviv
M. Dürst, University of Jena

- 1. Sherman L, Jackman A, Itzhaki H, Stoppler MC, Koval D and Schlegel R**
Inhibition of serum and calcium induced differentiation of human keratinocytes by HPV16 E6 oncoprotein role of p53 inactivation
Virology 237, 296-306 (1997)
- 2. Alfandari J, Shnitman-Magal S, Jackman A, Schlegel R, Gonen P and Sherman L**
HPV16 E6 oncoprotein inhibits apoptosis induced during serum-calcium differentiation of foreskin human keratinocytes
Virology 257, 383-396 (1999)
- 3. Sherman L, Itzhaki H, Jackman A, Chen JJ, Koval D and Schlegel R**
Inhibition of serum- and calcium-induced terminal differentiation of human keratinocytes by HPV 16E6: Study of the association with p53 degradation, inhibition of p53 transactivation, and binding to E6BP
Virology 292, 309-320 (2002)

Ca 75 Y. Groner, The Weizmann Institute of Science, Rehovot
M. Schwab, DKFZ, Heidelberg

- 1. Levanon D, Eisenstein M and Groner Y**
Site directed mutagenesis supports a three dimensional model of the runt domain
J. Mol. Biol. 277, 509-512 (1998)
- 2. Levanon D, Goldstein RE, Bernstein Y, Tang H, Goldenberg D, Stifani S, Paraoush Z and Groner Y**
Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Gro co-processors
Proc. Natl. Acad. Sci. USA 95, 11590-11595 (1998)
- 3. Ben Aziz-Aloya R, Levanon D, Karn H, Kidron D, Goldenberg D, Lotem J, Polak S and Groner Y**
Expression of AML1-d, a short isoform of human AML1, in embryonic stem (ES) cells suppresses in vivo tumorigenicity and differentiation
Cell Death & Differentiation 5, 765-773 (1998)
- 4. Praml C, Savelyeva L, Perri P and Schwab M**
Cloning of the human Aflatoxin B1-Aldehyde Reductase gene at 1p35-36 in a region frequently altered in human tumor cells
Cancer Research 58, 5014-5018 (1998)
- 5. Perri P, Praml C, Savelyeva L, Pillmann A and Schwab M**
Fine mapping of distal 1p loci reveals TP73 at D1S468
Cell Genet. 84, 111-114 (1999)
- 6. Pozner A, Negreanu V, Goldenberg D, Le SY, Elroy-Stein O, Levanon D and Groner Y**
Transcription coupled-translation control of AML1/RUNX1 is mediated by Cap- and IRES-dependent mechanisms
Mol. Cell Biol. 27, 2297-2307 (2000)



Ca 76 A. Hochberg, Hebrew University, Jerusalem
D. Komitowski, DKFZ, Heidelberg

1.* Rachmilewitz J, Goshen R, Elkin M, Ne'eman Z, Giloh H, Strauss B, Komitowski D, de Groot N and Hochberg A

The interaction between cytotrophoblasts and their derived tumor cells
Gyn. Oncol. 57, 356-365 (1995)

2.* Goshen R, Ariel I, Komitowski D, Lustig-Yaniv O, Pode D, Pizov G, de Groot N and Hochberg A

The use of computerized image analysis of tissue specimens and cell cultures in the early identification and the understanding of the pathogenesis of malignant tumors
Harefuah 9, 329-336 (1995) (in Hebrew)

3.* Goshen R, Schreck H, Komitowski D, Karnaoukhova S, Gonick B, Weinstein D, de Groot N and Hochberg A

Morphologic characteristics of the interaction between normal cytotrophoblasts and their malignant counterpart in the development of trophoblastic neoplasia
J. Soc. Gynecol. Invest. 3, 209-215 (1996)

4.* Cooper M, Fischer M, Komitowski D, Shevelev A, Schulze E, Ariel I, Tykocinski M, Miron S, Ilan J, de Groot N and Hochberg A

Developmentally imprinted genes as markers for bladder tumor progression
J. Urology 155, 2120-2133 (1996)

5.* Ariel I, Ayeshe S, Perlman EJ, Pizov G, Tano V, Schneider T, Erdmann VA, Podeh D, Komitowski D, Quasem AS, de Groot N and Hochberg A

The product of the imprinted H19 gene is an oncofetal RNA
J. Clin. Pathol.: Mol. Pathol. 50, 34-44 (1997)

6.* Lustig Yariv O, Schulze E, Komitowski D, Erdmann V, Schneider T, de Groot N and Hochberg A

The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines Is H19 a tumor suppressor gene?
Oncogene 15, 169-177 (1997)

7. Tzancheva M and Komitowski D

Latent chromosomal instability in cancer patients
Hum. Genet. 99, 47-51 (1997)

8. Ariel I, Miao HQ, Ji XR, Schneider T, Roll D, de Groot N, Hochberg A and Ayeshe S
Imprinted H19 oncofetal RNA is a candidate tumor marker for hepatocellular carcinoma
Mol. Pathol. 51, 21-25 (1998)

9. Kopf E, Bibi O, Ayeshe S, Tykocinski M, Vitner K, Looijenga LHF, de Groot N and Hochberg A

The effect of retinoic acid on the activation of the human H19 promoter by a 3' downstream region
FEBS Letters 432, 123-127 (1998)

10. Elkim M, Ayeshe S, Schneider T, de Groot N, Hochberg A and Ariel I

The dynamics of the imprinted H19 gene expression in the mouse model of bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine
Carcinogenesis 19, 2095-2099 (1998)

11. Komitowski D and Tzancheva M

Latent chromosomal instability in cancer patients
Hum. Genet. 103, 370-371 (1998)

12. Ariel I, de Groot N and Hochberg A

The imprinted H19 gene expression in embryogenesis and human cancer
Am. J. of Medical Genetics 91, 46-50 (2000)



- 13. Erdmann VA, Szymanski M, Hochberg A, de Groot N and Barciszewski J**
Non-coding mRNA-like RNAs database Y2K
Nucleic Acid Res. 28, 197-200 (2000)
- 14. Ariel I, Sughayer M, Felig Y, Pizov G, Ayesh S, Podeh D, Abu-Libdeh B, Levy C, Birman T, Tykocinski ML, de Groot N and Hochberg A**
The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma
J. Clin. Path.: Mol. Path. 53, 320-324 (2000)
- 15. Abdul-Ghani R, Ohana P, Matouk I, Ayesh S, Laster M, Bibi O, Giladi H, Molnar-Kimber K, de Groot N and Hochberg A**
Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selected killing of cancer cells
Mol. Therapy 2, 539-544 (2000)
- 16. Banet G, Bibi O, Matoik I, Ayesh S, Lester M, Molner-Kimber K, Tykocinski M, de Groot N, Hochberg A and Ohana P**
Characterization of human and mouse H19 regulatory sequences
Mol. Biol. Rep. 27, 157-165 (2001)
- 17. Erdmann V, Barciszewska MZ, Szymanski M, Hochberg A, de Groot N and Barciszewski J**
The non-coding RNAs as riboregulators
Nucleic Acid Research 29, 189-193 (2001)
- 18. Erdmann VA, Barciszewska MZ, Szymanski M, Hochberg A, de Groot N and Barciszewski J**
The non-coding RNAs as riboregulators
Cell. and Mol. Life Sciences 58, 960-977 (2001)
- 19. Shochina M, Fellig Y, Sughayer M, Pisov G, Vitner K, Podeh D, Hochberg A and Ariel I**
Nitric oxide synthase immunoreactivity in human bladder cancer
J. Clin. Mol. Path. 54, 248-252 (2001)
- 20. Goldberg D, Ayesh S, Schneider T, Papu O, Jurim O, Eid A, Fellig Y, Dadun T, Ariel I, de Groot N, Hochberg A and Galun E**
Analysis of differentially expressed genes in hepatocellular carcinoma, using cDNA arrays
Mol. Carcinogenesis 33, 113-124 (2002)
- 21. Ohana P, Matouk I, Levi C, Berman T, Ariel I, Schneider T, Ayesh S, Giladi H, de Groot N and Hochberg A**
The use of H₁₉ regulatory sequences for targeted therapy in cancer
Int. J. of Cancer 98, 64-650 (2002)
- 22. Ayesh S, Matouk I, Schneider T, Ohana P, Lester M, Al-Sharef W, de Groot N and Hochberg A**
The possible physiological role of H₁₉ RNA
Mol. Carcinogenesis 35, 63-74 (2002)
- 23. Schachter PP, Ayesh S, Schneider T, Lester M, Czerniak A and Hochberg A**
Expression of kinase genes in primary hyperparathyroidism: Adenoma versus hyperplastic parathyroid tissue
Surgery 132, 1094-1099 (2002)
- 24. Ayesh B, Matouk I, Ohana P, Sughayer MA, Birman T, Ayesh S, Schneider T, de Groot N and Hochberg A**
Inhibition of tumor growth by DT-A expressed under the control of IGF₂ P₃ and P₄ promoter sequences
Mol. Ther. 7(4), 535-541 (2003)



Ca 77 N. Arber, Tel Aviv Med. Center, Tel Aviv
W. Pyerin, DKFZ, Heidelberg

- 1. Wirkner U, Voss H, Ansorge W and Pyerin W**
Genomic organization and promoter identification of the human protein kinase CK2 catalytic subunit α (CSNK2A1)
Genomics 48, 71-78 (1998)
- 2. Poppe M, Hahm B, Eickelbaum W, Arand M, Paweletz N and Knehr M**
Use of PCR to screen for promoter elements in genomic Dann library clones
Bio.Techniques 26, 718-726 (1999)
- 3. Grein S, Raymond K, Cochet C, Pyerin W, Chambaz EM and Filhol O**
Two hybrid screening to search for interaction partners of protein kinase CK2 subunit α
Mol. Cell. Biochem. 191, 105-109 (1999)
- 4. Grein S and Pyerin W**
BTF3 is a potential new substrate of protein kinase CK2
Mol. Cell. Biochem. 191, 121-128 (1999)
- 5. Ackermann K and Pyerin W**
Protein kinase CK2 α may affect gene expression but unlikely as a transcription factor
Mol. Cell. Biochem. 191, 129-134 (1999)
- 6. Lorenz P, Ackermann K, Simoes-Wuest P and Pyerin W**
Serum-stimulated cell cycle entry of fibroblasts requires undisturbed phosphorylation and non-phosphorylation interactions of the catalytic subunits of protein kinase CK2
FEBS Letters 448, 283-288 (1999)
- 7. Pancetti F, Bosser R, Krehan A, Pyerin W, Itarte E and Bachs O**
Heterogeneous nuclear ribonucleoprotein A2 interacts with protein kinase CK2
Biochem. Biophys. Res. Commun. 260, 17-22 (1999)
- 8. Li M, Strand D, Krehan A, Pyerin W, Heid HW, Neumann B and Mechler BM**
Protein kinase CK2 binds and phosphorylates the nucleosome assembly protein-1 (NAP1) in *Drosophila melanogaster*
J. Mol. Biol. 293, 1067-1084 (1999)
- 9.* Kaznov D, Stern B, Pick M, Deutsch VR, Brazowski E, Shapira I, Fabian I, Pyerin W and Arber N**
Down regulation of bak expression in normal enterocytes by anti-sense construct results in malignant transformation
Gastroentrol. 118, A442 (2000)
- 10. Krehan A, Ansuini H, Böcher O, Grein S, Wirkner U and Pyerin W**
Transcription factors Ets1, NF κ B, and SP1 are major determinants of the promoter activity of human protein kinase CK2 α gene
J. Biol. Chem. 275, 18327-18336 (2000)
- 11.* Kazanov D, Stern B, Pyerin W, Boecher O, Strul H, Moshkowitz M, Strier L, Shamir R and Arber N**
CENP-C: an oncogene or tumor suppressor gene? A possible new tumor marker
Gastroenterol. 122, A299 (2001)
- 12. Krehan A, Schmalzbauer R, Böcher O, Ackermann K, Wirkner U, Brouwers S and Pyerin W**
Ets1 is a common element in directing transcription of the α and β genes of human protein kinase CK2
Eur. J. Biochem. 268, 3243-3252 (2001)
- 13. Ackermann K, Waxmann A, Glover CVC and Pyerin W**
Genes targeted by protein kinase CK2: A genome-wide expression array analysis in yeast
Mol. Cell. Biochem. 227, 59-66 (2001)



14. Kazanov D, Shapira I, Pick M, Kolker O, Liberman E, Deutch V, Strier L, Dvory Sobol H, Kunik T and Arber N
Oncogene transformation of normal enterocytes by overexpression of cyclin D1
Dig. Dis. Sci. 48, 1251-1261 (2003)

Ca 78 **R. Bar-Shavit, Hadassah-Univ. Hospital, Jerusalem**
P. Altevogt (V. Schirrmacher), DKFZ, Heidelberg

1. Even-Ram S, Uziel B, Cohen P, Grisaru-Granovsky S, Ginzburg Y, Maoz M, Reich R, Voldavsky I and Bar-Shavit R

Thrombin receptor overexpression in malignant and physiological invasion processes
Nature Medicine 4, 909-914 (1998)

2. Kadmon G, Montgomery AMP and Altevogt P

L1 makes immunological progress by expanding its relations
Dev. Immunology 6, 205-213 (1998)

3. Beer S, Oleszewski M, Gutwein P, Geiger C and Altevogt P

Metalloproteinase-mediated release of the ectodomain of L1 adhesion molecule
J. Cell. Sci. 112, 2667-2675 (1999)

4. Oleszewski M, Beer S, Katich S, Geiger C, Zeller Y, Rauch U and Altevogt P

Integrin and neurocan binding to L1 involves distinct Ig-domains
J. Biol. Chem. 274, 24602-24610 (1999)

5. Landau E, Tirosh R, Pinson A, Banai S, Even-Ram S, Maoz M, Katzav S and Bar-Shavit R

Protection of thrombin receptor expression under hypoxia
J. Biol. Chem. 275, 2281-2287 (2000)

6. Gutwein P, Oleszewski M, Mechtersheimer S, Agmon-Levin N, Krauss K and Altevogt P

Role of src kinases in the ADAM mediated release of L1 adhesion molecule from human tumor cells
J. Biol. Chem. 275, 1490-15497 (2000)

7. Oleszewski M, Gutwein P, von der Lieth W, Rauch U and Altevogt P

Characterization of the L1-neurocan binding site: Implications for L1-L1 homophilic binding
J. Biol. Chem. 44, 34478-34485 (2000)

8.* Even-Ram S, Maoz M, Pokroy E, Reich R, Katz BZ, Gutwein P, Altevogt P and Bar-Shavit R

Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the $\alpha v \beta 5$ integrin
J. Biol. Chem. 276, 10952-62 (2001)

9. Mechtersheimer S, Gutwein P, Agmon-Levin N, Oleszewski M, Riedle S, Fogel M, Lemmon V and Altevogt P

Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins
J. Cell. Biol. 155, 661-673 (2001)

10. Bar-Shavit R, Maoz M, Yongjun Y, Groysman M, Dekel I and Katzav S

Signalling pathways induced by protease-activated receptors and integrins in T cells
Immunology 105, 35-46 (2002)

11. Nassar T, Akkawi S, Bar-Shavit R, Haj YA, Bdeir K, Al MA, Tarshis M and Higazi AA

Human α -defensin regulates smooth muscle cell contraction: a role for low-density lipoprotein receptor-related protein/ α 2-macroglobulin receptor



Blood 100, 4026-4032 (2002)

12. Schiffenbauer YS, Meir G, Maoz M, Even-Ram S, Bar-Shavit R and Neeman M
Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by $\alpha(v)$ -integrin
Gynecol. Oncol. 84, 296-302 (2002)

Ca 79 **A. Ben-Ze'ev, B. Geiger, The Weizmann Institute of Science, Rehovot**
W. Franke, DKFZ, Heidelberg

1. Salomon D, Sacco P, Guha Roy S, Simcha I, Johnson KR, Wheelock MJ and Ben-Ze'ev A

Regulation of β -catenin levels and localization by overexpression of plakoglobin and inhibition of the ubiquitin-proteasome system
J. Cell. Biol. 139, 1325-1335 (1997)

2. Schmidt A, Langbein L, Rode M, Prazel S, Zimbelmann R, and Franke W
Plakophilins 1a and 1b: widespread nuclear proteins recruited in specific epithelial cells as desmosomal plaque components
Cell Tissue Res. 290, 481-499 (1997)

3. Simcha I, Shtutman M, Salomon D, Zhurinsky J, Sadot E, Geiger B and Ben-Ze'ev A

Differential nuclear translocation and transactivation potential of β -catenin and plakoglobin
J. Cell. Biol. 141, 1433-1448 (1998)

4. Sadot E, Simcha I, Shtutman M, Ben-Ze'ev A and Geiger B
Inhibition of β -catenin-mediated transactivation by cadherin derivatives
Proc. Natl. Acad. Sci. USA 95, 15339-15344 (1998)

5. Ben-Ze'ev A and Geiger B
Differential molecular interactions of β -catenin and plakoglobin in adhesion, signaling and cancer
Curr. Opin. Cell. Biol. 10, 629-639 (1998)

6. Ben-Ze'ev A
Cytoskeletal plaque proteins: their role in the regulation of tumorigenesis
In: G Proteins, Cytoskeleton and Cancer (H Maruta and K Kohama, eds.) pp. 101-109 (1998) RG Landes Press, Austin, TX

7. Kurzen H, Moll I, Moll R, Schäfer S, Simics E Amagai M, Wheelock M and Franke W

Compositionally different desmosomes in the various compartments of the human hair follicle
Differentiation 63, 295-304 (1998)

8. Dalamas A, Ben-Ze'ev A, Simcha I, Martinez Leal JF, Zhurinsky J, Shtutman M, Geiger B and Oren M

Excess β -catenin promotes accumulation of transcriptionally active p53
EMBO J. 18, 3054-3063 (1999)

9. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, and Ben-Ze'ev A

The cyclin D1 gene is a target of the β -catenin/LEF-1 pathway
Proc. Natl. Acad. Sci. USA 96, 5522-5527 (1999)

10. Lyubimova A, Bershadsky A and Ben-Ze'ev A

The autoregulation of actin synthesis requires the 3'-UTR of actin mRNA and protects cells from actin overproduction



J. Cell. Biochem. 76, 1-12 (1999)

11. Paffenholz R, Kuhn C, Grund C, Stehr S and Franke W

The arm-repeat protein NPRAP (neurojungin) is a constituent of the plaques of the outer limiting zone in the retina, defining a novel type of adhering junction
Exp. Cell. Res. 250, 452-464 (1999)

12. Mertens C, Kuhn C, Moll R, Schwetlick I and Franke W

Desmosomal plakophilin 2 as a differentiation marker in normal and malignant tissues
Differentiation 64, 277-290 (1999)

13. Schmidt A, Langbein L, Prätzel S, Rode M, Rackwitz HR and Franke W

Plakophilin 3 – a novel cell-type-specific desmosomal plaque protein
Differentiation 64, 291-306 (1999)

14. Zhurinsky J, Shtutman M and Ben-Ze'ev A

Differential mechanisms of LEF/TCF-dependent transcriptional activation by β -catenin and plakoglobin
Mol. Cell. Biol. 20, 4238-4252 (2000)

15. Sadot E, Simcha I, Iwai K, Ciechanover A, Geiger B and Ben-Ze'ev A

Differential interaction of plakoglobin and β -catenin with the ubiquitin-proteasome system
Oncogene 19, 1992-2001 (2000)

16. Zhurinsky J, Shtutman M and Ben-Ze'ev A

β -catenin and plakoglobin: protein interactions, regulation and biological roles
J. Cell. Sci. 113, 3127-3139 (2000)

17. Ben-Ze'ev A, Shtutman M, and Zhurinsky J

Integration of cell adhesion with gene expression: the role of β -catenin
Exp. Cell. Res. 261, 75-82 (2000)

18. Borrman CM, Mertens C, Langbein L, Kuhn C and Franke W

Molecular diversity of plaques of epithelial – adhering junctions
Ann. NY Acad. Sci. 915, 144-150 (2000)

19. Simcha I, Kirkpatrick C, Sadot E, Shtutman M, Polevoy G, Geiger B, Peifer M, and Ben-Ze'ev A

Cadherin sequences that inhibit β -catenin signaling: a study in yeast and mammalian cells
Mol. Biol. Cell. 12, 1177-1188 (2001)

20. Sadot E, Geiger B, Oren M, and Ben-Ze'ev A

Downregulation of β -catenin by activated p53
Mol. Cell. Biol. 21, 6768-6781 (2001)

21. Mertens C, Hofman I, Wang Z, Teichman M, Chong SS, Schnölzer M and Franke W

Nuclear particles containing RNA polymerase III complexes associated with the junctional plaque protein plakophilin 2
PNAS 14, 7795-7800 (2001)

Ca 80 E. Canaani, The Weizmann Institute of Science, Rehovot
R. Paro, University of Heidelberg

1. Muyrers-Chen I and Paro R

Epigenetics: unforeseen regulators in cancer
Biochim. Biophys. Acta 1552, 15-26 (2001)

2.* Muyrers-Chen I, Rozovskaia T, Lee N, Nakamura R, Kersey J, Canaani E and Paro R

Expression of leukemic MLL fusion proteins in Drosophila affects cell cycle control and chromosome morphology



Ca 81 **A. Ciechanover, Technion, Haifa**
M. Scheffner, University of Cologne

- 1. Hengstermann A, Whitacker NJ, Zimmer D, Zentgraf H and Scheffner M**
Characterization of sequence elements involved in p53 stability regulation reveals cell type dependence of p53 degradation
Oncogene 17, 2933-2941 (1998)
- 2. Orian A, Schwartz AL, Israël A, Whiteside S, Kahana C and Ciechanover A**
Structural motifs involved in ubiquitin-mediated processing of the NF- κ B precursor p105: Roles of the glycine-rich region and a downstream ubiquitination domain
Mol. Cell. Biol. 19, 3664-3673 (1999)
- 3. Gonen H, Bercovich B, Orian A, Carrano A, Takizawa C, Yamanak K, Pagano M, Iwai K and Ciechanover A**
Identification of the ubiquitin carrier proteins, E2s, involved in signal-induced conjugation and subsequent degradation of I κ B α
J. Biol. Chem. 274, 14823-14830 (1999)
- 4. Gostissa M, Hengstermann A, Fogal V, Sandy P, Schwarz SE, Scheffner M and Del Sal G**
Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1
EMBO J. 18, 6462-6471 (1999)
- 5. * Reinstein E, Scheffner M, Oren M, Ciechanover A and Schwartz A**
Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: Targeting via ubiquitination of the N-terminal residue
Oncogene 19, 5944-5950 (2000)
- 6. Orian A, Gonen H, Bercovich B, Fajerman I, Eytan E, Israël A, Mercurio F, Iwai K, Schwartz AL and Ciechanover A**
SCF- β -TrCP ubiquitin ligase-mediated processing of NF- κ B p105 requires phosphorylation of its C-terminus by I κ B kinase
EMBO J. 19, 2580-2591 (2000)
- 7. * Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ and Scheffner N**
Complete switch from Mdm2 to HPV E6-mediated degradation of p53 in cervical cancer cells
Proc. Natl. Acad. Sci. USA 98, 1218-1223 (2001)
- 8. Cohen S, Orian A, and Ciechanover A**
Processing of p105 is inhibited by docking of p50 active subunits to the ankyrin repeat domain, and inhibition is alleviated by signaling via the carboxyl-terminal phosphorylation/ubiquitin-ligase binding domain
J. Biol. Chem. 276, 26769-26776 (2001)

Ca 82 **I. Friedberg, Tel Aviv University, Tel Aviv**
D. Kuebler (V. Kinzel), DKFZ, Heidelberg

- 1. * Friedberg I., Fichtman B, Shahbazian D, Bublil E and Kuebler D**
Inhibition of receptor tyrosine kinase signaling in malignant cells by phospho-activated growth inhibitor
J. Mol. Neurosci. 16, 69-70 (2001)



2. Wind M, Goscenca D, Kübler D and Lehmann WD

Stable isotope phospho-profiling of fibrinogen and fetuin subunits by element mass spectrometry coupled to capillary liquid chromatography
Analyt. Biochem. 317, 26-33 (2003)

**Ca 83 A. Levitzki, Hebrew University, Jerusalem
F. Roesl, DKFZ, Heidelberg**

1. Ben-Bassat H, Rosenbaum-Mitrani S, Hartzstark Z, Shlomai Z, Kleinberger-Doron N, Gazit A, Plowman G, Levitzki R, Tsvieli R and Levitzki A

Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes
Cancer Res. 57, 3741-50 (1997)

2. Ben-Bassat H, Rosenbaum-Mitrani S, Hartzstark Z, Levitzki R, Chaouat M, Shlomai Z, Klein BY, Kleinberger-Doron N, Gazit A, Tsvieli R and Levitzki A

Tyrphostins that suppress the growth of human papilloma virus 16-immortalized human keratinocytes

J. Pharmacol. Exp. Ther. 290, 1442-57 (1999)

3.* Baars B, Bachmann A, Levitzki A, Roesl F

Tyrphostin AG555 inhibits bovine papillomavirus transcription by changing the ratio between E2 transactivator/repressor function

J. Biol. Chem. 278, 37306-37313 (2003)

**Ca 84 A. Panet, A. Eldor, Hebrew University, Jerusalem
K-M. Debatin, University of Ulm**

1. Mador N, Goldenberg D, Cohen O, Panet A and Steiner I

Herpes simplex virus type 1 latency-associated transcripts suppress viral replication and reduce immediate-early gene mRNA levels in a neuronal cell line

J. Virol. 72(6), 5067-75 (1998)

2. Alian A, Sela-Donenfeld D, Panet A and Eldor A

Avian Hemangiona Retrovirus induces cell proliferation via envelope (env) gene
Virology 276, 161-168 (2000)

3. Alian A, Eldor A, Falk H and Panet A

Viral mediated gene transfer to sprouting blood vessels during angiogenesis

J. Viral. Methods 105, 1-11 (2002)

**Ca 85 A. Kimchi, Weizmann Institute of Science, Rehovot
M. Schwab, DKFZ, Heidelberg**

1.* Wittke I, Madge B, Wiedemeyer R, Kimchi A and Schwab M

DAP-5 is involved in MycN/IFN γ -induced apoptosis in human neuroblastoma cells
Cancer Lett. 162, 27-243 (2001)

2. Henis-Korenblit S, Shani G, Sines T, Marash L, Shohat G and Kimchi A

The caspase-cleaved DAP5 protein supports internal ribosome entry site-mediated translation of death proteins



Proc. Natl. Acad. Sci. USA 99(8), 5400-5405 (2002)

3. Wiedemeyer R, Westermann F, Wittke I, Nowock J and Schwab M

Ataxin-2 promotes apoptosis of human neuroblastoma cells

Oncogene 22, 401-411 (2003)

4. Wittke I, Wiedemeyer R, Pillmann A, Savelyeva L, Westermann F and Schwab M

Neuroblastoma-derived sulfhydryl oxidase/quiescine6 family, regulates sensitization to Interferon γ -induced cell death in human neuroblastoma cell

Cancer Research 63, 7742-7752 (2003)

**Ca 86 M. Oren, Weizmann Institute of Science, Rehovot
P. Krammer, DKFZ, Heidelberg**

1. Maya R, Balass M, Kim ST, Shkedy D, Leal JFM, Shifman O, Moas M, Buschmann T, Ronai Z, Shiloh Y, Kastan MB, Katzir E and Oren M

ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage

Genes Dev. 15, 1067-1077 (2001)

2. Damalas A, Kahan S, Shtutman M, Ben-Ze'ev A and Oren M

Deregulated β -catenin induces p53 through E2F1 and ARF and elicits a p53-dependent senescence-like state

EMBO J. 20, 4912-4922 (2001)

3. Krueger A, Schmitz I, Baumann S, Krammer PH and Kirchhoff S

Cellular FLICE inhibitory protein splice variants inhibit different Steps of caspase-8 activation at the CD95 death-inducing signaling complex

J. Biol. Chem. 276, 20633-20640 (2001)

4. Gottlieb TM, Leal JFM, Seger R, Taya Y and Oren M

Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis

Oncogene 21, 1299-1303 (2002)

5. Michael D and Oren M

P53 and Mdm2 families in cancer

Curr. Op. Gen. Dev. 12, 53-59 (2002)

6. Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JFM, Maya R, Moas M, Seger R, Taya Y and Ben-Ze'ev A

Regulation of p53: intricate loops and delicate balances

Biochem. Pharmacol. 64, 865-871 (2002)

7. Blander G, Zalle N, Taplick J, Daniely Y, Gray MD and Oren M

DNA damage-induced translocation of the Werner helicase is regulated by acetylation

J. Biol. Chem. 277, 50934-50940 (2002)

8.* Zalcenstein A, Stambolsky P, Weisz L, Muller M, Wallach D, Goncharov TM, Krammer PH, Rotter V and Oren M

Mutant p53 gain of function: repression of CD95 (Fas/APO-1) gene expression by tumor-associated p53 mutants

Oncogene 22, 5667-5676 (2003)

9. Oren M

Decision making by p53: life, death and cancer

Cell Death Diff. 10, 431-442 (2003)

10. Oren M

The p53 saga: the good, the bad and the dead

Lectures Harvey Lect. 97, 57-82 (2003)



Ca 87 E. Razin, Hebrew University, Jerusalem
P. Angel, DKFZ, Heidelberg

- 1. Razin E, Zhang ZC, Nechushtan H, Frenkel S, Lee YN, Arudchandran R and Rivera J**
Suppression of microphthalmia transcription factor activity by its association with protein kinase C interacting protein 1 in mast cells
J. Biol. Chem. 274, 34272-6 (1999)
- 2. Kolbus A, Herr I, Schreiber M, Debatin KM, Wagner EF and Angel P**
c-Jun-dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents
Mol. Cell. Biol. 20, 575-582 (2000)
- 3. Szabowski A, Maas-Szabowski N, Andrecht S, Kolbus A, Schorpp-Kistner M, Fusenig NE and Angel P**
c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin
Cell 103, 74-55 (2000)
- 4. Eichhorst ST, Muller M, Li-Weber M, Schulze-Bergkamen H, Angel P and Krammer PH**
A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs
Mol. Cell. Biol. 20, 7826-37 (2000)
- 5. Maas-Szabowski N, Szabowski A, Andrecht S, Kolbus A, Schorpp-Kistner M, Angel P and Fusenig NE**
Organotypic cocultures with genetically modified mouse fibroblasts as a tool to dissect molecular mechanisms regulating keratinocyte growth and differentiation
J. Invest. Dermatol. 116, 816-20 (2001)
- 6. Angel P, Szabowski A and Schorpp-Kistner M**
Function and regulation of AP-1 subunits in skin physiology and pathology
Oncogene 20, 2413-23 (2001)
- 7. Levy C, Nechushtan H and Razin E**
A new role for the STAT3 inhibitor, PIAS3: A repressor of microphthalmia transcription factor
J. Biol. Chem. 277, 1962-6 (2002)
- 8. Andrecht S, Kolbus A, Hartenstein B, Angel P and Schorpp-Kistner M**
Cell cycle promoting activity of JunB through cyclin A activation
J. Biol. Chem. 277, 35961-8 (2002)
- 9. Schorpp-Kistner M, Herrlich P and Angel P**
The AP-1 family of transcription factors: Structure, regulation and functional analysis in mice
In: Targets for Cancer Chemotherapy, NB LA Thangue and LR Bandara (Eds)
Humana Press, Totowa, New Jersey, p. 29-52 (2002)
- 10. Angel P and Szabowski A**
Function of AP-1 target genes in mesenchymal-epithelial cross-talk in skin
Biochem. Pharmacol. 64, 949-56 (2002)
- 11. Hartenstein B, Teurich S, Hess J, Schenkel J, Schorpp-Kistner M and Angel P**
The cell-specific cytokine expression and allergen-induced airway inflammation depend on JunB
EMBO J. 21, 6321-9 (2002)
- 12. Baumann S, Eichhorst S, Hess J, Krüger A, Angel P, Krammer P and Kirchoff S**
An unexpected function for FosB in activation-induced cell death in T cells
Oncogene 22, 1333-1339 (2003)



13. Angel P

The multi-gene family of transcription factor AP-1

In: Handbook of Cell Signalling (Vol 3) R Bradshaw and E Dennis (Eds) Elsevier Science, San Diego, Ca, USA p. 99-105 (2003)

14.* Lee YN, Tuckermann J, Nechushtan H, Schutz G, Razin E and Angel P

c-Fos as a regulator of degranulation and cytokine production in FcepsilonRI-activated mast cells

J. Immunol. 173, 2571-2577 (2004)

15. Lee YN, Nechushtan H, Figov N and Razin E

The function of lysyl-tRNA synthetase and Ap4A as signaling regulators if MITF activity in FcepsilonRI-activated mast cells

Immunity 20, 145-151 (2004)

16. Bierbaum H, Baumann S, Herr I, Tuckermann J, Hess J, Schorpp-Kistner M and Angel P

Early activation and induction of apoptosis in T cells is independent of c-Fos

Ann. NY Acad. Sci. 2003, 1010, 225-231 (2004)

Ca 88 G. Golomb, Hebrew University, Jerusalem R. Berger, DKFZ, Heidelberg

1. Cohen H, Levy RJ, Gao J, Fishbein I, Kousaev V, Sosnowski S, Slomkowski S and Golomb G

Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles

Gene Therapy 7, 1896-1905 (2000)

2.* Adwan H, Bäuerle T, Najajreh Y, Elazer V, Golomb G, Berger MR

Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB231 cells

Int. J. Oncol. 24, 1235-1244 (2004)

3.* Cohen-Sacks H, Elazar V, Gao J, Golomb A, Adwan H, Korchov N, Levy RH, Berger MR and Golomb G

Delivery and expression of pDNA from collagen matrices

J. Controlled Release 95, 309-320 (2004)

4. Adwan H, Bäuerle T and Berger MR

Down-regulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells

Cancer Gene Therapy 11, 109-120 (2004)

Ca 89 E. Keshet, Hebrew University, Jerusalem NE. Fusenig, DKFZ, Heidelberg

1. Fusenig NE, Skobe M, Vosseler S, Hansen M, Lederle W, Airola K Tomakidi P, Stark HJ, Steinbauer H, Mirancea N, Boukamp P and Breitkreutz D

Tissue models to study tumor-stroma interactions

In: Proteases and their Inhibitors in Cancer Metastasis RJ Muschel, J-M Foidart (eds), Kluwer Academic Publishers, Dordrecht, The Netherlands, pp. 205-223 (2002)



Ca 90 I. Vlodavsky, Y. Friedmann, Hadassah Univ. Hospital,
Jerusalem
V. Schirmacher, DKFZ, Heidelberg

1. Miao HQ, Elkin M, Aingorn E, Ishai-Michaeli R, Stein CA and Vlodavsky Y

Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and phosphorothioate oligodeoxynucleotides
Int. J. Cancer 83, 424-431 (1999)

2. Elkin M, Miao HQ, Nagler A, Aingorn E, Reich R, Hemo I, Dou HL, Pines M and Vlodavsky I

Halofuginone: a potent inhibitor of critical steps in angiogenesis progression
FASEB J. 14, 2477-2485 (2000)

3. Bentolila A, Vlodavsky I, Ishai-Michaeli R, Kovalchuk O, Haloun C, and Domb AJ

Poly(n-acryl amino acids) – a new class of biologically active polyanions
J. Medicinal Chem. 43, 2501-2600 (2000)

4 Elkin M, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I and Vlodavsky I

Heparanase as mediator of angiogenesis: mode of action
FASEB J. 15, 1661-1663 (2001)

5.* Goldsmidt O, Zacharia E, Abramovitch R, Metzger S, Aingorn H, Friedmann Y, Mitrani E, Schirmacher V and Vlodavsky I

Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis
Proc. Nat. Acad. Sci. USA 99, 10031-10036 (2002)

6. Benezra M, Ishai-Michaeli R, Ben-Sasson S and Vlodavsky I

Differential effect of synthetic heparin-mimicking compounds on release of bFGF from extracellular matrix, inhibition of SMC cell proliferation and inhibition of heparanase activity
J. Cell. Physiol. 192, 276-285 (2002)

Ca 91 Z. Fishelson, Tel Aviv University, Tel Aviv
M. Kirschfink, University of Heidelberg

1. Kraus S and Fishelson Z

Cell desensitization by sublytic C5b-9 complexes and calcium ionophores depends on activation of protein kinase C
Eur. J. Immunol. 30, 1272-1280 (2000)

2. Kraus S, Seger R and Fishelson Z

Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis
Clin. Exp. Immunol. 123, 366-374 (2001)

3. Fishelson Z, Hochman I, Greene LE and Eisenberg E

Contribution of heat shock proteins to cell protection from complement-mediated lysis
Int. Immunol. 8, 983-991 (2001)

4. Kirschfink M

Targeting complement in therapy
Immunol. Rev. 180, 177-189 (2001)

5.* Donin N, Jurianz K, Kirschfink M and Fishelson Z

Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid



Clin. Exp. Immunol. 131, 254-263 (2003)

6.* Fishelson Z, Donin N, Zell S, Schultz S and Kirschfink M

Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors

Mol. Immunol. 40, 109-123 (2003)

7.* Kirschfink M and Fishelson Z

Tumor cell resistance to complement-mediated lysis

In: The complement system: novel roles in health and disease, Szelenyi J, editor, Kluwer Academic Publishers, MA, pp. 271-309 (2004)

